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 Abstract 
 
Chromosomal imbalances are of major significance in cancer initiation and 
progression. Gains of chromosome 8 in human cancer have been described by a 
number of authors and are amongst the most common cytogenetic events that 
occur. However in childhood solid tumours, few studies have examined copy number 
changes of specific genes on chromosome 8. 
 
Somatic genomic events have been for many years an important component of 
diagnosis, prognosis and therapy selection in paediatric oncology. Different 
techniques have been designed to identify gene dosage or copy number changes in 
a quantitative fashion. In this project we used Multiplex Ligation-dependent Probe 
Amplification (MLPA), array Comparative Genomic Hybridization (aCGH) and 
quantitative PCR (qPCR).  
 
MLPA was used as a screening tool to assess chromosome 8 copy number changes 
in a cohort of 31 paediatric solid tumours - osteosarcoma n=5, Ewing sarcoma n=8, 
rhabdomyosarcoma n=8, and neuroblastoma n=10, and 6 breast cell lines (5 breast 
cancer and a non-tumorigenic cell line MCF-10A), some of which were expected to 
show defined copy number changes on chromosome 8. The SALSA MLPA KIT 
P014-A1 Chromosome 8 kit has 32 probes mapping to 30 chromosome 8 genes, 
and 9 reference probes mapping to other chromosomes. Using MLPA, 
osteosarcomas and neuroblastoma showed the greatest number of copy number 
changes at chromosome 8 loci with copy number gain/loss at 21/30 loci and 29/30 
loci, respectively.  Ewing sarcoma and rhabdomyosarcomas showed fewer 
  xii 
chromosome 8 copy number changes at 9/30 loci and 11/30 loci, respectively. In the 
breast cell lines, MLPA results confirmed as expected copy number loss at 8p loci in 
5/6 breast cell lines, and copy number gains at MYC in 5/6 cell lines, followed by 
TPD52 in 4/6 cell lines. As an additional finding, we obtained some discrepant 
results within the 4 MLPA experiments conducted for both cell lines and the solid 
tumour cohort.  MLPA results could not be consistently reproduced for EIF3E and 
EXT1.  
 
To obtain a broader view of copy number changes in this tumour cohort, we 
analysed genomic DNA samples using array Comparative Genomic Hybridization 
(aCGH). We used a customized 60-mer-oligonucleotide high-density Agilent eArray 
SurePrint G3 2x400K with 52,639 probes along chromosome 8, 39,654 probes in 95 
genes known to be important in cancer, and evenly spaced whole-genome coverage 
(253,502 probes) for the remainder of the human genome.  
 
aCGH chromosome 8 results showed that osteosarcoma samples had the most 
frequent copy number changes, between 9 and 21 per sample, congruent with the 
hallmarks of osteosarcoma that include an unusually high frequency of genome 
rearrangements. In Ewing sarcoma, a gain of whole chromosome 8 was detected in 
37% (3/8) of samples, consistent with this being one of the most prominent features 
of this solid tumour. Rhabdomyosarcomas and neuroblastoma showed infrequent 
gain or loss at chromosome 8 loci. From the list of cancer genes with lower 
oligonucleotide probe spacing, 5/5 osteosarcoma samples showed copy number loss 
at RB1, TP53 and APC, and 8/10 neuroblastoma samples showed copy number gain 
at MYCN, findings that are in agreement with the literature. From results generated 
  xiii 
from genome-wide probes, a chromosomal region located at chromosome 22 band 
q11.22 showed copy number gain in all 4 solid tumour types, and in 21/31 samples 
analysed. This region contained the PRAME gene or preferentially expressed 
antigen in melanoma, which has been proposed as a promising target for 
immunotherapy in some hematologic malignancies, but has not specifically been 
studied in osteosarcoma, rhabdomyosarcoma or Ewing sarcoma. In addition, the 
aCGH data presented in this thesis revealed some genes that had not previously 
been linked in literature with paediatric solid tumours, including KCNK9, that showed 
copy number gain in all osteosarcoma samples, and RECQL4 that showed copy 
number gain in most rhabdomyosarcomas. Further studies in these genes may 
prove to be beneficial for the understanding of tumourigenesis and progress in 
paediatric solid tumours. 
 
Comparison of MLPA versus aCGH copy number results was made based on the 
results for the 30 genes included in the chromosome 8 MLPA kit. Clear 
discrepancies in copy number measured by MLPA and aCGH were obtained. To 
quantify differences and propose genes to be used for copy number validation using 
a third technique, MLPA and aCGH results were compared. A list of genes was 
generated, from the ones that presented results with the greatest degree of 
disagreement to genes with least disagreement. From this list, 6 genes were chosen 
to be validated with a third technique namely qPCR, including MYC that was 
selected as a control because it presented the least disagreement between MLPA 
and aCGH results. Due to the small amount of DNA remaining for many samples 
after having applied both MLPA and aCGH techniques, 7 tumour samples (one 
osteosarcoma, 2 Ewing sarcomas, 2 rhabdomyosarcomas, and 2 neuroblastomas) 
  xiv 
and 2 cell lines were selected to perform qPCR analyses. Copy number results 
obtained using MLPA versus qPCR showed agreement percentages ranging from 
11.1-67%, and 78% of agreement for MYC. In contrast, qPCR versus aCGH showed 
100% agreement for all but one gene, EXT1, which showed 89% agreement (in 8/9 
samples). These results demonstrate that aCGH copy number results could be more 
frequently validated by qPCR than could MLPA results. 
 
In summary, copy number results produced by aCGH were more consistently in 
agreement with those produced by qPCR, making qPCR a more reliable technique 
for diagnostic purposes than MLPA. To the best of our knowledge, this is the first 
time that such a technical comparison has been performed for any MLPA kit 
targeting human chromosome 8. 
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Chapter 1 Literature review 
 
  2 
1. Introduction 
Chromosomal imbalances are of major significance in cancer initiation and 
progression. Gains of chromosome 8, as part of these chromosomal imbalances, 
have been described by a number of authors, and are amongst the most common 
cytogenetic events that occur in cancer. Nevertheless few studies have examined 
copy number changes of specific genes on chromosome 8 in childhood solid 
tumours. This thesis presents a literature review with a general introduction to 
childhood cancer.  
 
A clear association between DNA copy number changes and prognosis has been 
found in a variety of tumours. Consequently, this review will explore specific 
cytogenetic changes in childhood cancers, focusing upon the four types of tumours 
examined in this project, namely neuroblastoma, rhabdomyosarcoma, Ewing 
sarcoma and osteosarcoma, and their relevance to treatment and prognosis. This 
will be followed by a discussion of technical approaches to detect copy number 
changes in cancer. Finally, the introduction will describe chromosome 8q gain in 
adult cancers, and chromosome 8 gains in childhood cancers. 
1.1 General introduction to childhood cancer  
1.1.1 Classification of tumours in children 
The current standard for childhood cancer classification, termed “International 
Classification of Childhood Cancer Third edition” (ICCC-3) provides 12 groups of 
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childhood cancers (Table 1.1). This coding system is based on morphology rather 
than the primary site of origin, as in adults (Steliarova-Foucher et al., 2005).  
 
In the United States, cancer is the fourth most common cause of death among 
individuals aged 1 to 19 years old, with an increased incidence from 1.51 cases per 
million per year in 2002 to 1.66 cases per million per year in 2006 (Haddy et al., 
2010).  
 
In Australia, paediatric cancer was the second most common cause of death in 
2004-2008 after injuries, according to the Australian Institute of Health and Welfare 
(2009). From 1983-2006, 13,925 childhood cancers were diagnosed in Australia: 
leukaemia (34%) was the most common childhood cancer, followed by cancers of 
the central nervous system (23%), and lymphomas (10%). Similar distributions were 
also reported in the United States (Linabery et al., 2008), and Europe (Baade et al., 
2010; Kaatsch, 2010).  
 
Survival rates for childhood cancers have improved dramatically since 1960s, when 
the overall 5-year survival was estimated at 28%, due in part to more developed 
cytotoxic chemotherapies and radiotherapies. In general, the overall cure rate for 
children with cancer now stands at approximately 80% (Andam et al., 2008; Pui et 
al., 2011). 
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Table 1.1 International Classification of Childhood Cancer (ICCC-3) 
 Steliarova-Foucher et al. (2005) 
I II III IV 
Leukemias Lymphomas reticuloendothelial neoplasm 
Central nervous system and 
miscellaneous 
Neuroblastoma and other peripheral 
nervous cell tumours 
Lymphoid leukemias Hodgkin lymphoma Ependymomas and Neuroblastoma and 
  
choroid plexus tumour ganglioneuroblastoma 
Acute myeloid leukemias Non-Hodgkin lymphoma Astrocytomas Other peripheral 
diseases 
  
nervous cell tumours 
Chronic myeloproliferative Burkitt lymphoma Intracranial and intraspinal 
 
  
embryonal tumours 
 
Myelodysplastic syndrome  Miscellaneous Other gliomas 
 and other myeloproliferative 
disease lymphoreticular neoplasm 
  
Unspecified and other  Unspecified lymphomas Other specified intracranial 
 
specified leukemias 
 
and intraspinal neoplasm 
 
  
 
Unspecified intracranial 
 
  
and intraspinal neoplasm 
  
 
 
V VI VII VIII 
Retinoblastoma Renal Hepatic tumours Malignant bone 
 tumours  tumours 
 
Nephroblastoma Hepatoblastoma Osteosarcomas 
 
and other non epithelial Hepatic carcinoma 
 
 
renal tumours 
  
 
Renal carcinomas Unspecified malignant Chondrosarcomas 
  
hepatic tumours 
 
 
Unspecified malignant 
 
Ewing tumour and related 
 
renal tumours 
 
sarcomas of bone 
   
Other specified malignant 
   
bone tumours 
   
Unspecified malignant 
   
bone tumours 
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Table 1.1 International Classification of Childhood Cancer (ICCC-3) 
 Steliarova-Foucher et al. (2005) (cont.) 
 
IX X XI XII 
Soft tissue and Germ cell tumours Other malignant epithelial neoplasm 
Other and unspecified 
malignant 
other extraosseous trophoblastic tumours and malignant melanomas neoplasm 
sarcomas and neoplasm of gonads   
Rhabdomyosarcomas Intracranial and intraspinal Adrenocortical carcinomas 
Other specified malignant 
tumours 
 
germ cell tumours 
  
Fibrosarcomas, peripheral Malignant extracranial and Thyroid carcinomas Other unspecified malignant 
nerve sheath tumours 
extragonadal germ cell 
tumours 
 
tumours 
and other fibrous neoplasm       
Kaposi sarcoma Malignant gonadal germ  Nasopharyngeal carcinomas   
 
cell tumours 
  
Other specified  Gonadal carcinomas Malignant melanomas   
soft tissue sarcomas 
   
Unspecified soft   Other and unspecified Skin carcinomas   
tissue sarcomas malignant gonadal tumours 
  
    
Other and unspecified 
carcinomas   
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1.1.2 Solid tumours of childhood 
There are several differences between solid tumours in children and adults in terms 
of their origin and histological subtypes, etiologic characteristics, their responses to 
treatment and outcomes (Raymond et al., 2001). In fact, some solid tumours in 
children never develop in adults, such as neuroblastoma, Wilm’s tumour, 
rhabdomyosarcoma, some osteosarcomas, some Ewing sarcoma and 
retinoblastoma (Kline et al., 2003). During prenatal and postnatal periods of 
development, tissue growth and differentiation take place, which are regulated by 
cell division and apoptosis. From this point of view, childhood solid tumours are 
intimately linked to processes such as organogenesis, tissue growth and maturation 
(Scotting et al., 2005). 
1.1.3 Neuroblastoma 
In Australia, there were on average 36 cases of neuroblastoma (NB) diagnosed per 
year between 1983-2006 (Baade et al., 2010). NB is one of the most frequent 
extracranial solid tumours in children, the majority of which are diagnosed before the 
age of five years. NB is believed to originate from neural crest cells of the 
sympathetic nervous system (Aravindan et al., 2013). The main morphological 
features of NB are undifferentiated small round blue cells, with hyperchromatic nuclei 
and scant cytoplasm, pseudo-rosettes surrounding eosinophilic material in the 
interstitial space, and microcalcifications, which occur in up to 50% of tumours 
(Pearson, 2004). 
 
NB has a variable clinical course, ranging from spontaneous remission to rapid 
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disease progression and death (Messahel et al., 2005; Pui et al., 2011). Spontaneous 
remission of even large tumours has been well documented and seems to be a 
common event in infants, in which case NB is described as NB stage 4s (Hero et al., 
2008; Schilling et al., 2002; Woods et al., 2002). 
 
Shimada. et al. (1999) classified NB according to histopathological features as 
favourable or unfavourable, depending on the grade of cell differentiation. This 
system has since been modified several times, and today the main rationale is to find 
a system that clearly differentiates between embryonic NB, which will regress, and 
those NB that show aggressive clinical behaviour (Cohn et al., 2009; Pearson, 2004). 
1.1.4 Rhabdomyosarcoma 
In the decade from 1997-2006, an average of 16.5 cases of rhabdomyosarcoma 
(RMS) were diagnosed in Australia per year (Baade et al., 2010). The incidence of 
RMS in Australia between 2003-2007 was 107 (5.3%) cases in children (0-14 years), 
and 36  (1.7%) cases in adolescents and young adults (15-29 years), with 
percentages based on the total number of cancer cases diagnosed in patients 0-29 
years, over the 5 year period according to the Australian Institute of Health and 
Welfare (AIHW, 2011). The AIHW reported 102 new cases of rhabdomyosarcoma 
diagnosed between 1983-2007 in patients aged 15 - 19 years, which showed a 5 
year survival of 49%. This was the second lowest survival observed for all cancers in 
adolescents and young adults for that period (AIHW, 2011). 
 
RMS is the most common soft tissue sarcoma of childhood and adolescents and is 
identified on the basis of histopathology. It exhibits features of skeletal muscle and is 
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thought to derive from mesenchymal cell precursors that have failed to differentiate, 
or have otherwise developed aberrantly along the skeletal muscle axis (Meyer et al., 
2004). Originally defined under light microscopy by morphology, RMS are composed 
of small, round, blue cells that often exhibit cross-striations (Diao et al., 2014; 
Raymond et al., 2001).  
 
The two major variants of rhabdomyosarcomas are embryonal RMS (ERMS), whose 
name comes from the morphological appearance of fetal muscle, and alveolar RMS 
(ARMS), because it resembles pulmonary alveoli morphology (Davicioni et al., 
2009). The ERMS variant often occurs in the head, neck, or trunk, and is associated 
with genomic instability reflecting highly variable karyotypes. In general, ERMS 
shows less aggressive behaviour and better prognosis than ARMS (Missiaglia et al., 
2012).  
 
ARMS is diagnosed in up to 40% of RMS patients, often in the extremities, and 
shows characteristic translocations such as t(2;13)(q35;q14) and t(1;13)(p36;q14). 
These translocations form a fusion gene between the 5’ end of either PAX3 or PAX7 
and the 3’ end of FOXO1. The ARMS subgroup exhibiting translocations has been 
termed ARMSp (translocation positive) (Williamson et al., 2010). However 45% of 
ARMS cases do not exhibit these characteristic translocations, and have been 
classified as a third group, called ARMSn for “Alveolar rhabdomyosarcoma negative” 
(Davicioni et al., 2009). A previous study by Wachtel et al. (2004) also described a 
third RMS group, based on different protein expression profiles. Here ARMSp 
showed consistent high expression of AP2β and P-cadherin proteins, ERMS 
expressed endothelial growth factor and fibrillin-2, while ARMSn, although 
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presenting with the histopathology of ARMS also expressed some levels of ERMS 
proteins. This study described ARMSn as an intermediate between ARMSp and 
ERMS (Wachtel et al., 2004). Williamson et al. (2010) also described the presence of 
a third group, ARMSn, although some results showed that ARMSn and ERMS 
shared whole-chromosome copy number gains of chromosome 8, and high levels of 
expression of genes on this chromosome (Williamson et al., 2010). Stratification of 
patients with RMS uses a combination of clinical parameters with the presence or 
absence of PAX3/FOXO1 chimeric genes (Missiaglia et al., 2012). 
1.1.5 Ewing Sarcoma 
Ewing sarcoma (ES) is the second most common primary bone cancer after 
osteosarcoma that affects adolescent and young adults (Toomey et al., 2010). 
Baade et al. (2010) described the incidence of ES to be 12.5 cases per year in 
Australia between 1997-2006. The most recent study by the Cancer Institute of NSW 
reported 25 new cases of Ewing sarcoma (16 males and 9 females) between 2004-
2008 in children aged 0-14 years (Tracey et al., 2010) . 
 
James Ewing originally described ES in 1921. It is a highly aggressive bone and soft 
tissue associated malignancy, the most common sites being the lower extremities 
(45%), followed by the pelvis (20%), upper extremities (13%), axial skeleton and ribs 
(13%), and face (2%) (Burchill, 2003). ES’s aggressive biological behavior is 
reflected by the presence of metastases in around 25% of patients at diagnosis 
(Surdez et al., 2012). Morphologically, ES displays both mesenchymal stem cell and 
neural crest stem cell features, contains a tumour cell subpopulation with cancer 
stem cell properties, and is thought to arise from primary mesenchymal stem cells 
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(Suva et al., 2009). Sixty percent of patients with localized ES are treated with 
intensive chemotherapy, followed by surgery and/or radiotherapy. Metastatic ES has 
a poor prognosis, with 80% of these patients dying earlier than 5 years after 
diagnosis (Spraker et al., 2012). 
1.1.6 Osteosarcoma 
Osteosarcoma  (OS) is the most common type of bone cancer in children, with an 
average number of 12.1 cases diagnosed per year in Australia between 1997-2006 
(Baade et al., 2010). Between 2003-2007, 62 OS cases were diagnosed in children 
0-14 years old, whereas 88 cases were diagnosed in adolescents or young adults 
15-29 years old, representing 3% and 4.2% of cancers diagnosed, respectively 
(AIHW, 2011). 
 
The defining characteristic of OS is the production of osteoid, which is the 
unmineralized organic portion of the bone matrix that forms prior to the maturation of 
bone tissue, in malignant mesenchymal neoplastic cells (Ottaviano et al., 2010). OS 
can be divided into two broad groups, namely those that appear within the bone or 
intramedullary OS, which are highly malignant and most frequently occur during 
adolescence, and those that arise in the surface of bone, are classified as being less 
aggressive and contain cells that are either well or moderately differentiated (Rytting 
et al., 2000). Intramedullary OS in patients younger than 20 years of age originate 
from the metaphyseal region of long bones of arms and legs and the knees and 
shoulders in areas of rapid growth (Tan et al., 2009). OS is associated with 
progressive lung metastases (Longhi et al., 2006). An unusually high frequency of 
genome rearrangements and the presence of a complex karyotype are also 
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hallmarks of OS (Man et al., 2004). The most important predicting factor outcome 
remains the histologic response, or “regression grade”, to neoadjuvant 
chemotherapy, that aims to eradicate micrometastases and reduce tumour burden. 
This remains the gold standard for predicting outcome in patients with non-
metastatic OS at the time of surgery (Bacci et al., 2002; Smida et al., 2010). 
1.2 Cytogenetic changes in childhood cancers - relevance to prognosis 
1.2.1 Introduction to cytogenetic changes in cancer 
Events that could initiate tumourigenesis have been widely studied. These include 
the acquisition of somatic copy number aberrations (gains and losses in the number 
of gene copies) that involve amplification of oncogenes and/or loss of tumour 
suppressor genes (Fridlyand et al., 2006), point mutations, and structural 
rearrangements of the genes themselves. Such changes could reflect one or more 
mechanisms that work to maintain genomic integrity and/or to regulate cell cycle 
progression (Mattison et al., 2009; Snijders et al., 2003). 
 
The concept of gene amplification refers to an increase of at least five copies of a 
DNA segment that is less than 20 megabases in length, while gene gain refers to a 
lower copy number increase (Myllykangas et al., 2007). Gene gain results from 
ploidy changes or unequal translocations, is directed towards intact chromosomes, 
entire chromosome arms, or larger chromosomal regions and usually involves only 
one intra-chromosomal break-point (Myllykangas et al., 2007).  
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Amplification is one of the major mechanisms activating oncogenes in the course of 
cancer progression (Myllykangas et al., 2008). On the other hand, additional 
common events in cancer are the absence, loss or silencing of functional tumour 
suppressor genes. This occurs through chromosomal or intra-chromosomal 
deletions, inactivation of the remaining copy of the tumour suppressor gene through 
point mutations or by shutting down the gene promoter region by hypermethylation, 
leaving no functional tumour suppressor gene to protect the organism (Herman et 
al., 2003; Mao et al., 2007).  
1.2.2. Cytogenetic changes in neuroblastoma 
The DNA content of NB is usually divided into two categories. Near diploid/tetraploid 
cases suggest a less aggressive tumour with a fundamental defect in mitosis that 
produce whole chromosome gains or losses (Brodeur, 2003). In contrast, 
hyperdiploid tumours are more malignant, with a fundamental defect in genomic 
stability, and show chromosomal rearrangements, and unbalanced translocations 
(Caren et al., 2010). Amplification of the MYCN oncogene located on the distal short 
arm of chromosome 2 (2p24.3) is a prognostic marker for NB that was identified 
more than 20 years ago (Schwab et al., 2003). This oncogene is amplified in 20 - 
30% of all NB (Goto et al., 2001) and MYCN amplification is strongly associated with 
advanced disease stage and poor outcome. Tumours with MYCN copy number 
higher than 10 are classified as a high risk (Castel et al., 2007). Amplification of 
MYCN has also been described in RMS and ES (Williamson et al., 2005).  
 
A member of the tyrosine kinase family, Anaplastic Lymphoma Kinase (ALK), located 
at 2p23-24, is amplified in about 8% of all sporadic NB (Janoueix-Lerosey et al., 
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2008). This gene has a role in NB pathogenesis, along with deletion of KIF1B 
located at 1p36.2 and loss of CADM1 located at 11q23.3 (De Preter et al., 2006) 
(Kumps et al., 2013).  
Two different groups of aggressive NB have been identified, these being NB with 
MYCN amplification, and NB with chromosome 11q deletion (Cohn et al., 2009). 
Allelic loss of 11q is present in 35 - 45% of primary NB and is rarely observed in 
MYCN-amplified tumours (Attiyeh et al., 2005). Many other chromosomal 
abnormalities such as chromosome 1p, 3p and 11q deletions have also been 
identified as statistically significant prognostic factors in NB (Janoueix-Lerosey et al., 
2009). Genes targeted by cytogenetic changes in NB are summarized in Table 1.2. 
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Adapted from: Ambros et al. (2009), Boeva et al. (2013), Van Maerken et al. (2011) 
and Van Roy et al. (2009).  
 
  
 
Table 1.2 Genes targeted by cytogenetic changes in neuroblastoma  
 Cytogenetic Event Gene(s) targeted Cytoband(s) Prognostic factor 
    
Gene Amplification MYCN 2p24.3 Poor prognosis 
Copy number gain NME1, NME2, PPM1D 17q Poor prognosis 
Copy number gain Whole chromosome Chr 17+ Good prognosis 
Gene Amplification ALK 2p23-24 Poor prognosis 
 
  
 
Gene deletion CHD5, KIF1B 1p36.31 Increased risk of relapse 
Gene deletion CADM1 11q23.2 Poor prognosis 
Gene deletion RASSF1A 3p21.31 Poor prognosis 
Somatic Mutations TP53 17p13.1 Poor prognosis 
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1.2.3. Cytogenetic changes in rhabdomyosarcomas 
Genomic analysis shows that ERMS tumours have more structural and copy number 
variations than ARMS (Williamson et al., 2010). ERMS are typically characterized by 
loss of heterozygosity (LOH), which is understood as a gross chromosomal event 
leading to the loss of entire genes and surrounding regions (Joseph et al., 2014). 
This can include LOH of the short arm of chromosome 11 (11p15.5) where Kratz et 
al. (2007) found the same somatic HRAS mutation in 5 sporadic ERMS cases.  
 
ERMS has also been associated with mutations in the RAS/NF1 pathway, which are 
significantly associated with intermediate and high-risk prognosis (Chen. et al., 
2013). Many other chromosomal gains such as chromosomes 2, 7, 8, 12, 13 and 17 
have been associated with ERMS (Davicioni et al., 2009; Rao et al., 2010). However 
many more studies are needed to establish with certainty the prognostic significance 
of some of these chromosomal rearrangements (Chen. et al., 2013). Genes targeted 
by cytogenetic changes in ERMS are summarized in Table 1.3. 
 
Structural abnormalities of chromosomes result from chromosomal breakage and 
rejoining of the broken ends to form new combinations. In a reciprocal translocation, 
chromosomal material is exchanged between two or more nonhomologous 
chromosomes (Sandberg et al., 2000). ARMS are characterized by balanced 
translocations such as t(2;13)(q35;q14)  that produces a fusion gene between PAX3 
and FOXO1A, detected in 70% of  ARMS cases. The translocation t(1;13)(p36;q14) 
fuses PAX7 to FOXO1A in an analogous manner, and is detected in 10 - 15% of 
ARMS cases.  ARMS that do not present with typical translocations are called ARMS 
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negative (ARMSn), may harbour atypical translocations t(2:2) (p23;q35) or t(2;8) 
(q35;q13) leading to PAX3/NCOA1  and PAX3/NCOA2 fusions respectively, being 
detected in a subset of ARMSn cases (Sumegi et al., 2010). Other gene 
amplification events in ARMS may target genes such as MYCN (2p24), CDK4 
(12q13-q14) and MIR17HG (13q31), which encodes the polycistronic microRNA 
miR-17-92 cluster (Barr et al., 2009; Reichek et al., 2011) (Table 1.4). 
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     Table 1.3 Genes targeted in embryonal rhabdomyosarcoma 
 oncogeness 
     
Cytogenetic Event Gene(s) Targeted Cytoband(s) Prognostic significance 
Copy number gain TTC7A 2p21 Poor prognosis 
Copy number gain TNS1 2q35 Poor prognosis 
Copy number gain GLI2 2q14.2 Poor prognosis 
Copy number gain MOGAT1 2q36.1 Poor prognosis 
Copy number gain FGFR4 5q35.2-q35.3 Poor prognosis 
Copy number gain CREB3L1, DGKZ 11p11.2 Poor prognosis 
Copy number gain 
 
GLI1, GEFT, OS9, CDK4 12q13.3-q14.1 Poor prognosis 
Copy number loss PPP1R12B 1q32.1 Not yet identified  
Copy number loss PTPRG, FHIT 3p14.2 
 
Not yet identified  
Copy number loss 
 
F11, ANKRD37, UFSP2, 4q35.1-35.2 
 
Not yet identified  
Copy number loss CDKN2A/B 9p21.3 
 
Not yet identified  
Copy number loss NF1 17q11.2 
 
Poor prognosis 
Copy number loss ATXN10 22q13.31 
 
Not yet identified  
Somatic Mutations KRAS, NRAS  
 
12p12.1, 1p13.2,  
 
Poor prognosis 
Somatic Mutations PIK3CA 3q26.3 
 
Not yet identified  
Somatic Mutations TP53 17p13.1 
 
Not yet identified  
Loss of heterozygosity HRAS 11p15.5 Less aggressive 
    
 
Adapted from: Chen. et al. (2013), Davicioni et al. (2009), Kratz et al. (2007), Rao et 
al. (2010), and Shern et al. (2014). 
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Table 1.4 Genes targeted in alveolar rhabdomyosarcoma  
 
Cytogenetic Event Gene(s) Targeted Cytoband(s) Prognostic significance 
    
Gene amplification MYCN 2p24 Poor survival 
Gene amplification CDK4 12q13-q14 Poor survival 
Gene amplification miR-17-92 cluster 13q31 Poor survival 
 
 
 
 
 Chromosomal translocations PAX3/FOXO1A t(2;13)(q35;q14) Aggressive 
 Chromosomal translocations PAX7/FPOXO1A t(1;13)(p36;q14) 
Less aggressive than PAX3 
translocations 
 Chromosomal translocations PAX3/NCOA1 t(2;2)(p23;q35) Aggressive 
 Chromosomal translocations PAX3/NCOA2 t(2;8)(q35; q13) Aggressive 
    
 
Adapted from: Barr (2012), Cao et al. (2010), Kratz et al. (2007), Paulson et al. 
(2011) and Shern et al. (2014).  
 
  
  19 
1.2.4. Cytogenetic changes in Ewing sarcoma 
Ewing sarcoma (ES) is another example of a malignancy driven by a fusion 
oncogene. Characteristic causal translocations have been identified between the 
EWS gene on chromosome 22q12 and genes encoding two ETS transcription 
factors, namely FLI1 in chromosome 11q24 or ERG on chromosome 21q22 (Toomey 
et al., 2010). The EWS gene encodes a multifunctional protein involved in various 
cellular processes including gene expression, cell signalling and RNA processing 
and transport (Oakland et al., 2013; Paronetto et al., 2011).  Around 85% of ES 
cases present with t(11;22)(q24;q12) translocations which generate EWS/FLI1 fusion 
genes whereas another 5-10% present with t(21;22)(q22;q12) translocations that 
generate a ERG/EWS fusions (Toomey et al., 2010).  
 
The remaining 5% of ES shows alternate translocations that fuse EWSR1 (or a 
highly similar gene, TLS/FUS) (Ng et al., 2007; Shing et al., 2003) to genes encoding 
other ETS family transcription factors including ETV1, ETV4 and FEV (Im et al., 
2000; Jedlicka, 2010). EWS/FLI1 and alternate fusions have been classified as 
oncogenes based on their ability to transform immortalized murine NIH3T3 cells 
(Braunreiter et al., 2006). Jedlicka (2010) and Ludwig (2008) have proposed that 
tumour development occurs because the fusion between EWSR1 and FLI1 leads to 
the formation of a potent, highly expressed aberrant transcription factor able to 
activate an oncogenic program in the affected cells.  
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Other genomic alterations in ES include recurrent copy number gains of 
chromosome 1q, 8, 12, and 20 as well losses of 16q and 9p21 (Jahromi et al., 2012) 
(Table 1.5).   
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Table 1.5 Genes targeted in Ewing sarcoma 
    
Cytogenetic Event Gene(s) Targeted Cytoband(s) Prognostic significance 
    
Chromosomal translocation EWSR1-FLI1 t(11;22)(q24;q12) Good prognosis 
Chromosomal translocation EWSR1-ERG t(21;22)(q22;q12) Good prognosis 
Chromosomal translocation EWSR1-ETV1 t(7;22)(p22;q12) Good prognosis 
Chromosomal translocation EWSR1-ETV4 t(17;22)(q12;q12) Good prognosis 
Chromosomal translocation EWSR1-FEV t(2;22)(q33;q12) Good prognosis 
Chromosomal translocation FUS-ERG t(16;21)(p11;q22) Good prognosis 
Chromosomal translocation FUS-FEV t(2;16)(q35;p11) Good prognosis 
Chromosomal translocation EWSR1-ZSG inv(22) Good prognosis 
Copy number gain RELN 7q22.1-q31.1 Metastasis 
Copy number gain MYC 8q11.1-qter Poor prognosis 
Trisomy  Whole Chr 8+ 
 
Poor prognosis 
Copy number gain ZNF217, SUMO1P1, BCAS1 20p13-pcen 
 
Poor prognosis 
Copy number gain CEBPB 20q11.21-qter 
 
Poor prognosis 
Copy number gain SMARCB1 22q11.1-qter Metastasis 
Somatic Mutations TP53 17p13.1 Poor prognosis 
    
 
Adapted from: Huang et al. (2005), Jahromi et al. (2012), Jain et al. (2010) and 
Szuhai et al. (2012). 
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1.2.5. Cytogenetic changes in osteosarcoma 
As osteosarcoma (OS) is genetically unstable, with many translocations, 
amplifications and deletions, finding a common tumour-specific marker has not been 
possible (Wang, 2005). Nevertheless, common gains of chromosome arms 6p, 8q, 
12q and 17p were highlighted when the results of array comparative genomic 
hybridization were compared (Man et al., 2004; Sadikovic et al., 2009; Squire et al., 
2003). 
 
A variety of oncogenes have been implicated in OS tumourigenesis. Up to 12% of 
OS show MYC amplification, while MYC expression is also associated with a higher 
risk of relapse (Tang et al., 2008). Another oncogene associated with OS is MDM2, 
located on chromosome 12q14, and an important negative regulator of p53. MDM2 
is amplified in up to 10% of OS (Lopes et al., 2001). In the same genomic region lies 
CDK4, which is an important kinase regulating cell-cycle progression, and MDM2 
and CDK4 are reported to be often co-amplified (Martin et al., 2012; Smida et al., 
2010).  
 
At least three tumour suppressor genes have been associated with osteosarcoma, 
namely RB1, P16INK4A and TP53. RB1, in its hypophosphorylated state, acts as a 
tumour suppressor by binding to and inactivating E2F3, resulting in cell cycle arrest 
(Kansara et al., 2014). Approximately 70% of sporadic osteosarcoma cases have 
RB1 mutations, and RB1 inactivation has been implicated as a poor prognostic factor 
in OS (Marina et al., 2004). P16INK4A has been associated with the RB1 signalling 
pathway, and mutations in this gene mimic the RB1 mutation phenotype (Kansara et 
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al., 2007). P16INK4A mutations also serve as a poor prognostic factor in paediatric 
OS (Mohseny et al., 2009). TP53 is frequently mutated in patients with OS (Wagner 
et al., 2011). TP53 is a transcription factor that regulates cell cycle progression 
through apoptotic and DNA repair mechanisms (Sandberg et al., 2003). Studies 
have frequently reported point mutations, gene rearrangements, and allelic loss at 
the TP53 locus in OS (Tang et al., 2008) (Table 1.6). 
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Table 1.6 Genes targeted in osteosarcoma  
 
Cytogenetic Event Gene(s) Targeted Cytoband(s) 
Prognostic 
significance 
    
Copy number gain 
HIST2H2BE, HIST2H4B, FLG, 
 ARNT 1q21.1-q21.2 Metastases 
Copy number gain RUNX2 6p12.3-p21.1 Metastases 
Gene amplification CCND3-PTK7, RUNX2 6p12-p21 Poor prognosis 
Gene amplification VEGFA 6p21-p23 Poor prognosis 
Gene amplification FGFR1 8p11.2 Metastases 
Gene amplification MYC 8q24.21 Poor prognosis 
Copy number gain RECQL4 8q24.4 Poor prognosis 
Copy number gain FGF19 11q13 Poor prognosis 
Copy number gain EGFR 7p11.2 Poor prognosis 
Gene amplification VEGFA 6p21.1 Poor prognosis 
Gene amplification MDM2 12q13 Metastases 
Gene amplification CDK4 12q14 Poor prognosis 
Gene amplification E2F3 6p22 Poor prognosis 
Gene deletion LSAMP 3q13.31 Poor prognosis 
Gene deletion 
CDKN2A (also known as P16 and 
INK4A) 9p21 Poor prognosis 
Loss of heterozygosity PCDH15, ZWINT1 10q21.1 Poor prognosis 
Loss of heterozygosity PTEN 10q23.3 Poor prognosis 
Gene deletion WEE1, ST5, LMO1 11p15.1-15.4 Poor prognosis 
Mutation- Loss of 
heterozygosity RB1 
13q14.13-
13q14.2 Poor prognosis 
Mutation- Loss of 
heterozygosity TP53 17p13 Metastases 
 
   
 
Adapted from: Kansara et al. (2007), Kansara et al. (2014) Martin et al. (2012), 
Sadikovic et al. (2009), Sadikovic et al. (2013), Smida et al. (2010)   and Wagner et 
al. (2011). 
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1.2.6 Cytogenetic changes relevant to cancer therapy 
Many genes affected by the cytogenetic changes characterizing different types of 
tumours have been key to developing different targeted therapies. These include 
targeted agents that inhibit molecular pathways crucial for tumour growth and 
maintenance, and cancer immunotherapy that attempts to stimulate a host immune 
response to trigger long-lived tumour destruction (Vanneman et al., 2012). Targeted 
therapies and cytotoxic agents also modulate immune responses, which raises the 
possibility that these treatment strategies might be effectively combined with 
immunotherapy to improve clinical outcomes (Mellman et al., 2011; Vanneman et al., 
2012). 
 
Small-molecule drugs have been heavily explored and used as targeted therapies. 
The upper molecular weight limit of approximately 900 Daltons offers the advantage 
of compounds reaching intracellular sites easily. These small molecules can inhibit a 
specific function of a multifunctional protein, or disrupt protein-protein interactions 
(Arkin et al., 2004).  
  
There are many targeted agents in clinical trials, such as the small molecule Nutlin-3 
(Van Maerken et al., 2006). Preclinical data have shown potential therapeutic use of 
nutlin-3 in various paediatric tumours, including NB, RMS, ES and OS (Smith et al., 
2012).  Nutlin-3 belongs to the class of selective inhibitors of the p53-MDM2 
interaction that is currently most advanced in clinical development (Saha et al., 
2013).   
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1.3 Technical approaches to detect copy number changes in cancer 
1.3.1 Classical cytogenetics 
Classical cytogenetic analysis is based on chromosome banding patterns, most 
commonly produced by the Giemsa stain, that produces G banding. The number of 
alternating light and dark bands detectable with G-banding in the haploid genome 
varies with the level of chromosomal contraction in each metaphase cell, with a 
range of 350–550 bands per haploid set (Gersen, 2005). Since each band 
represents approximately 5-10 Mb of DNA, each band could potentially contain 
hundreds of genes (Kirchhoff et al., 2001) (Fig. 1.1). Despite classical cytogenetics 
not being considered a high-resolution technique, a significant strength is that it 
provides a global assessment of both numerical and structural abnormalities in a 
single assay (Table 1.7).  
 
The numerical abnormalities manifest as changes in complete sets of chromosomes, 
as triploid (3 N) or tetraploid (4 N) complements, or in the number of individual 
chromosomes, such as loss (monosomy) or gain (e.g. trisomy) of a single 
chromosome. However standard cytogenetic analysis is also a labour-intensive, 
comparatively costly, low-throughput technique reliant on highly trained technical 
staff, and is associated with a sample culture failure rate of 10 – 40% (Gersen, 
2005). There are additional concerns that the process of in vitro culturing may select 
for chromosomal abnormalities that are more viable under these conditions 
(Caramins et al., 2011).  
 
Mitelman et al. (2004) reported that although solid tumours represent most malignant 
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diseases, they could be under investigated due to difficulties in obtaining high-quality 
metaphase spreads compared with leukaemias, where metaphase chromosomes 
are readily obtained, and as a consequence, had been more thoroughly investigated 
using classical cytogenetics (Ozkinay et al., 1979). To overcome this metaphase 
quality problem, Bauman et al. (1980) first used Fluorescence In Situ Hybridization 
(FISH) to detect cryptic/submicroscopic abnormalities, leading to the rise of 
molecular cytogenetics, based on in situ hybridization (ISH) techniques (Bridge, 
2008). 
 
FISH was initially applied to metaphase chromosome spreads (Van Prooijen-Knegt 
et al., 1982) and since then, many applications have been found, including revealing 
trisomies, monosomies, fusion genes, specific genes, and translocations, among 
other applications (Lee et al., 2010). An important advantage of FISH, as opposed to 
conventional cytogenetics, is that it can be performed on nondividing (interphase) 
cells from fresh or aged samples (e.g., touch imprint cytological preparations, 
cytospin preparations, blood smears), sections of paraffin-embedded tissue, and 
disaggregated cells retrieved from fresh, frozen, or paraffin-embedded material. 
Importantly, this procedure can provide results when the tissue is insufficient or 
unsatisfactory for cytogenetic analysis, when conventional cytogenetic analysis has 
failed, or when cryptic rearrangements are present (Bridge, 2008). 
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Resolution capability  
 
 
Figure 1.1. Resolution capability of different methods to reveal different sized 
genomic imbalances. Karyotyping can detect large chromosome rearrangements 
with low resolution (5-10 Mb). FISH provides higher resolution (100 kb) for detecting 
submicroscopic genomic imbalances. Multiplex Ligation-dependent Probe 
Amplification (MLPA) and reverse transcription PCR (RT-PCR) complement FISH 
and Sanger DNA sequencing, but these methods present limited throughput, low 
information and the requirement of choosing candidate target genes before the test. 
High-resolution microarrays (Oligo microarrays, BAC array CGH) provide the most 
efficient means to identify genomic imbalances widely, with a resolution less than 500 
bp. Figure reproduced from Shen et al. (2009) 
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Table 1.7 Advantages and limitations of classical cytogenetic analysis 
 
 
Advantages 
 
• Gives global information in a single assay, includes primary and secondary 
anomalies 
• Knowledge of anticipated anomaly or historical diagnosis not necessary 
• Variants undetectable by interphase FISH or RT-PCR may be uncovered  
• Sensitive and specific 
• Can be performed on fine-needle aspirates 
• Provides direction for molecular studies of pathogenetically important genes 
 
Limitations 
 
• Requires fresh tissue 
• Although direct preparations can be performed, cell culture required (1-10 
days) 
• May encounter complex karyotypes with suboptimal morphology 
• Submicroscopic or cryptic rearrangements may result in false-negative results 
• Normal karyotypes may be observed following therapy-induced tumour 
necrosis or overgrowth of normal supporting stromal cells 
• Difficulties with bone tumours and release of cells from bone matrix 
 
 
Adapted from Bridge (2008), Gersen (2005). 
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1.3.2 Comparative Genomic Hybridization (CGH) and array CGH 
1.3.2.1 Comparative Genomic Hybridization (CGH) 
A. Kallioniemi et al. (1992) developed and were among the first to use Comparative 
Genomic Hybridization (CGH) in cell lines and primary bladder tumours. This 
technique, as originally developed, characterizes gross copy number changes, 
based on the same principles of FISH. However instead of hybridizing a 
chromosome band, or part of a fusion gene, fluorescently labelled DNA is applied 
throughout the entire genome (Holcomb et al., 2011). CGH uses two different DNAs, 
namely a reference DNA (usually normal DNA, typically labeled with a green 
fluorochrome) and a test DNA (tumour DNA, typically labeled red). The DNAs are co-
hybridized to a normal metaphase chromosome spread. The resulting fluorescence 
ratios of test to reference are then quantified by digital image analysis and used to 
identify genomic losses or gains in the test sample (Morozova et al., 2008). 
 
The resolution of CGH is relatively low (5-10 Mb) (Holcomb et al., 2011). CGH also 
required at least two weeks of meticulous work in the laboratory and the ability to 
accurately karyotype the human genome (Mantripragada et al., 2004). Limitations 
include being unsuitable to detect reciprocal translocations, Robertsonian 
translocations, inversions, and ploidy (Carter, 2007). On the other hand, CGH does 
not require previous knowledge of chromosomal imbalances to start the analysis and 
obtain satisfactory results (Morozova et al., 2008) 
  31 
1.3.2.2 Array Comparative Genomic Hybridization (aCGH) 
To overcome the problems of low resolution conventional CGH, Kallioniemi et al. 
(2008), using similar CGH principles, replaced metaphase chromosomes with 
arrayed DNA probes attached to a glass slide as targets for hybridization. This 
improved the performance of the technique and opened it to a range of possibilities 
and platforms for the array CGH (aCGH) age (Kallioniemi, 2008). 
 
 Different aCGH platforms have been developed, the first using bacterial artificial 
chromosomes (BAC), each containing 100-200 kb of genomic sequence. Due to this 
large target size, signals were more intense, resulting in better sensitivity to detect 
copy number changes (Pinkel et al., 2005). However BACs allowed only low 
genomic resolution, typically 1.5 Mb (Albertson et al., 2000). In 2004, a new version 
of BAC array, called tiling arrays, was able to cover a whole genome using 
overlapping sequences, achieving high resolution analysis of a test genome 
(Krzywinski et al., 2004). However, producing and maintaining approximately 30,000 
genomic clones (the number required for a full human genomic tiling path) was 
demanding and time consuming (Holcomb et al., 2011).  
 
Since 2004, other probe substrates have been used in aCGH including small insert 
genomic clones (1.5-2.5 kb), cDNA’s (0.5-2 kb), PCR products (0.1-1.5 kb) and 
oligonucleotides (25-85 bp) (Carter, 2007). Also the completion of the human 
genome project had an impact on the availability of probes for aCGH; as probe 
availability was previously been restricted by available knowledge (Zhang et al., 
2009). The spacing and lengths of the DNA probes determine the genomic resolution 
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of different aCGH platforms. Oligonucleotide arrays can provide higher resolution 
(usually 5-50 kb), but show lower sensitivity, and can fail to reliably detect low-copy 
number changes due to poorer signals (De Lellis et al., 2007). 
 
One of the first uses for CGH was in cancer, and similarly aCGH has been used in 
different types of cancers such breast cancer, glioblastoma, rhabdomyosarcoma, 
ovarian cancer, gastric cancer, prostate cancer (Kallioniemi, 2008; Shinawi et al., 
2008; Watson et al., 2007), haematological cancers (Schwaenen et al., 2004), and 
bladder tumours (Shaffer et al., 2004). Similarly, aCGH has been applied to human 
genetic disorders, such as Cri du Chat syndrome caused by partial deletion of 
chromosome 5p (Levy et al., 2002), Prader-Willi syndrome, and Angelman syndrome 
(Buiting, 2010). In both syndromes, the majority of cases are the result of a 3–5 Mb 
deletion of the Prader-Willi syndrome, and Angelman syndrome critical region on 
chromosome 15q. These small aberrations cannot be detected using cytogenetics or 
conventional CGH, but can be readily detected using aCGH (L'Hermine et al., 2003) 
(Table 1.8). 
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Table 1.8 Advantages and limitations of aCGH 
 
 
Advantages 
• High reproducibility and precise mapping of aberrations 
• No need for cell culture, so turn around time is shorter than with cytogenetic 
methods 
• Requires only few micrograms of DNA 
• aCGH can reveal unsuspected genomic imbalances 
• aCGH detects genomic duplications that cannot be identified by metaphase or 
interphase FISH analysis 
 
Limitations 
• Unable to identify balanced rearrangements such as translocations and 
inversions 
• Unable to detect polyploidy 
• Costly equipment and reagents 
 
 
Adapted from: Ballif et al. (2006), Shinawi et al. (2008) and Holcomb et al. (2011).  
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1.3.3 Multiplex Ligation-dependent Probe Amplification (MLPA) and 
Quantitative Polymerase Chain Reaction (qPCR) 
Basic principles for conventional Polymerase Chain Reaction (PCR) will be 
mentioned because MLPA and quantitative PCR (qPCR) are based on this 
technique. PCR amplifies a single copy or a few copies of a piece of DNA across 
several orders of magnitude, generating thousand to millions of copies of a particular 
DNA sequence (Bartlett et al., 2003). The method relies on the thermal cycling, 
consisting of cycles of repeated heating and cooling of the reaction for DNA melting 
and enzymatic replication of the DNA. The PCR uses a DNA template (target DNA), 
at least one pair of specific primers (short fragments of DNA, that contain sequences 
complementary to the target region), deoxyribonucleotides (dNTPs), a suitable buffer 
solution and a thermo-stable DNA polymerase.  
 
In the first step, the two strands of the DNA double helix are separated (or 
“denatured”) at a high temperature of 94-98°C. In the second step, the temperature 
is lowered to 50-65°C to allow PCR primer annealing for selective target DNA 
amplification and this temperature cycle is repeated many times. In the third step, the 
temperature rises 72°C and the DNA polymerase synthesizes a new DNA strand. 
The extension time depends both on the DNA polymerase used, and the length of 
the DNA fragment to be amplified. The final step is usually performed at 70-74°C for 
5-15 minutes after the last PCR cycle to ensure that any remaining single-stranded 
DNA is fully extended (Carr et al., 2012). Thus, PCR presents three stages, namely 
exponential amplification, in which the amount of product doubles every cycle, the 
levelling off stage, where the reaction slows as the DNA polymerase loses activity 
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and as consumption of reagents such as dNTPs and primers causes them to 
become limiting, and finally the plateau stage, where no more product accumulates 
due to exhaustion of reagents and enzyme (Pavlov et al., 2004). 
1.3.3.1 Multiplex ligation-dependent probe amplification (MLPA) 
Multiplex ligation-dependent probe amplification (MLPA) is a technique for detecting 
copy number changes of human genomic DNA sequences using DNA samples 
derived from blood, amniotic fluid, or tumours (Buffart et al., 2009; Kluwe et al., 2005; 
Slater et al., 2003). MLPA is a variant of multiplex PCR, in that MLPA amplifies 
multiple target genes at the same time. The MLPA reaction can be divided in four 
main steps as outlined in Fig 1.2.  
 
The first step involves DNA denaturation and probe hybridization, each probe being 
composed of two “half probes” forward and reverse primer sequences, respectively. 
Both halves with a target-specific sequence flanked by a universal primer; one of 
these half probes also has a variable length stuffer fragment in between to generate 
the size differences necessary in the probe to allow electrophoretic resolution. In the 
second step, a specific ligase enzyme ligates the two parts of each MLPA probe to 
each other. This is followed by PCR amplification using the universal primer pair. 
Finally, DNA fragments are separated according to the unique length of each 
amplicon, followed by quantification according to peak height or area, allowing the 
calculation of relative amounts of target DNA sequences in the input DNA sample 
(Kozlowski et al., 2008; Langerak et al., 2005; Patrinos et al., 2009; Stuppia et al., 
2012) (Figure 1.2).  
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Figure 1.2 Outline of Multiplex Ligation-dependent Probe Amplification 
technique. The MLPA reaction can be divided in four main steps: (1) DNA 
denaturation and probe hybridization; (2) ligation reaction, (3) PCR amplification, and  
(4) DNA fragment separation and data analysis. Reproduced from MRC-HOLLAND 
MLPA®. https://www.mlpa.com. 
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The MLPA technique has been applied to neuromuscular disorders, as they are 
generally caused by deletions or duplications of specific genes (Uwineza et al., 
2013). MLPA has been applied to the diagnosis of spinal muscular atrophy (SMA), 
Charcot Marie Tooth, and hereditary neuropathy with liability to pressure palsies 
(HNPP) (Stuppia et al., 2012). MLPA has been demonstrated to be a powerful tool 
for the study of disorders that are caused by deletions or duplications of specific 
genes (Table 1.9). 
 
1.3.3.2 MLPA and Cancer 
MLPA has been used to analyze germline deletions/duplications in genes related to 
hereditary cancer, for example BRCA1 and BRCA2 in ovarian and breast cancers, 
APC in familial adenomatous polyposis, and mismatch repair genes in hereditary 
non-polyposis colorectal cancer (Chan et al., 2006; Montagna et al., 2003; Nielsen et 
al., 2007). This technique has also been applied to assess amplification of the HER-
2/neu gene encoding a transmembrane tyrosine kinase, which represents a 
prognostic marker and a therapeutic target for breast cancer (Purnomosari et al., 
2006). 
MLPA has been used to study paediatric cancers such as leukaemia. Veronese et al. 
(2013) compared the results obtained using MLPA and interphase FISH (iFISH) in 
77 chronic lymphocytic leukaemia (CLL) patients, based on characteristic 
chromosome abnormalities of this leukaemia. They used a commercial MLPA kit for 
CLL, and concluded that MLPA could be used as first-line diagnostic test to detect 
recurrent aberrations in CLL, however this technique needs to be complemented 
with iFISH and other molecular techniques.  MLPA has been used for diagnosis of 
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melanocytic tumours since the histopathology sometimes presents problems 
(McGinnis et al., 2002). Takata et al. (2005) analysed paraffin-embedded tissue 
sections of 24 primary melanomas, 14 Spitz nevi and 17 common melanocytic nevi, 
using commercially available MLPA kits that showed copy number changes in 76 
genes spanning almost all chromosome arms. Results from this study concluded that 
MLPA could be used as an adjunctive diagnostic tool for melanocytic tumours 
(Takata et al., 2005). This technique has also been used in Wilm’s tumour (Hollink et 
al., 2009), Li-Fraumeni syndrome (Ruijs et al., 2010), medulloblastoma (Jackson et 
al., 2009), ependymoma (Evans et al., 2007), retinoblastoma (Quelin et al., 2009) 
and gliomas (Jeuken et al., 2007).  
 
MLPA may be used for detecting common genetic alterations in neuroblastoma, and 
new kits have been tuned by the manufacturer to fit specific needs. In cooperation 
with SIOP Europe Neuroblastoma Biology MLPA Committee, a new kit was 
developed for risk evaluation in neuroblastoma based on 310 neuroblastomas and 8 
neuroblastoma cell lines, and results were validated by FISH, BAC array-CGH and 
SNP-array. This study resulted in the redesign of the corresponding MLPA kit and a 
formulation of interpretation standards that were much more successful, making this 
technique cost-effective, reliable and robust for this type of cancer (Ambros et al., 
2011). In terms of the scope of the current project, it is worth highlighting that MLPA 
has not been previously used in a mixed tumour cohort including the types of solid 
tumours under study.  
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Table 1.9 Advantages and limitations of MLPA 
 
 
Advantages 
• Semi-quantitative technique that can discriminate sequences that differ by only a 
single nucleotide 
• Reported to require only 20 ng genomic DNA 
• High throughput technique, as results can be available within 24 hours when loading 
a maximum number of 96 samples (depending on thermocycler capacity) 
• Can examine more than 40 genes per reaction 
• Less expensive per sample than FISH, requires less manpower and is not observer 
dependent  
• Works well on fragmented DNA 
• Could be used as an initial screening tool in research and diagnostic settings 
 
Limitations 
• Only relative changes in copy number are detected. It is not possible to distinguish 
polyploidy from diploidy or haploidy.  
• Does not detect balanced translocations or inversions 
• Not suitable for the detection of unknown point mutations 
• More sensitive to contaminants (e.g., small remnants of phenol) and DNA 
degradation than conventional PCR 
• In tumour samples, it is difficult to detect gene deletions if the sample from which the 
DNA was derived contained less than 50% cancer cells. 
• Results may be compromised by the presence of unreliable MLPA probes and 
unsuited reference material 
 
 
Adapted from: Bravaccini et al. (2012), Homig-Holzel et al. (2012), Nicholson et al. 
(2013), Schouten et al. (2002) and Stuppia et al. (2012).  
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1.3.3.3 Quantitative Polymerase Chain Reaction (qPCR) 
In conventional PCR, amplicons are detected by end-point analysis, whereas in real-
time PCR, accumulation is measured as the reaction progresses or in real time, also 
known as quantitative PCR (qPCR) (Vandesompele et al., 2002). Detection is made 
possible by including a fluorescent molecule that reports an increase in the amount 
of DNA, with a proportional increase in fluorescent signal as the PCR progresses. 
PCR amplicon accumulation can be measured by a variety of fluorescent detection 
chemistries, such as the generic double-stranded DNA binding dye SYBR Green I, 
or sequence-specific probes such TaqMan, adjacent hybridization probes, or 
molecular beacons.  
 
The excitation and emission maxima of SYBR Green I, allow the use of this dye with 
any real-time thermocycler (Zipper et al., 2004), also it requires the use of melting 
curve analysis. Detection takes place during the extension step of real-time PCR. 
The fluorescent signal is directly proportional to the DNA concentration, and the 
linear correlation between PCR product and fluorescent intensity is used to calculate 
the amount of template present at the beginning of the reaction.  
 
Absolute quantification requires the addition of external standards in every reaction 
to determine the absolute amount of the target nucleic acid of interest. Quantities 
obtained from a qPCR experiment must be normalized in such a way that the data 
become biologically meaningful. This is done by using a normalizer or housekeeping 
gene to correct for intersample variations between different experiments, and to 
adjust or standardize the obtained target quantity to the unit amount of sample 
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(number of cells or micrograms of nucleic acid) used as a PCR template (Sails et al., 
2009) (Table 1.10). 
 
qPCR has been used in different fields. In microbiology, qPCR is used to analyze 
food safety, food spoilage and fermentation and for microbial risk assessment of 
water quality (Gadkar et al., 2013). qPCR is applied for diagnosing infectious disease 
(Sails et al., 2009), such as the Swine flu outbreak in humans (Poon et al., 2009).  
 
qPCR remains the method of choice for validating results obtained from whole-
genome screening techniques such as aCGH (Benes et al., 2010), and is also an 
important technique for the analysis of circulating tumour cells (CTC). These cells 
are released from the primary tumour and enter the blood circulation, from where 
they can migrate to distant organs, implant and produce metastasis. Analysis of CTC 
includes an initial enrichment step with use of specific markers to identify the cells 
and distinguish them from leukocytes. qPCR offers a significant improvement over 
conventional reverse transcription PCR, as the quantification of markers present in 
both tumour and non-tumour cells allows the discrimination between authentic CTCs 
and contaminant cells (Alunni-Fabbroni et al., 2010; Xi et al., 2007).  
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Table 1.10 Advantages and limitations of qPCR 
 
 
Advantages 
• Simple and straightforward technique  
• No need for post-PCR manipulations 
• High throughput screening capacity and degree of automation 
• Can be performed with minimal amounts of sample (25 ng of DNA) in a few 
hours time 
• High technical sensitivity (<5 copies) and a high precision (<2% standard 
deviation)  
 
Limitations 
• The amplicon size cannot be monitored without opening the system  
• Requires a reliable source of template of known concentration for absolute 
quantification  
• Costly compared to MLPA and conventional PCR 
• Standards must be amplified in parallel with the sample every time the 
experiment is performed, which increases the cost and time per reaction  
 
 
Adapted from: Bartlett et al. (2003), Bustin et al. (2009), Dhanasekaran et al. (2010), 
Wang et al. (2013a) and Zipper et al. (2004).  
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1.4 Chromosome 8q gain in adult cancers  
The gain of the long arm of chromosome 8 is one of the most common cytogenetic 
events that occur in cancer. The entire chromosomal arm is often gained, which may 
reflect that chromosome 8q harbours multiple oncogenes. Proposed chromosome 8q 
amplification targets include MYC, MAL2, WWP1, and TPD52 (Saramaki et al., 
2007), but there are likely others to be identified. As will be described, it is not fully 
understood whether the same or different genes are targeted in different tumours. 
1.4.1 Breast cancer 
Several studies have demonstrated that chromosome 8 is very frequently altered in 
breast cancer. Rummukainen et al. (2001) reported chromosome 8q gains that often 
included either the whole q arm or the telomeric region, whereas chromosome 8p 
showed either diploid copy number or loss. Naylor et al. (2005) also underlined the 
gain of 8q24 from 139.3-144.8 Mb in 79% (37/47) primary breast tumours and 83% 
(15/18) breast cancer cell lines. This emphasized a number of genes of potential 
interest such as MYC, PTK2 and KCNK9. Two years later, using a high resolution 
BAC array, Rodriguez et al. (2007) revealed many novel regions of copy number 
gain/loss in the SK-BR-3 breast cancer cell line, with amplification of LACTB2, 
ZFHX4, MMP16, and DECR1, all located on chromosome 8, as well as copy number 
loss at TP53INP1, ZFPM2 and COL22A1. These new findings were validated using 
FISH probes (Rodriguez et al., 2007). One of the most commonly amplified genes in 
breast cancer is the oncogene MYC located at 8q24, and its role as a driver in the 
8q24 amplicon is well established (Kao et al., 2009; Rodriguez et al., 2007). MYC is 
amplified in approximately 5% of breast cancers and is associated with high grade, 
  44 
advanced stage, and poor patient survival (Chen et al., 2008; Rodriguez-Pinilla et al., 
2007).  
 
Other chromosome 8q amplicons have been associated with breast cancer. 
Choschzick et al. (2010) used a tissue microarray that contained 2000 breast 
cancers to study the significance of proximal chromosome 8q21 amplification in 
terms of breast cancer phenotype and patient prognosis. TMEM70 amplification was 
found to be significantly associated with reduced overall survival (Choschzick et al., 
2010). Other specific amplicons at chromosome 8q24.3, 8p11.2, and 17q21.33-
q25.1 were associated with early relapse in estrogen receptor-positive breast 
cancers, despite adjuvant hormonal therapy (Bilal et al., 2012).  
 
The chromosomal region 8p11-p12 has been found frequently amplified in 10%-15% 
breast carcinoma cases (Ethier, 2003). Turner et al. (2010) confirmed that 
overexpression of FGFR1 located at 8p11-p12 was highly correlated with copy 
number gain. FGFR1 amplification was also a frequent event in the proliferative 
luminal B subtype, and ER-positive breast cancers, suggesting that FGFR1 
overexpression may contribute to the poor prognosis of breast cancer (Turner et al., 
2010).  
1.4.2 Prostate cancer  
Aberrations of chromosome 8 are one of the most frequent cytogenetic changes in 
prostate cancer (Hughes et al., 2006), with deletions of 8p and gains of 8q being 
among the most frequent genomic alterations (El Gammal et al., 2010). Using FISH, 
El Gammal et al. (2010) analysed 1,954 prostate cancers in tissue microarray 
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format, and concluded that whereas 8p deletions and 8q gains were relatively rare in 
early stage prostate cancer, 8q gains markedly increased from primary to metastatic 
cancers (El Gammal et al., 2010). Monoallelic deletions on chromosome 8p were 
associated with more advanced invasive and aggressive prostate cancers (Bethel et 
al., 2006).  
1.4.3 Colorectal cancer 
One of the most common cancers is colorectal cancer (CRC) and in the majority of 
patients the tumour has already metastasized to lymph nodes and/or the liver at the 
time of diagnosis (Ghadimi et al., 2003). Chromosomal abnormalities occur in a non-
random pattern along the pathway from adenoma to carcinoma and then to 
advanced lesions and the formation of metastases (Berg et al., 2010). Using data 
from 244 CRC cases previously analysed by CGH Li et al. (2011) applied a 
branching tree and multiple distance-based tree models to identify the six most 
common gains of chromosomal regions. Chromosome 8q gain was present in 48.3% 
of cases, and loss of chromosome 8p12-p23 in 50.9% of cases was also among the 
nine most common losses (Li et al., 2011).  
1.4.4 Human cancer cell lines 
By combining high-resolution aCGH analysis of 598 human cancer cell lines with 
insertion sites from 1,005 mouse tumours, Mattison et al. (2010) created a cross-
species oncogenomic data-set to reveal candidate tumour suppressor genes and 
oncogenes mutated in both human and mouse tumours. In this study, 27 genes were 
recurrently amplified in human tumours, with 6 genes located on chromosome 8, 
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namely MYC, SLA, TRP53INP1, PTP4A3, PAG1, and TPD52 (Mattison et al., 2010). 
Some of these genes are already well-known oncogenes, or genes implicated in 
cellular processes including growth, and tumourigenesis. This study again 
highlighted that chromosome 8 has an important role in tumourigenesis and cancer 
progression (Mattison et al., 2010). 
1.5 Chromosome 8 gain in childhood cancers  
A clear association between DNA copy number aberrations and prognosis has been 
found in a variety of childhood tumours (section 1.2). However, chromosome 8q gain 
has been poorly characterized in childhood tumours, relative to common adult 
cancers. 
1.5.1 Neuroblastoma 
The MYC family has three members: MYC, MYCN and MYCL, and all have been 
implicated in different cancer types (Prochownik et al., 2007).In human 
neuroblastoma (NB), a significant body of literature describes basic, translational, 
and clinical data on MYCN whereas little is known and reported about the role of 
MYC on chromosome 8q24.21 (Wang et al., 2013b). Some MYC transcription 
factors, including MYCN, also induce apoptosis, a function that should inhibit tumour 
formation and could be involved in spontaneous tumour regression, a phenomenon 
that is present in some NB (Adhikary et al., 2005).  
 
Interestingly, neuroblastoma-derived cell lines that lacked amplified MYCN, 
expressed MYC at abnormal levels (Westermann et al., 2008). Similarly, MYC 
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protein expression was almost exclusively found in MYCN-non-amplified tumours, 
and this was associated with poor prognosis for the undifferentiated subtype (Wang 
et al., 2013b). Although chromosome 8 aberrations are not the most common in NB, 
Pezzolo et al. (2009) reported 6/23 NB cases with chromosome 8q24.3 gain using 
aCGH (Fig 1.3). Similarly, Ambros et al. (2011) reported, among other chromosome 
aberrations, infrequent additional segmental aberrations in chromosome 8 in 4/10 
neuroblastic tumours: copy number gain in chromosome 8p in 2 cases, and copy 
number gain and loss of chromosome 8q in the other 2 cases (Ambros et al., 2011).  
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Figure 1.3 Summary of patterns of total gains and losses detected in 23 
localized resectable neuroblastoma samples. Summary of patterns of total gains 
(right, green lines), and losses (left, red lines), with numbers of cases on top of each 
line in 23 neuroblastomas using array-CGH. Reproduced from Pezzolo et al. (2009). 
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1.5.2 Rhabdomyosarcoma 
Gain of chromosome 8 is one of the most common chromosomal alterations in 
ERMS and ARMSn (Fig 1.4) (Williamson et al., 2010). Increased expression of 
chromosome 8 genes was reported in ERMS tumours with chromosome 8 gains 
relative to those tumours without gain (Chen. et al., 2013). ARMSn cases may 
harbour atypical t(2;8)(q35;q13) translocations producing PAX3/NCOA2 fusion 
genes (Sumegi et al., 2010), which have been postulated to play a dual role in RMS 
tumourigenesis by inhibiting myogenic differentiation and promoting cell proliferation 
(Yoshida et al., 2013). Using hierarchical clustering analysis of gene expression in 
160 RMS, two main groups of RMS were found.  The group that expressed the 
chimeric transcription factor PAX3/FOXO1 or PAX7/FOXO1 were mainly ARMS. It 
was noted that genes with increased expression in tumours lacking PAX/FOXO1 
translocations were mostly localized on chromosome 8q, specifically at chromosome 
8q24 (Davicioni et al., 2009). 
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Figure 1.4 Frequency of specific amplifications and gains in ARMSp versus 
ARMSn and ERMS. A. Plots of frequency of gains (red), losses (green), and 
amplifications (black) by subtype ARMSp are represented by PAX3/FOXO1 and 
PAX7/FOXO1 fusion positive cases, whereas ERMS and ARMSn involve more 
whole-chromosome changes B. Frequency of specific changes listed by RMS 
subtype. Reproduced from Williamson et al. (2010).  
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1.5.3 Ewing Sarcoma 
Gain of chromosome 8 is one of the most frequent chromosome alterations in Ewing 
sarcoma (Toomey et al., 2010). For example, in the study of Savola et al. (2009), 
gain of chromosome 8q was the most frequent copy number change, occurring in 
67% (21/31) cases (Fig 1.5). Trisomies of chromosome 8, 12 and gain of 
chromosome 1q have been associated with poor clinical outcome in Ewing sarcoma 
(Amiel et al., 2003; Roberts et al., 2008). MYC was proposed as a candidate driver 
linked to poor prognosis, as trisomy 8 can be full or partial, and sporadic cases can 
show focal MYC gain (Jahromi et al., 2012). Full or partial trisomy 8 is associated 
with poor clinical outcome and this significance increased when focal MYC gains 
were considered (Jahromi et al., 2012; Mackintosh et al., 2010). 
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Figure 1.5 Chromosomal locations of copy number changes in Ewing sarcoma 
samples (n=31). The ideogram shows the summary of gains and losses of DNA 
copy number and their frequencies in Ewing sarcomas (n=31) analysed by aCGH. 
Gains (green) are shown on the right of each chromosome and losses (red) on the 
left (numbers refer to the percentages of gain or loss per band). Reproduced from 
Savola et al. (2009).  
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1.5.4 Osteosarcoma 
Chromosome 8q gain was identified as the most frequent aberration in 47 high-grade 
osteosarcoma samples (Ozaki et al., 2002). Copy number gain at 8q24 harbouring 
MYC is one of the most frequent genomic alterations that has been also associated 
with adverse overall survival (Mirabello et al., 2010; Smida et al., 2010).  
 
Other regions on chromosome 8q including 8q21.3-8q23, and 8q21 commonly 
present copy number gain, suggesting that other oncogenes located within these 
bands could have roles in osteosarcoma pathogenesis (Fig 1.6) (Batanian et al., 
2002; Bayani et al., 2003; Kresse et al., 2009). Copy number loss on 8p also has 
been associated with sporadic osteosarcoma (Atiye et al., 2005; Squire et al., 2003). 
An integrative approach involving integrative whole-genome analysis of DNA copy 
number, promoter methylation, and gene expression analysis in 10 primary 
osteosarcomas showed the region with the most significant copy number loss was 
chromosome 8p21.2-p21.3 (Sadikovic et al., 2009).  
  
  54 
 
  
 
 
 
 
 
 
 
Figure 1.6 Genetic aberrations in human osteosarcomas samples 
The X axis numbered with 1-22 denotes chromosome numbers, whereas the Y axis 
shows the fractions of tumours with gain or loss. Red denotes significantly recurrent 
amplifications and green denotes significantly recurrent deletions. Grey represents 
nonsignificant of aberrations. A. Genetic aberrations in 20 osteosarcomas measured 
using aCGH B. Genetic aberrations in 36 Norwegian osteosarcomas measured 
using BAC arrays. Reproduced from Du et al. (2014). 
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1.6 Statement of the problem, hypothesis and aims of this research  
Human chromosome 8 contains a number of important genes that are amplified in 
adult cancers. Specifically, the long arm of chromosome 8 is often gained, reflecting 
the multiple oncogenes it harbours, including MYC, WWP1 and TPD52, although 
others may remain to be identified. In contrast, chromosome 8 gain has been 
comparatively poorly characterized in paediatric solid tumours. 
 
In this research, we will explore and determine the significance of copy-number 
changes on chromosome 8 in 4 different types of paediatric solid tumours, namely 
osteosarcoma, Ewing sarcoma, rhabdomyosarcoma and neuroblastoma. The study 
will be based on a total of 31 cases obtained from the Tumour Bank, Children’s 
Hospital at Westmead. 
1.6.1 Hypotheses 
(1) Critical chromosome 8 amplification target genes contribute to the formation 
and progression of paediatric solid tumours. 
Aim: To produce and mine genomic profiles for a cohort of human cancer 
cell lines, and paediatric solid tumours diagnosed at Children’s Hospital at 
Westmead using the MLPA Salsa kit for chromosome 8, and high-density 
array comparative genomic hybridization. 
(2) Different methods of detecting copy number changes should produce 
comparable results.  
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Aim: To compare results obtained using MLPA and high-density aCGH. A 
validating third technique, quantitative PCR, will be used to examine 
agreements or disagreements between the techniques. 
 
In summary, this project has the capacity to identify novel amplified genomic regions, 
particularly in childhood cancers that have been under-investigated relative to other 
types, and to compare MLPA and aCGH as research and diagnostic tools. 
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Chapter 2  
Materials and Methods 
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2.1 Materials 
   
Table 2.1 Reagents and suppliers   
   
   
Reagent Supplier Application 
   
   
Agarose Bio-Rad DNA quality 
verification 
DNase/RNase-free distilled water 
 
Invitrogen aCGH, qPCR, 
MLPA 
DNeasy Blood & Tissue Kit Qiagen DNA extraction 
Ethanol (95% to 100% molecular biology grade) 
 
Promega DNA extraction, 
aCGH 
Proteinase K Qiagen DNA extraction 
QuantiFast SYBR Green Kit Qiagen qPCR 
Male genomic DNA Promega MLPA 
SALSA MLPA Probemix P014-B1 Chromosome 8 MRC-Holland MLPA 
Genomic DNA Enzymatic labelling kit Agilent aCGH 
Rsa I BioLabs aCGH 
Alu I BioLabs aCGH 
Agilent Oligo aCGH hybridization kit Agilent aCGH 
Agilent Oligo aCGH wash buffer 1 and 2 set Agilent aCGH 
Hybridization chamber Agilent aCGH 
Stabilization and Drying solution Agilent aCGH 
1x TE (pH 8.0), Molecular grade  Promega aCGH 
Amicon Ultra-0.5, ultracel-30 Membrane, 30kDa. Millipore aCGH 
SurePrint G3 CGH Customized microarrays 2X400K  Agilent aCGH 
Hybridization chamber, stainless Agilent aCGH 
Human Cot-1 DNA Invitrogen aCGH 
Male and female human reference DNA Coriell Institute aCGH 
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2.2 Breast cell lines  
This project used 5 breast cancer cell lines AU-565, HCC2157, MCF-7, 
MDA-MB-231, and SK-BR-3 and a breast epithelial cell line MCF-10A, a near normal 
breast cell line that was spontaneously immortalized and does not show 
characteristics of invasiveness or tumour formation (Marella et al., 2009). All cell 
lines were already in the laboratory from previous projects, and all of them had been 
previously short tandem repeat-typed to ensure they were correct and 
uncontaminated. In general the cell lines were stored in liquid nitrogen and thawed 
by placing sample tubes in a room temperature water bath until half of each tube 
was thawed. Thereafter cells were transferred to a new tube containing 500µL RPMI 
media, centrifuged for 1 min at 2000 rpm at RT, and the supernatant was discarded. 
Cells were plated in 10 cm tissue culture dishes and cultured in RPMI media (Life 
Technologies) supplemented with 10% foetal bovine serum (FBS) (Life 
Technologies) in a humidified incubator at 37˚C with 5% CO2 until 80% of cells were 
confluent. Cells were then harvested by scraping the tissue culture dish for genomic 
DNA extraction.  
2.3 Paediatric solid tumour cohort 
Tumour tissues was removed through surgery from patients by qualified staff and 
stored in the Tumour Bank at the Children’s Hospital at Westmead. Parental or 
guardian consent was obtained for the use of tissue samples in unspecified future 
research. Four different types of solid tumours were received, namely osteosarcoma 
(5 samples), Ewing sarcoma (8 samples), rhabdomyosarcoma (8 samples) and 
neuroblastoma (10 samples), for a total of 31 tumour tissue samples. All samples 
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were from different patients; 26 tumour samples were taken at diagnosis and 5 
tumour samples were post chemotherapy (Table 2.2). Tumour tissue specimens 
were then stored at -80˚C in the Tumour Bank at the Children’s Hospital at 
Westmead. Frozen tumour tissues were used for genomic DNA extraction.  
Patients were diagnosed between 1986 and 2009. Specimens were de-identified 
with a laboratory number to protect patient identity (Table 2.2). Dr Lesley Thwe and 
Ms Amanda Rush obtained relevant clinical data through their access to patient 
databases and medical records of The Children’s Hospital at Westmead.  
This project was approved by the Human Research Ethics Committee, Sydney 
Children’s Hospitals Network and the Children’s Hospital Tumour Bank at 
Westmead. 
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Table 2.2 Summary of paediatric tumour cohort 
     
Sample 
ID 
Patient 
Gender Diagnosis   Age at diagnosis 
Sample 
status 
F 9-O F Osteosarcoma 13 years - 6 months Diagnosis 
F 10-O F Osteosarcoma 9 years -11 months Diagnosis 
M 11-O M Osteosarcoma 15 years Diagnosis 
F 12-O F Osteosarcoma 4 years - 9 months Diagnosis 
M 46-O M Osteosarcoma 10 years - 11 months Diagnosis 
M 13-E M Ewing Sarcoma 2 years - 5 months Diagnosis 
M 14-E M Ewing Sarcoma 10 years -1 month Diagnosis 
F 15-E F Ewing Sarcoma 11 years - 2 months Diagnosis 
M 16-E M Ewing Sarcoma; PNET 11 years - 2 months Diagnosis 
F 17-E F Ewing Sarcoma 10 years - 9 months Diagnosis 
F 18-E F Ewing Sarcoma 5 years - 3 months Diagnosis 
M 22-E M Ewing Sarcoma 13 years -11 months 
Diagnosis 
F 24-E F Ewing Sarcoma 7 years - 10 months Diagnosis 
M 25-R M Rhabdomyosarcoma; Embryonal 7 years - 10 months Diagnosis 
F 26-R F Rhabdomyosarcoma; Embryonal 1 year - 7 months Diagnosis 
M 27-R M Rhabdomyosarcoma; Alveolar 13 years - 3 months Diagnosis 
F 28-R F Rhabdomyosarcoma; Embryonal 10 years - 8 months Diagnosis 
F 29-R F Rhabdomyosarcoma; Embryonal 2 years - 7 months Diagnosis 
M 31-R M Rhabdomyosarcoma; Embryonal 4 years - 4 months Diagnosis 
M 32-R M Rhabdomyosarcoma; Alveolar 13 years - 8 months Diagnosis 
M 35-R M Rhabdomyosarcoma; Embryonal 3 years - 1 month Post-chemo 
M 36-N M Neuroblastoma 4 years - 1 month Diagnosis 
F 37-N F Neuroblastoma 1 year - 2 months Diagnosis 
F 38-N F Neuroblastoma 7 months Diagnosis 
M 39-N M Neuroblastoma 1 year - 11 months Diagnosis 
F 40-N F Ganglioneuroblastoma 3 years - 3 months Post-chemo  
M 41-N M Neuroblastoma 6 years - 9 months Post-chemo 
F 42-N F Neuroblastoma 1year - 9 months Post-chemo 
M 43-N M Neuroblastoma 1year - 6 months Diagnosis 
F 44-N F Neuroblastoma 2 months Diagnosis 
F 45-N F Neuroblastoma 1year - 2months Post-chemo 
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2.4 Genomic DNA extraction from frozen tissues and cultured cells 
The DNeasy blood & Tissue (QIAGEN) kit was used to extract genomic DNA from 
frozen tissue and cultured cells, with the primary difference being that tissue required 
a longer incubation after adding ALT tissue lysis buffer and proteinase K. Frozen 
tissue was cut into small pieces of approximately 0.2-0.4 cm length, placed in a 1.5 
ml microcentrifuge tube, and then 180µL of buffer ALT and 20µL ready-to-use 
proteinase K solution [40 mAU/mg solution] were added. Samples were vortexed 
occasionally during incubation at 56˚C, and then placed at 56˚C overnight in a 
rotating oven until the tissue was completely lysed. Cultured cells were harvested via 
trypsinisation, washed with 200µL PBS, and then 20µL ready-to-use proteinase K 
solution and 180µL Lysis buffer (AL) were added, mixed thoroughly by vortexing, 
and samples were incubated at 56˚C for 10 min. 
 
After incubation at 56˚C, 200µL 100% ethanol was added to each tube, and mixed 
by vortexing. Each sample was immediately loaded onto a DNeasy Mini spin column, 
which was placed in a 1.5mL collection tube. Tubes and columns were centrifuged at 
6000xg for 1 min at RT, the flow-through was discarded and the DNeasy Mini spin 
column was placed in a fresh collection tube. Spin columns were washed with 500µL 
AW1 Buffer and then centrifuged at 6000xg for 1 min. The spin column was placed in 
a fresh collection tube and a second wash of 500µl AW2 Buffer was added to the 
spin column. To elute DNA, the spin column was placed in fresh collection tube, 
200µL AE Buffer was added directly onto the DNeasy membrane and incubated for 1 
minute at RT. Spin columns were then centrifuged at 6000xg for 1 minute at RT and 
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the eluted genomic DNA was then stored at ‐20°C until required for quantification 
and later use. 
2.5 Spectrophotometric and electrophoretic analysis of genomic DNA  
DNA samples were quantified with a ND-1000 UV-VIS NanoDrop spectrophotometer 
(Thermo Scientific), with A260/A280 ratios used as an indicator of DNA purity and 
A260/A230 ratios used to detect other contaminations such as EDTA, carbohydrates, 
phenol, and TRIzol reagent that absorb at 230nm (NanoDrop software v3.1.2) 
(Thermo-scientific, 2011) . Accepted parameters were 50-300 ng/µL for DNA 
concentration, 1.70 - 2.0 for A260/A280 ratios, and 1.90 - 3.0 for A260/A230 ratios. 
Furthermore, DNA quality (high molecular weight) was assessed by performing 
electrophoresis with 10 ng DNA on a 0.8% (w/v) agarose gel in 1X TBE.  
 
Agarose gels were run at 180 V for 40 minutes using a Bio-Rad Powerpac 300 
electrophoresis power supply. The gel was stained with ethidium bromide by adding 
50 µg ethidium bromide to a 100 ml agarose gel. The DNA was visualised using a 
UV transilluminator (Advanced Technocracy Inc.) and photographed with a UVP 
PhotoDoc-It DigiCam 70.  
2.6 Multiplex Ligation-dependent Probe Amplification (MLPA) 
The SALSA MLPA KIT P014-A1 Chromosome 8 kit (MRC Holland, Amsterdam) was 
used, which contains 32 probes in 30 genes along chromosome 8, and 9 control 
probes located in 6 genes on other chromosomes (chromosomes 3, 5, 11, 12, 13 
and 17) (Table 2.3). MLPA products were analysed using an ABI-prism 3100 DNA 
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sequencer, and raw data were analysed using PeakScanner Software v1.0 (Applied 
Biosystems). For copy number quantification, peak area values were exported to an 
Excel template file (Microsoft 7) developed by Sydney Genome Diagnostics at 
Children’s Hospital at Westmead. 
  
The manufacturer states that probe ratios below 0.7 indicate heterozygous deletion 
(copy number change from two to one allele), and that probe ratios above 1.3 
indicate allele duplication (copy number change from two to three alleles) or greater 
(MRC-Holland, 2011). Thus, the presence of two copies of a target sequence is 
indicated by probe ratios of 0.7-1.3 (Schouten et al., 2002). The quality of each 
MLPA reaction was evaluated by the results obtained for a normal control. In this 
project we used a commercially available human male genomic DNA pool 
(Promega), similar to Buffart et al. (2009). This was run in triplicate with each run to 
provide information about amplification efficiency and whether the correct amount of 
DNA had been used for each MLPA reaction (Caceres et al., 2011). 
2.6.1 MLPA reactions (day 1) 
Five microliters (10-20 ng/µL) genomic DNA extracted and quantified according to 
sections 2.4 and 2.5, was added to a 0.2 mL PCR tube, placed in a 9600 Perkin-
Elmer thermocycler and denaturation was performed at 98°C for 5 min. The normal 
male DNA reference sample was included in triplicate, as per MRC-Holland 
recommendations. These reference samples were distributed randomly over the 
sample plate to account for placement variation. Samples were allowed to cool to 
25°C before proceeding with the following steps. 
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Hybridisation master mix for each sample was prepared using 1.5 µL MLPA buffer 
and 1.5 µL probemix in a clean PCR tube. The sample was mixed by pipetting, and 3 
µL hybridization master mix was added to each sample at 25°C, and mixed by 
pipetting. Samples were incubated at 95°C for 1 min and then the hybridization 
program was run at 60°C for 16-20 hours. 
 
The next day, ligase master mix was prepared for each reaction using 3 µL Ligase-
65 buffer A, 3 µL Ligase-65 buffer B and 25 µL dH2O in a clean tube, and mixed by 
pipetting. Finally, 1 µL Ligase-65 was added to the master mix, and then 32 µL 
ligase master mix was added to each sample tube at 54°C and mixed by pipetting. 
Samples were incubated at 54°C for 15 min to allow ligation. Heat inactivation of 
ligase-65 was performed at 98°C for 5 min. Samples were allowed to cool to 15°C 
before proceeding with the next steps. 
2.6.2 MLPA reactions (day 2) 
PCR buffer mix was prepared using 4 µL SALSA PCR buffer and 26 µL dH2O, which 
were mixed briefly by vortexing. A total of 30 µL PCR buffer mix was transferred to 
each sample tube containing ligation product. A polymerase master mix was 
prepared using 2 µL SALSA PCR primers, 2 µL SALSA enzyme dilution buffer, 5.5 
µL dH2O and 0.5 µL SALSA polymerase, mixed by pipetting and stored on ice until 
required. Sample tubes containing PCR buffer mix and ligation product were placed 
in the 9600 thermocycler at 60°C, and 10 µL polymerase master mix was added to 
each sample tube and mixed by pipetting. The thermocycler program was as follows: 
30 cycles of (95°C for 30 sec, 60°C for 30 sec and 72°C 60 sec) followed by an 
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incubation at 72°C for 20 min. Samples were cooled to 15°C and stored at 4°C until 
required.  
2.6.3 MLPA Fragment separation and peak pattern evaluation 
The Australian Genome Research Facility (AGRF) at Westmead processed all 
samples using capillary electrophoresis fragmentation, a process that was conducted 
with the ABI-prism 3100 sequencer equipment and according to the manufacturer’s 
specific conditions for the SALSA MLPA Chromosome 8 kit.  
 
Visual peak patterns were evaluated using the PeakScanner Software v1.0 (Applied 
Biosystems). The kit contained four DNA quality control fragments (Q-fragments) 
(64,70,76, and 82 bp) and one ligation-dependent control fragment at 92 bp. These 
fragments already contained both MLPA primer sequences, meaning that they did 
not need to be hybridised or ligated to be amplified as they act as a “quality control 
reaction”, to provide a warning when insufficient sample DNA is present (MRC-
Holland, 2011).  
 
In consequence, they are present in very small quantities and their amplification 
should be easily outcompeted by MLPA probes when the latter are present in normal 
amounts. Thus when the peaks of the Q-fragments are low or invisible, this signifies 
that sufficient DNA sample was present and the ligation reaction was successful. In 
contrast, when the peaks of all four Q-fragments were higher than one third of the 
height of the 92 bp ligation-dependent control fragment and the MLPA probes, this 
was an indication of insufficient DNA or that the ligation reaction had failed (MRC-
Holland, 2011). 
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2.6.4. Data analysis 
All data that passed the peak pattern evaluation were subjected to analysis. Intra-
sample normalization of electrophoresis results was conducted to correct for 
common sources of results variability such as pipetting accuracy, bleaching of the 
fluorescent label and variations in capillarity. The intra-normalised probe ratio of a 
sample was divided by the average intra-normalised probe ratio of all (n=3) 
reference samples. This step provides a probe ratio for each probe for each sample 
(MRC-Holland, 2011). 
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Table 2.3 Coordinates of genes examined using MLPA according to the hg18 
genome assembly. (UCSC Genome Browser Mar. 2006 NCBI36) 
   Gene 
 Size 
Cyto 
Band 
MLPA Probes 
 
Gene 
Chromosome  
Coordinates 
Exon 
N0 
 Product 
Size (bp) 
      	
  Chromosome 8    	
       
1 DLGAP 1,484,199-1,644,049 159,851 bp 8p23.3 9	 166 
2 MFHAS 8,679,409-8,788,541 109,133 bp 8p23.1 1	 481 
3 MSRA 9,990,476-10,323,805 333,330 bp 8p23.1 3	 364 
4 GATA4 11,599,126-11,603,846 4,721 bp 8p23.1 7	 418 
5 CTSB 11,737,443-11,763,055 25,613 bp 8p22 9	 136 
6 TUSC3 15,442,101-15,666,366 224,266 bp 8p22 5	 184 
7 ChGn 19,341,621-19,504,550 162,930 bp 8p21.3 6	 454 
8 FGFR1 38,396,208-38,444,520 48,313 bp 8p11.2 4	 373 
9 PRKDC 48,848,222-49,035,296 187,075 bp 8q11.21 7	 400 
10 MOS 57,188,055-57,189,095 1,041 bp 8q11.23 1	 247 
11 CHD7 61,753,893-61,942,021 188,129 bp 8q12.2 15	 256 
12 MYBL 67,636,968-67,687,729 50,762 bp 8q13.1 14	 177 
13 NCOA2 71,186,821-71,478,574 291,754 bp 8q13.3 3	 337 
14 TPD52 80,993,650-81,155,565 161,916 bp 8q21.13 9	 202 
15 E2F5 86,287,162-86,314,006 26,844 bp 8q21.2 6	 274 
16 RAD54B 95,459,972-95,518,308 58,337 bp 8q22.1 2	 292 
17 ST7 105,578,376-105,670,344 91,969 bp 8q22.3 5	 355 
18 EIF3E 109,283,148-109,330,135 46,988 bp 8q23.1 7	 142 
19 EIF3H 117,726,236-117,847,675 121,440 bp 8q24.11 8	 427 
20 EXT1 118,880,783-119,193,239 312,457 bp 8q24.11 1	 328 
21 RNF139 125,556,189-125,570,040 13,852 bp 8q24.13 2	 409 
22 MYC 128,817,498-128,822,855 5,358 bp 8q24.21 3	 238 
23 MYC 128,817,498-128,822,855 5,358 bp 8q24.21 3	 157 
24 DDEF1 131,268,664-131,509,230 240,567 bp 8q24.22 27	 301 
25 KCNQ3 133,210,438-133,562,186 351,749 bp 8q24.22 13	 436 
26 SLA 134,130,006-134,156,557 26,552 bp 8q24.22 9	 220 
27 KHDR 136,538,898-136,729,030 190,133 bp 8q24.22 4	 382 
28 KCNK9 140,699,431-140,784,481 85,051 bp 8q24.3 1	 346 
29 PTK2 141,737,683-142,080,514 342,832 bp 8q24.3 26	 319 
30 PTP4A 142,501,189-142,510,802 9,614 bp 8q24.3 3	 265 
31 RECQL4 145,707,479-145,714,008 6,530 bp 8q24.3 17	 463 
32 RECQL4 145,707,479-145,714,008 6,530 bp 8q24.3 13	 211 
       
  Reference probes     
       
1 VHL 10,18,319-10,168,746 10,428bp 3p25.3 2 391 
2 IL4 132,037,272-132,046,267 8,996bp 5q31.1 1 130 
3 EHF 34,599,244-34,639,657 40,414bp 11p12 8 472 
4 HIPK3 33,235,744-33,332,515 96,772bp 11p13 17 193 
5 CTTN 69,922,260-69,960,338 38,079bp 11q13 16 229 
6 CD27 6,424,312-6,431,145 6,834bp 12p13 6 444 
7 ABCC4 94,470,084-94,751,688 281,605bp 13q32 23 
24 
148 
 8 ARHGEF7 110,565,625-110,745,543 179,919bp 13q34 310 
9 PMP22 15,073,821-15,104,818 30,998bp 17p12 4 283 
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2.7 Array Comparative Genomic Hybridization (aCGH) 
aCGH is a molecular cytogenetic technique designed for detecting relative 
differences in copy number between test (sample to be interrogated) and reference 
genomes (Morozova et al., 2008). After hybridization, the amount of fluorescent 
signal can be measured and a ratio between test and reference DNA can be 
calculated based on the ratio of the signal intensity (Fig 2.1). 
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Figure 2.1 Illustration of general principles of aCGH. Reproduced from Shinawi 
et al. (2008).  
(a) Patient or test and control or reference DNA are labeled with fluorescent dyes 
and applied to the microarray. Test and reference DNA compete to attach, or 
hybridize to the microarray. 
(b) The microarray scanner measures the fluorescent signal from the slides and 
these are converted into image files 
(c) An output of scanning depicts thousands of spots with different ratios of the 
fluorescent intensities 
(d) Computer software analyses the data and generates a copy number plot. 
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2.7.1 Array description 
The aCGH was performed using a customized design from the Agilent eArray 
SurePrint G3 2x400K. This array contained a total of 420,288 distinct biological 60-
mer oligonucleotide probes. High resolution was provided for chromosome 8, with 
median probe spacing of 1.97 kb, and in approximately 100 genes important in 
oncology, with a median probe spacing of 250 bp (Table 4.2). The rest of the human 
genome was interrogated with even whole-genome coverage of 253,502 probes, and 
a 11.8 kb median probe spacing. Probe sequences and gene annotations were 
based on the NCBI Build 37 of the human genome and UCSC version hg19 released 
in February 2009. 
2.7.2 Sample preparation 
The SurePrint G3 2x400K array must be hybridised with a mapped reference DNA. 
For this purpose we used commercially available HAPMAP reference DNA from The 
Coriell Institute for Medical Research, catalogue numbers NA12891 (European male) 
and NA12878 (European female), as test and reference DNA samples must be sex-
matched. All DNA samples were assessed for concentration and purity as described 
in section 2.5. 
2.7.3 Restriction digestion of test and reference DNA samples 
DNA samples have to be cut into small pieces (approximately 0.3-2.0 kb), to be able 
to hybridize to the oligonucleotide probes present on the microarray. Restriction 
digestion was performed using the Genomic DNA enzymatic labelling kit (Agilent). 
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The manufacturer’s recommendations were to use a digestion master mix that 
contained 2 µg of each test genomic DNA and corresponding reference genomic 
DNA sample, 5U Alu I and 5U Rsa I, 2.5 µL of 10x NE Buffer 4 (New England 
BioLabs), 0.2 µL 10 µg/ µL BSA  (New England BioLabs), and 1.3 µL water. Five µL 
master mix was added to 20 µL genomic DNA for a final volume of 25 µL for each 
reaction. After mixing, the samples were centrifuged for 1 min at 8,000xg 
(Spectrafuge 24D Labnet). Tubes were incubated at 37˚C for 2.5 to 3 h to allow 
digestion of the double stranded DNA into smaller fragments. 
2.7.4 Labeling of test and reference DNA samples 
After the DNA was digested, test and reference DNA samples were labeled in order 
to be displayed when the test or reference DNA samples hybridize with 
oligonucleotide-probes on the microarray, using an Agilent Genomic DNA Labeling 
Kit (Agilent). From the kit 5 µL random primers were added to each 25 µL sample, 
denatured at 95˚C for 5 min and incubated at 4˚C for 1 min on the thermocycler 
(Eppendorf). Tubes were then removed from the thermocycler and briefly 
centrifuged. A labelling master mix was made using the reagents provided in the kit, 
5 µL dNTPs, 10 µL Buffer, 3 µL 1 mM dUTP (Cy5 test samples, Cy3 for reference), 1 
µL water and 1 µL KLENOW enzyme in a final reaction volume of 20 µL dispensed 
into each corresponding PCR tube. All test and reference samples were incubated at 
37˚C for 16 - 20 hours overnight. 
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2.7.5 Clean-up of labelled DNA samples 
The individually labeled test and reference DNA samples were purified using Amicon 
ultra columns (Millipore), by adding 25 µL test or reference DNA, and 410 µL 1xTE 
buffer, and centrifuging columns at 8,000xg for 10 min at RT. Supernatants were 
discarded and this step was repeated. Columns were inverted and placed in new 
collection tubes, centrifuged at 4,000xg for 1 min at RT, and then the eluted samples 
were retained. 
 
2.7.6 Hybridization 
Following purification, the appropriate Cy3-labeled test and Cy5-labeled reference 
samples were mixed together and combined with 60.5 µL 1x TE buffer (Promega), 
25 µL 1.0 mg/mL Cot-1 DNA, 26 µL 10x Blocking Agent (Agilent), and 130 µL 2x 
Hi-RPM Buffer (Agilent). Tubes were centrifuged at 8,500xg for 1 min at RT, then 
placed in the thermocycler (Eppendorf) for denaturation at 95 ˚C for 5 min and then 
incubated at 37˚C for 30 min. 
 
The hybridization mixture was slowly dispensed onto a 2x400K microarray slide and 
assembled in an Agilent SureHyb chamber. The assembled slide chamber was 
placed in a rotator rack in a hybridization oven at 65˚C set to constant 20 rpm 
rotation for 18 -24 h.  
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2.7.7 Post-hybridization washing and scanning 
A Coplin jar was filled with Oligo aCGH wash buffer 1 (Agilent) at RT. The 
hybridization chamber was disassembled and the array gasket was transferred to be 
completely immersed in the Coplin jar. Each microarray was removed and placed 
into the slide rack in Oligo aCGH wash buffer 1 at RT. This was incubated on a 
shaking incubator for 5 min at 37°C, with constant agitation at 60 rpm. Slides were 
then transferred into a slide rack containing Oligo aCGH wash buffer 2 (Agilent) pre- 
warmed at 37°C, and then shaken for 1 min at 37˚C at 60 rpm. The slide rack was 
removed and drained very carefully, and the edges of each slide were wiped to 
remove excess wash solution. After washing, each slide as loaded into individual 
slide holders and covered with a plastic coverslip. Microarray slides were loaded into 
Agilent microarray scanner bundle G2565BA with 5-µm resolution immediately after 
washing, to minimize the impact of environmental oxidants on fluorescent signals. 
The number of slots as selected and each slide was given a laboratory identification 
number. Slides were scanned into image (.tif) files and translated into log ratios, to 
allow the identification of the copy number aberrations.  
 
2.7.8 Data analysis 
Captured images were transformed to data with Feature Extraction version 10.10 
(Agilent), and then imported into Agilent CytoGenomics Software version 2.7.2 for 
analysis, as well as Nexus copy number version 7.5 software (BioDiscovery Santa 
Clara, CA). 
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Nexus Copy Number, v 7.5 (BioDiscovery) is a microarray analytical software for the 
analysis of genomic microarray datasets. The algorithms contained within Nexus 
perform the normalization, segmentation, and identification of corresponding copy 
number events from the raw data of all genomic files within a single project, using 
build 37 (human genome 19) of the genome as the common scaffold for all tumour 
profiles. 
Agilent CytoGenomics v 2.7.2 was used primarily to visualise first results from 
aCGH, although it was not versatile enough for our analysis. Nexus v7.5, on the 
other hand, offered better user experience, and plotting functionality and frequency 
of copy number alteration across the genome not available in CytoGenomics. 
 
In Nexus, for the rank segmentation algorithm we used the following parameters. A 
mean log2 ratio of 0.25 - 0.75 was classified as copy number gain, > 0.75 was 
classified as high-level copy number gain, < - 0.25 was classified as hemizygous 
loss, and < - 0.75 was classified as homozygous loss. The categories high copy gain 
and gain were combined, as well as the categories loss and homozygous loss. The 
threshold setting to make a positive call was at least 5 consecutive probes located in 
the gene or region of interest. 
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2.8 Quantitative real-time Polymerase Chain Reaction (qPCR) 
Quantitative PCR was used to validate the results of MLPA and aCGH. Due to the 
small amount of DNA that remained after applied the other techniques, we were 
unable to perform qPCR for all samples and all genes, so a representative group 
was selected. Six genes were amplified, RECQL4, PTP4A3, KCNK9, EXT1, TPD52, 
and MYC, in 7 samples (one osteosarcoma, 2 Ewing sarcomas, 2 
rhabdomyosarcomas, 2 neuroblastomas and 2 cell lines). 
 
The sequences of PCR primers used in this study are shown in Table 2.4. VAV2, 
located on chromosome 9, has been previously validated for use in qPCR by Mosse 
et al. (2007) and since then has been similarly employed by other groups (Lau et al., 
2013) (Bower et al., 2012). VAV2 was also disomic in all tumours analysed by aCGH 
using Nexus copy number software. The relative copy number of target genes was 
therefore determined by normalization to VAV2 copy number using the relative 
standard curve method with serial dilutions (1:10, 1:20, 1:40, 1:80,1:160, 1:320) of 
DNA from the AU 565 cell line.  
 
Quantitative PCR was performed in a Rotor-Gene Q (Qiagen) using 1 x Quanti-
FAST SYBR Green master mix (Qiagen), 5 µL 1ng/µL DNA template and 
corresponding primers for each gene (Table 2.4), in a final reaction volume of 25 µL. 
Each sample was measured in triplicate to compare gene copy number to that of the 
VAV2 endogenous control that was performed to standardize the amount of DNA 
sample added to a reaction. The amount of target and endogenous reference is 
determined from the appropriate standard curve. Then, the target amount was 
divided by the endogenous control amount to obtain a normalized target value. 
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Again, the calibrator in our project was a genomic female DNA control (Promega) or 
1x sample. Each of the normalized target values is divided by the calibrator 
normalized target value to generate the copy number. 
The PCR conditions were as follows: one cycle of 5 min at 95˚C, followed by 35 
cycles of (15 sec at 95°C, 30 sec at 61°C and 20 sec at 72°C) for all sets of primers. 
Relative DNA copy numbers were calculated using Rotor-Gene 6 (Version 6.1) 
software (Qiagen) by normalizing raw data obtained for each gene against the VAV2 
gene as a control. A single peak in the appropriate melting curve was used to 
determine that there was only one PCR product amplified per PCR primer set. 
 
Table 2.4 Sequences of PCR primers used in this study. 
PRIMER 
No 
Gene 
Name 
Size 
bp 
Sense primer 
5’è3’ 
Antisense Primer 
5’è3’ 
1 VAV2 103 TGGGCATGACTGAAGATGAC ATCTGCCCTCACCTTCTCAA 
2 TPD52 115 CAGTTTAGAGCCCAG GGA AA CGATCATCCAACGTA GCATG 
3 MYC 162 AGGACTATCCTGCTGCCAAG TTAGCTCGTTCCTCCTCTGG 
4 EXT1 175 CACTTGTGGAACAATGGTAGGA 
CCTTAGAAAAGAGGGGAATAG
AAAC 
5 KNCK9 150 TCTGTCCCTCATCGTCTGC TCCTCGCTGCTGATGTTGTA 
6 RECQL4 129 CCTCGATTCCATTATCATTTACTGC GACACCAGCTCTATCCATAC 
7 PTP4A3 106 CATGTCTGCTTCCCTCCGTA CCTCACAGAACTTGGCCTTC 
2.9 Statistical Analyses 
Statistically significant differences between expected copy number change events for 
each category and actual 8p and 8q events for the same was assessed using 
Fisher’s exact test for each type of tumour. A p-value of 0.05 or less was considered 
statistically significant. Fisher’s Exact test was performed using the 5 by 2 calculator 
from “SISA Five by 2 exact” (Uitenbroek, 1997), using the exact option.  
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Chapter 3  
Analysis of chromosome 8 copy number in 
paediatric solid tumours using MLPA
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3.1 Introduction 
Most normal individuals contain a diploid copy number for autosomal genes or, in 
terms of dosage, a normal expected dosage quotient (DQ) of 1.0 (Lake et al., 2012; 
Wallace, 2003). In contrast, a distinctive characteristic of cancer is alterations in copy 
number from total or partial loss to the gain of one copy or many gene copies. 
Moreover, the presence of deletions or duplications of specific genes has been 
associated with specific types of cancer (Lee et al., 2010). However, normal 
individuals can also present copy number variations that are considered benign and 
will not directly cause disease. Some known benign variants are summarized in the 
Database of Genomic Variants (Macdonald et al., 2014). 
 
Myllykangas et al. (2007) studied different models of gene amplification specificity 
and applied the cell type lineage model, which presumes that the evolution of 
molecular changes in cancer cells is a consequence of specific properties of the 
precursor stem cells. They concluded that gene amplification appears to be 
characteristic of solid tissue tumourigenesis rather than specific translocations, even 
though amplifications are also present in haematological malignancies but at lower 
frequencies (Myllykangas et al., 2007). The DNA amplification mechanism implies 
that two independent double-strand breaks have to occur to allow the intermediate 
DNA to amplify (Myllykangas et al., 2007). The same research group defined the 
concept of amplification versus copy number gain. Amplification is the main 
mechanism in oncogene activation and refers to an increase of at least five copies of 
a DNA segment that is less than 20 megabases in length, whereas gain is a low 
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copy number increase (less than 5), which results from ploidy changes or unequal 
translocations (Myllykangas et al., 2007). 
 
Chromosome 8 is one of the most frequently gained chromosomes in different 
cancer types (Myllykangas et al., 2007 & 2008). Using machine-learning techniques, 
Myllykangas et al., aimed to classify human cancers based on their amplification 
patterns. Copy number amplification was studied across 4400 tumour cases 
representing 82 cancer types. Among other results, they found that amplifications 
were selected according to the anatomical locations and biological background of the 
cancers. In fact, 14 different types of cancers showed amplification in 4 different 
genes located on chromosome 8, demonstrating amplification hot spots at FGFR1 
(8p11-12), MYC (8q24.1), PTK2 (8q24.3), EIF3S3 (8q24.11), and GATA4 (8p23.1-
p22). 
 
Different techniques have been designed to identify gene dosage or copy number 
changes in a quantitative fashion, such as Fluorescence In Situ Hybridization (FISH), 
array Comparative Genomic Hybridization (aCGH), quantitative PCR (qPCR) and 
Multiplex Ligation-dependent Probe Amplification (MLPA), among others. MLPA has 
remained stable since 2010, indicating that this technique is still widely used, 
including cancer. According to HighWire http://highwire.stanford.edu the word 
“MLPA” appeared in 81 scientific articles since the creation of the technique in 2002 
until 2005. Searching for “MLPA” and “cancer” identified 51 papers in the same 
period. From 2006 until 2010, “MLPA” appeared in 669 articles, with 386 articles 
containing both “MLPA” and “cancer” (Fig 3.1). These data show the increasing 
  81 
interest in MLPA within the scientific community, and highlight its relevance in cancer 
research, which is our focus in this study. 
 
 
Figure 3.1: Number of instances of the term “MLPA”, (blue bars) and “MLPA” (red 
bars) and “cancer” in the research literature per year, according to the HighWire 
search engine. Exact numbers of publications are also listed below the X axis. 
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MLPA is a valuable tool to support and complement classic pathology. It presents 
many advantages, including the ability to work with very small amounts of DNA (20 - 
200 ng), being compatible with DNA extracted from paraffin-embedded as well as 
fresh-frozen material and having a low cost per reaction (Homig-Holzel et al., 2012). 
Furthermore, results can be obtained within 24 hours, and it is also suitable for 
cancer risk screening, where large numbers of samples have to be analysed 
independently of an acute indication (Homig-Holzel et al., 2012). 
 
In our project, this technique was used as a screening tool to assess chromosome 8 
copy number changes in a cohort of 31 paediatric solid tumours. As the SALSA 
MLPA KIT P014-A1 Chromosome 8 kit has not been tested before in this setting, we 
also determined copy number changes in 6 cell lines, some of which were expected 
to show defined copy number changes on chromosome 8. 
  83 
3.2 Aims for chapter 3  
1. To assess chromosome 8 copy number changes in a cohort of 31 paediatric 
solid tumours and 6 cell lines, using the SALSA MLPA KIT P014-A1 
Chromosome 8 kit (MRC Holland, Amsterdam).  
 
2. To identify recurrent regions of copy number gain and loss, both within the 
overall cohort and according to tumour type. 
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3.3 Results 
MLPA is a multiplex PCR assay that in this project utilized 32 probes mapping to 
chromosome 8 loci (Fig 3.2, Table 2.3), and 9 reference probes mapping to other 
chromosomes. One of the differences between PCR and MLPA is the use of normal 
controls, usually around three, but depending on the number of total samples could 
be more (MRC-Holland, 2011). These controls provide not only a reference for 
performance of the MLPA reaction, but will also be used to normalize the copy 
number ratio, which is the quotient between the actual dosage per gene versus the 
expected dosage, calculated based on the normal controls. In this study, the overall 
dosage numbers were determined by the PeakScanner software v 1.0 (Applied 
Biosystems).  
 
As a normal control we used a male genomic DNA sample (Promega). The MLPA kit 
manufacturers recommended running the normal control in triplicate, within each 
experiment (MRC-Holland, 2011). MLPA copy number results are presented as 
means ± standard error, as calculated from 4 independent experiments. For MYC 
and RECQL4 genes, two probes were used in each gene (Table 2.3), and the results 
obtained for the two probe sets were averaged.  
 
Copy numbers from raw data were converted to categories, for comparison with 
results from other techniques. A sample ratio above 1.3 thus considered a gain 
(coded as 2), while sample ratios between 0.7 and 1.3 were classed as normal range 
or disomic (coded as 1). Sample ratios below 0.7 were classed as losses (coded as 
0) (MRC-Holland, 2011). 
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Table 2.2 summarizes the paediatric tumour cohort used for both the MLPA and 
array Comparative Genomic Hybridization (aCGH) studies of Chapters 3 and 4. 
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                  Chr 8 (p23.3-q24.3) 
 1.  DLGAP2 8p23.3 
 2.  MFHAS 8p23.1 
 3.  MSRA 8p23.1 
 4.  GATA4 8p23.1 
 5.  CTSB 8p22 
 6.  TUSC3 8p22 
 7.  ChGn 8p21.3 
 8.  FGFR 8p11.2 
  
 9.  PRKDC 8q11.21 
 10. MOS 8q11.23 
 11. CHD7 8q12.2 
 12. MYBL 8q13.1 
 13. NCOA2 8q13.3 
 14. TPD52  8q21.13 
 15. E2F5  8q21.2 
 16. RAD54B  8q22.1 
 17. ST7  8q22.3 
 18. EIF3E  8q23.1 
 19. EIF3H  8q24.11 
 20. EXT1  8q24.11 
 21. RNF139  8q24.1 
 22. MYC  8q24.21 
 23. MYC  8q24.21 
 24. DDEF1  8q24.22 
 25. KCNQ3  8q24.22 
 26. SLA  8q24.22 
 27. KHDRBS3      8q24.22 
 28. KCNK9  8q24.3 
 29. PTK2  8q24.3 
 30. PTP4A  8q24.3 
 31. RECQL4  8q24.3 
 32. RECQL4      8q24.3 
Figure 3.2 Location of MLPA probe set on chromosome 8 using the UCSC human genome browser. Genes for which MLPA 
probes were included in the P014-A1 chromosome 8 kit are shown at left, with vertical lines showing the location of each gene 
with respect to the ideogram above. The vertical line located at the centromere, separates probes located 8pter from 8qter. 
 
UCSC Genome Browser on Human Mar. 2006 NCBI36/hg18 Assembly 
Chromosome 8: 1,484,199-145,739,091 
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3.3.1 Use of known copy number changes in 6 breast cell lines, as positive 
controls for this paediatric tumour study. 
Cell lines are a renewable and reliable resource, of proven utility in the study of any 
particular tissue type. Ideally, such cell lines will comprise a clonal cell population, of 
uniform genotype, ultimate for comparison with any uncharacteristic “test” cells, or 
tissue. Furthermore, breast cancer cell lines retain significant molecular features 
common to clinically recognised breast cancers (Riaz et al., 2013). In this project, we 
worked with 6 breast cell lines, with previously described patterns of chromosome 8 
gains and losses (Table 3.1). 
 
As expected (given the previously known findings in Table 3.1), 5 of these 6 breast 
cell lines showed copy number loss at 8p loci using the MLPA analysis performed 
within the present study (Table 3.2). One example (cell line SK-BR-3) is represented 
in figure 3.3, showing focal copy number loss from the region 8p23.3-p11.2. On the 
other hand, cell line HCC2157 was exceptional, as its TUSC3 copy number lies 
within the disomic range, MCF-10A was the only cell line found to have no loss 
within 8p, being disomic for all chromosome 8 genes tested (Table 3.2). 
 
Also as expected (Table 3.1), copy number gains were frequently identified at 
chromosome 8q loci, among the 6 breast cell lines examined.  Gains of MYC were 
detected in 5/6 (83%) cell lines, and gain of TPD52 in 4/6 (66.7%) (Table 3.3). Within 
8q, two genes MOS and E2F5 were predominantly disomic, while KCNK9 showed 
copy number loss in 4/6 cell lines tested or 66.7% (Table 3.3). 
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Most reference loci were disomic in most cell lines. In particular CTTN and HIPK3 
were disomic in 5/6 cell lines (Table 3.4), although other loci did show gain or loss, 
(e.g. EHF, CD27, ABCC4, and PMP22). As reference probe in the kit are used to 
normalise the results for each sample, it is reasonable to expect some copy number 
changes at reference loci in breast cell lines, as for example AU565, MDA-MB-231, 
MCF-7, and SK-BR-3 cell lines, have all been reported to show copy number loss at 
PMP22 (Saito et al., 2009). 
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Table 3.1 Literature describing chromosome 8 showing copy number gain and/or loss in breast cell lines used in this study 
 
Cell lines AU565 HCC2157 MCF-7 MCF-10A MDA-MB-231 SK-BR-3 
Authors 
      
Rummukainen et al. (2001) 
CGH   
Loss 8p 
   
  
Gain 8q23-qter 
  
Amplification MYC  
Schouten et al. (2002) 
MLPA 
     Amplification MYC 
     
(2 different probes) 
Jonsson et al. (2007) 
BAC-array CGH 
  
Loss 8p 
 
Loss 8p 
 
  
Gain 8q 
Gain entire Chr 
8  Amplification MYC 
     
8q23.3-q24.13 
Rodriguez et al. (2007) 
BAC array -FISH 
     Loss 8p 
     Gain 8q (TPD52 & MYC) 
Kao et al. (2009) 
aCGH  
Loss 8p Loss 8p Disomic 8p Loss 8p Loss 8p 
 
Gain 8q Gain MYC Gain MYC Gain MYC Gain MYC 
Marella et al. (2009) 
aCGH       
   
Gain entire Chr 8 
 
Saito et al. (2009) 
aCGH 
Loss 8p 
 
Loss 8p 
 
Loss 8p Loss 8p 
Gain 8q 
 
Gain 8q 
 
Gain 8q Gain 8q 
Roslan et al. (2013) 
QPCR 
High copy 
 
Gain TPD52 
 
Gain TPD52 High copy number 
number  TPD52 
    
TPD52 
Rondon-Lagos et al. (2014) 
G banding - M-FISH 
  
Deletion of entire 
Chr -8    
  der(8)t(8;15)(p11;?)   
+8, der(8) t(8;21)(p23;?) 
t(8;21)(q24;?), dup(8); 
t(8;17)(q24;?) 
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Table 3.2 Chromosome 8p copy number status in 6 breast cell lines studied in the current project 
                  
 
Categories: 2=Gain; 1=Disomic; 0=Loss 
         Samples DLGAP2 MFHAS MSRA GATA4 CTSB TUSC3 ChGn FGFR1 
AU 565 0 0 0 0 0 0 0 0 
HCC2157 0 0 0 0 0 1 0 0 
MCF-7 0 0 0 0 0 0 0 0 
MCF-10A 1 1 1 1 1 1 1 1 
MDA-MB-231 0 0 0 0 0 0 0 0 
SK-BR-3 0 0 0 0 0 0 0 0 
         
 
DLGAP2 MFHAS MSRA GATA4 CTSB TUSC3 ChGn FGFR1 
        
Gain 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 
Disomy 1(17%) 1(17%) 1(17%) 1(17%) 1(17%) 2(33%) 1(17%) 1(17%) 
Loss 5(83%) 5(83%) 5(83%) 5(83%) 5(83%) 4(66.6%) 5(83%) 5(83%) 
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Figure 3.3 MLPA probe ratios obtained for the SK-BR-3 cell line studied in the current 
project. Results shown are mean probe ratio ± SE from 4 independent experiments. On the 
X-axis, brown columns represent genes located on chromosome 8p, blue columns 
represent genes located on chromosome 8q, and red columns represent reference probes. 
Probe ratios are shown on the Y-axis. Probe ratios between 0.7 and 1.3 were considered in 
the normal range or disomic, indicated on the graph as a rectangular dashed region. Probe 
ratios below 0.7 were considered copy number loss, and probe ratios above 1.3 were 
considered copy number gain. 
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Table 3.3 Chromosome 8q copy number status in 6 breast cell lines studied in 
the current project 
                  
 
Categories: 2=Gain; 1=Disomic; 0=Loss 
 
         
Samples PRKDC MOS CHD7 MYBL NCOA2 TPD52 E2F5 
RAD54
B 
AU565 0 1 1 1 1 2 1 0 
HCC2157 2 2 2 2 2 2 2 2 
MCF-7 1 1 1 1 0 1 1 2 
MCF-10A 1 1 1 1 1 1 1 1 
MDA-MB-231 2 1 2 2 1 2 1 1 
SK-BR-3 1 1 1 1 1 2 1 0 
         
 
PRKDC MOS CHD7 MYBL NCOA2 TPD52 E2F5 
RAD54
B 
        
Gain 2(33.3%) 1(16.7%) 2(33.3%) 2(33.3%) 1(16.7%) 4(66.7%) 1(16.7%) 2(33.3%) 
Disomy 3(50.0%) 5(83.3%) 4(66.7%) 4(66.7%) 4(66.7%) 2(33.3%) 5(83.3%) 2(33.3%) 
Loss 1(16.7%) 0(0.0%) 0(0.0%) 0(0.0%) 1(16.7%) 0(0.0%) 0(0.0%) 2(33.3%) 
         
 
 
 
 
                
 
Categories: 2=Gain; 1=Disomic; 0=Loss 
        Samples ST7 EIF3E EIF3H EXT1 RNF139 MYC DDEF1 
        
AU565 0 0 2 2 2 2 1 
HCC2157 1 2 2 1 1 2 1 
MCF-7 2 2 1 1 2 2 2 
MCF-10A 1 1 1 1 1 2 1 
MDA-MB-231 1 1 1 1 0 1 2 
SK-BR-3 0 0 2 2 2 2 1 
        
 
ST7 EIF3E EIF3H EXT1 RNF139 MYC DDEF1 
       
Gain 1(16.7%) 2(33.3%) 3(50.0%) 2(33.3%) 3(50.0%) 5(83.3%) 2(33.3%) 
Disomy 3(50.0%) 2(33.3%) 3(50.0%) 4(66.7%) 2(33.3%) 1(16.7%) 4(66.7%) 
Loss 2(33.3%) 2(33.3%) 0(0%) 0(0%) 1(16.7%) 0(0%) 0(0%) 
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Table 3.3 Chromosome 8q copy number status in 6 breast cell lines studied in  
the current project (cont.) 
                 
 
Categories: 2=Gain; 1=Disomic; 0=Loss  
        
Samples KCNQ3 SLA KHDRBS3 KCNK9 PTK2 PTP4A RECQL4 
AU565 0 0 0 0 0 0 1 
HCC2157 1 1 1 1 1 1 2 
MCF-7 1 1 1 0 1 1 1 
MCF-10A 1 2 1 1 1 1 1 
MDA-MB-231 1 1 1 0 1 1 1 
SK-BR-3 0 1 0 0 0 0 0 
        
 
KCNQ3 SLA KHDRBS3 KCNK9 PTK2 PTP4A RECQL4 
       
Gain 0(0%) 1(16.7%) 0(0%) 0(0%) 0(0%) 0(0%) 1(16.7%) 
Disomy 4(66.7%) 4(66.7%) 4(66.7%) 2(33.3%) 4(66.7%) 4(66.7%) 4(66.7%) 
Loss 2(33.3%) 1(16.7%) 2(33.3%) 4(66.7%) 2(33.3%) 2(33.3%) 1(16.7%) 
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Table 3.4 Copy number status at 9 reference genes in 6 breast cell lines studied in 
the current project 
                    
 
Categories: 2=Gain; 1=Disomic; 0=Loss 
 
 
 
Ref 3p Ref 5q Ref 11p Ref 11p Ref 11q Ref 12p Ref 13q Ref 13q Ref 17p 
Gene  VHL 
 
IL4 
 
EHF 
 
HIPK3 
 
CTTN 
 
CD27 
 
ABCC4 
 
ARHGEF7 
 
PMP22 
 
Samples          
AU565 0 0 0 1 1 0 0 1 0 
HCC2157 1 1 1 0 1 0 0 0 0 
MCF-7 1 1 0 1 1 1 0 0 1 
MCF-10A 1 2 1 1 1 2 1 1 1 
MDA-MB-231 1 1 1 1 1 1 1 1 2 
SK-BR-3 0 0 0 1 0 0 1 1 0 
          
 
Ref 3p Ref 5q Ref 11p Ref 11p Ref 11q Ref 12p Ref 13q Ref 13q Ref 17p 
Gene  VHL 
 
IL4 
 
EHF 
 
HIPK3 
 
CTTN 
 
CD27 
 
ABCC4 
 
ARHGEF7 
 
PMP22 
 
Gain 0(0%) 1(16.7%) 0(0%) 0(0%) 0(0%) 1(16.7%) 0(0%) 0(0%) 1(16.7%) 
Disomy 4(66.7%) 3(50.0%) 3(50.0%) 5(83.3%) 5(83.3%) 2(33.3%) 3(50.0%) 4(66.7%) 2(33.3%) 
Loss 2(33.3%) 22(33.3%) 3(50.0%) 1(16.7%) 1(16.7%) 3(50.0%) 3(50.0%) 2(33.3%) 3(50.0%) 
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3.3.2 Copy number changes on chromosome 8p in the paediatric solid tumour 
cohort 
Among the four classes of paediatric tumour we have tested (Table 3.5), 
osteosarcomas show more frequent chromosome 8p changes. Two of the five 
osteosarcoma samples show loss for at least half of the loci examined, while one 
shows copy number gain at 3 loci on 8p (Tables 3.5, 3.6). By contrast, most Ewing 
sarcomas and rhabdomyosarcomas show no evidence of copy number gain or loss 
at any of the 8p loci tested (Tables 3.5, 3.6). The neuroblastoma cohort showed 
frequent copy number loss at ChGn (5/10, or 50% cases) followed by MSRA (4/10, 
40% cases) (Tables 3.5, 3.6). 
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Table 3.5 Chromosome 8p copy number status in solid tumour cohort 
                  
 
Categories: 2=Gain; 1=Disomic; 0=Loss 
         Gene  DLGAP2 MFHAS MSRA GATA4 CTSB TUSC3 ChGn FGFR1 
Samples         
F9Oa 1 1 1 1 1 1 1 1 
F10O 1 1 1 1 1 1 1 1 
M11O 1 1 2 1 1 2 2 1 
F12O 0 1 0 0 0 1 0 0 
M46O 0 0 0 0 1 1 1 1 
M13E 1 1 1 1 1 1 1 1 
M14E 1 1 1 1 1 2 1 1 
F15E 1 1 1 1 1 1 1 1 
M16E 1 1 1 1 1 1 1 1 
F17E 1 1 1 1 1 2 1 1 
F18E 1 2 1 1 0 1 1 1 
M22E 1 1 1 1 1 2 1 1 
F24E 1 1 1 1 1 1 1 1 
M25R 1 1 1 1 1 1 1 1 
F26R 1 1 1 1 1 1 1 1 
M27R 1 1 1 1 1 1 1 1 
F28R 1 1 1 1 1 2 1 1 
F29R 1 1 1 1 1 1 1 1 
M31R 1 1 1 1 1 2 1 1 
M32R 1 1 1 1 1 1 1 1 
M35R 1 1 1 1 1 2 1 1 
M36N 1 1 1 1 1 1 0 1 
F37N 1 2 0 1 2 1 0 2 
F38N 2 1 0 1 1 1 0 1 
M39N 1 2 0 1 1 1 0 1 
F40N 1 1 1 1 1 1 1 1 
M41N 1 1 1 1 1 2 1 1 
F42N 1 1 1 1 1 2 1 1 
M43N 1 1 1 1 1 1 1 1 
F44N 1 1 1 1 1 1 1 1 
F45N 2 0 0 0 2 2 0 0 
         
 
DLGAP2 MFHAS MSRA GATA4 CTSB TUSC3 ChGn FGFR1 
        
Gain 2 (6.5%) 3  (9.7%) 1  (3.2%) 0  (0%) 2  (6.5%) 10(32.3%) 1  (3.2%) 1  (3.2%) 
Disomy 27(87.1%) 26(83.9%) 24(77.4%) 28(90.3%) 27(87.1%) 21(67.7%) 24(77.4%) 28(90.3%) 
Loss 2 (6.4%) 2  (6.4%) 6  (19.4%) 3  (9.7%) 2  (6.4%) 0  (0%) 6  (19.4%) 2  (6.5%) 
         
a Sample identifiers ending in “O” are osteosarcomas, “E” are Ewing sarcomas, “R” are 
rhabdomyosarcomas, “N” are neuroblastomas. 
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        Table 3.6 Chromosome 8p copy number status by gene and solid tumour type
 
          
 Osteosarcoma n=5 
  
         
Gene  DLGAP2 MFHAS MSRA GATA4 CTSB TUSC3 ChGn FGFR1 
Samples 
        Gain 0(0%) 0(0%) 1(20.0%) 0(0%) 0(0%) 1(20.0%) 1(20.0%) 0(0%) 
Disomy 3(60.0%) 4(80.0%) 2(40.0%) 3(60.0%) 4(80.0%) 4(80.0%) 3(60.0%) 4(80.0%) 
Loss 2(40.0%) 1(20.0%) 2(40.0%) 2(40.0%) 1(20.0%) 0(0%) 1(20.0%) 1(20.0%) 
  
  
Ewing sarcoma n=8 
  
         
Gene  DLGAP2 MFHAS MSRA GATA4 CTSB TUSC3 ChGn FGFR1 
Samples         
Gain 0(0%) 1(12.5%) 0(0%) 0(0%) 0(0%) 3(37.5%) 0(0%) 0(0%) 
Disomy 8(100.0%) 7(87.5%) 8(100.0%) 8(100.0%) 7(87.5%) 5(62.5%) 8(100.0%) 8(100.0%) 
Loss 0(0%) 0(0%) 0(0%) 0(0%) 1(12.5%) 0(0%) 0(0%) 0(0%) 
 
          
Rhabdomyosarcoma n=8 
  
         
Gene  DLGAP2 MFHAS MSRA GATA4 CTSB TUSC3 ChGn FGFR1 
Samples         
Gain 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 3(37.5%) 0(0%) 0(0%) 
Disomy 8(100.0%) 8(100.0%) 8(100.0%) 8(100.0%) 8(100.0%) 5(62.5%) 8(100.0%) 8(100.0%) 
Loss 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 
 
          
Neuroblastoma n=10 
  
         
Gene  DLGAP2 MFHAS MSRA GATA4 CTSB TUSC3 ChGn FGFR1 
Samples         
Gain 2(20.0%) 2(20.0%) 0(0.0%) 0(0.0%) 2(20.0%) 3(30.0%) 0(0.0%) 1(10.0%) 
Disomy 8(80.0%) 7(70.0%) 6(60.0%) 9(90.0%) 8(80.0%) 7(70.0%) 5(50.0%) 8(80.0%) 
Loss 0(0.0%) 1(10.0%) 4(40.0%) 1(10.0%) 0(0.0%) 0(0.0%) 5(50.0%) 1(10.0%) 
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3.3.3 Copy number changes on chromosome 8q and at reference genes in the 
paediatric tumour cohort. 
In the osteosarcoma group, six chromosome 8q genes were gained in 2/5 (40%) of 
cases, these being MYBL, TPD52, EIF3E, EIF3H, EXT1 and SLA. Only KCNK9 
showed copy number loss in 2/5 (40%) cases (Tables 3.7, 3.11). Ewing sarcoma 
samples were predominantly disomic at chromosome 8q loci. Gains were found in 
EXT1 and SLA in 2/8 (25%) cases, and copy number losses were measured at 
KCNK9 2/8 (25%) cases (Tables 3.8, 3.11). Rhabdomyosarcoma samples showed 
gain at TPD52 (3/8, 37.5% cases), RAD54 (2/8, 25% cases), whereas losses were 
reported at EXT1 (3/8, 37.5% cases) and PTP4A and KCNK9  (2/8, 25% cases) 
(Tables 3.9, 3.11). In neuroblastoma samples losses were more frequent, RECQL4 
was gained in 4/10  (40%) cases, whereas TPD52 was gained 3/10 (30%) cases, 
KHDRBS3 locus showed reduced copy number in 3/10 (30%) cases, and RAD54, 
ST7, EIF3E, KCNQ3, KCNK9 and PTP4A all showed copy number loss in 2/10 
(20%) cases (Tables 3.10, 3.11). Overall, TPD52 was predicted to be gained most 
frequently, in 9/31  (29%) of the overall cohort followed by SLA in 6/31 (19.4%) 
cases (Table 3.11). 
 
Fisher's exact test was used to assess differences in the numbers per copy number 
category between 8p loci and 8q loci for each type of tumour. P-values <0.05 were 
considered statistically significant. Only for osteosarcoma samples did this statistical 
test show significant differences between 8p and 8q loci. Here, the count of copy 
number losses at 8p was significantly higher than expected; conversely, the number 
of copy number gains at 8q was higher than expected (Appendix 1). For the other 
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three types of tumours, Fisher's exact test did not reach statistical significance 
(Appendix 1). 
 
Reference probes showed disomic copy number in most samples examined (18/31, 
58% of cases, Table 3.12). The reference probes for ARHGEF7 on chromosome 
13q24 showed disomic copy number in 31/31 (100%) cases of the paediatric solid 
tumour cohort. However some cases showed obvious copy number changes at 
reference probe loci (Fig 3.4).  
 
3.3.4 Additional MLPA results 
Some discrepant results were observed within the 4 MLPA runs for both cell lines 
and the solid tumour cohort. Discrepant results were obtained at a number of loci, 
including at EIF3E located at 8q23.1 and EXT1 located at 8q24.11 (Figs 3.5 and 
3.6).  
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Table 3.7 Chromosome 8q copy number changes in osteosarcomas n=5 
    
    
Gene Gain Disomy Loss 
    
PRKDC 0(0.0%) 5(100.0%) 0(0.0%) 
MOS 0(0.0%) 4(80.0%) 1(20.0%) 
CHD7 1(20.0%) 4(80.0%) 0(0.0%) 
MYBL 2(40.0%) 3(60.0%) 0(0.0%) 
NCOA2 1(20.0%) 4(80.0%) 0(0.0%) 
TPD52 2(40.0%) 2(40.0%) 1(20.0%) 
E2F5 0(0.0%) 4(80.0%) 1(20.0%) 
RAD54B 1(20.0%) 4(80.0%) 0(0.0%) 
ST7 1(20.0%) 3(60.0%) 1(20.0%) 
EIF3E 2(40.0%) 3(60.0%) 0(0.0%) 
EIF3H 2(40.0%) 3(60.0%) 0(0.0%) 
EXT1 2(40.0%) 3(60.0%) 0(0.0%) 
RNF139 1(20.0%) 4(80.0%) 0(0.0%) 
MYC 1(20.0%) 4(80.0%) 0(0.0%) 
DDEF1 0(0.0%) 5(100.0%) 0(0.0%) 
KCNQ3 0(0.0%) 5(100.0%) 0(0.0%) 
SLA 2(40.0%) 3(60.0%) 0(0.0%) 
KHDRBS3 1(20.0%) 4(80.0%) 0(0.0%) 
KCNK9 0(0.0%) 3(60.0%) 2(40.0%) 
PTK2 0(0.0%) 4(80.0%) 1(20.0%) 
PTP4A 0(0.0%) 4(80.0%) 1(20.0%) 
RECQL4 0(0.0%) 4(80.0%) 1(20.0%) 
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Table 3.8 Chromosome 8q copy number changes in Ewing sarcomas n=8 
    
    
Gene Gain Disomy Loss 
    
PRKDC 0(0.0%) 8(100.0%) 0(0.0%) 
MOS 1(12.5%) 7(87.5%) 0(0.0%) 
CHD7 1(12.5%) 7(87.5%) 0(0.0%) 
MYBL 1(12.5%) 7(87.5%) 0(0.0%) 
NCOA2 0(0.0%) 8(100.0%) 0(0.0%) 
TPD52 3(37.5%) 5(62.5%) 0(0.0%) 
E2F5 0(0.0%) 8(100.0%) 0(0.0%) 
RAD54B 2(25.0%) 6(75.0%) 0(0.0%) 
ST7 0(0.0%) 8(100.0%) 0(0.0%) 
EIF3E 1(12.5%) 6(75.0%) 1(12.5%) 
EIF3H 0(0.0%) 8(100.0%) 0(0.0%) 
EXT1 2(25.0%) 6(75.0%) 0(0.0%) 
RNF139 0(0.0%) 8(100.0%) 0(0.0%) 
MYC 0(0.0%) 8(100.0%) 0(0.0%) 
DDEF1 0(0.0%) 8(100.0%) 0(0.0%) 
KCNQ3 0(0.0%) 8(100.0%) 0(0.0%) 
SLA 2(25.0%) 6(75.0%) 0(0.0%) 
KHDRBS3 0(0.0%) 8(100.0%) 0(0.0%) 
KCNK9 0(0.0%) 6(75.0%) 2(25.0%) 
PTK2 0(0.0%) 8(100.0%) 0(0.0%) 
PTP4A 0(0.0%) 8(100.0%) 0(0.0%) 
RECQL4 0(0.0%) 8(100.0%) 0(0.0%) 
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Table 3.9 Chromosome 8q copy number changes in rhabdomyosarcomas n=8 
    
    
Gene Gain Disomy Loss 
    
PRKDC 0(0.0%) 8(100.0%) 0(0.0%) 
MOS 1(12.5%) 7(87.5%) 0(0.0%) 
CHD7 1(12.5%) 7(87.5%) 0(0.0%) 
MYBL 1(12.5%) 7(87.5%) 0(0.0%) 
NCOA2 0(0.0%) 8(100.0%) 0(0.0%) 
TPD52 3(37.5%) 5(62.5%) 0(0.0%) 
E2F5 0(0.0%) 8(100.0%) 0(0.0%) 
RAD54B 2(25.0%) 6(75.0%) 0(0.0%) 
ST7 0(0.0%) 8(100.0%) 0(0.0%) 
EIF3E 0(0.0%) 8(100.0%) 0(0.0%) 
EIF3H 0(0.0%) 8(100.0%) 0(0.0%) 
EXT1 0(0.0%) 5(62.5%) 3(37.5%) 
RNF139 0(0.0%) 8(100.0%) 0(0.0%) 
MYC 1(12.5%) 7(87.5%) 0(0.0%) 
DDEF1 0(0.0%) 8(100.0%) 0(0.0%) 
KCNQ3 0(0.0%) 8(100.0%) 0(0.0%) 
SLA 1(12.5%) 7(87.5%) 0(0.0%) 
KHDRBS3 0(0.0%) 8(100.0%) 0(0.0%) 
KCNK9 0(0.0%) 6(75.0%) 2(25.0%) 
PTK2 0(0.0%) 8(100.0%) 0(0.0%) 
PTP4A 0(0.0%) 6(75.0%) 2(25.0%) 
RECQL4 0(0.0%) 8(100.0%) 0(0.0%) 
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Table 3.10 Chromosome 8q copy number changes in neuroblastomas n=10 
    
    
Gene Gain Disomy Loss 
    
PRKDC 0(0.0%) 7(70.0%) 3(30.0%) 
MOS 1(10.0%) 9(90.0%) 0(0.0%) 
CHD7 0(0.0%) 9(90.0%) 1(10.0%) 
MYBL 1(10.0%) 6(60.0%) 3(30.0%) 
NCOA2 1(10.0%) 9(90.0%) 0(0.0%) 
TPD52 3(30.0%) 5(50.0%) 2(20.0%) 
E2F5 0(0.0%) 8(80.0%) 2(20.0%) 
RAD54B 0(0.0%) 9(90.0%) 1(10.0%) 
ST7 0(0.0%) 7(70.0%) 3(30.0%) 
EIF3E 1(10.0%) 9(90.0%) 0(0.0%) 
EIF3H 0(0.0%) 6(60.0%) 4(40.0%) 
EXT1 0(0.0%) 8(80.0%) 2(20.0%) 
RNF139 0(0.0%) 8(80.0%) 2(20.0%) 
MYC 0(0.0%) 10(100.0)% 0(0.0%) 
DDEF1 0(0.0%) 9(90.0%) 1(10.0%) 
KCNQ3 0(0.0%) 8(80.0%) 2(20.0%) 
SLA 1(10.0%) 9(90.0%) 0(0.0%) 
KHDRBS3 0(0.0%) 7(70.0%) 3(30.0%) 
KCNK9 0(0.0%) 8(80.0%) 2(20.0%) 
PTK2 0(0.0%) 9(90.0%) 1(10.0%) 
PTP4A 0(0.0%) 8(80.0%) 2(20.0%) 
RECQL4 4(40.0%) 5(50.0%) 1(10.0%) 
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Table 3.11 Chromosome 8q copy number status in tumour cohort 
                  
 
Categories: 2=Gain; 1=Disomic; 0=Loss 
 
         Gene  PRKDC MOS CHD7 MYBL NCOA2 TPD52 E2F5 RAD54B 
Samples         
F9Oa 1 1 1 1 1 2 1 1 
F10O 1 0 1 2 1 2 1 1 
M11O 1 1 1 1 1 1 1 1 
F12O 1 1 2 2 2 0 0 1 
M46O 1 1 1 1 1 1 1 2 
M13E 1 1 1 1 1 1 1 1 
M14E 1 1 1 1 1 1 1 1 
F15E 1 1 1 1 1 1 1 1 
M16E 1 1 1 1 1 1 1 1 
F17E 1 1 2 1 1 2 1 1 
F18E 1 1 1 1 1 1 1 1 
M22E 1 1 1 1 1 1 1 1 
F24E 1 1 1 1 1 1 1 1 
M25R 1 1 1 1 1 1 1 1 
F26R 1 1 1 1 1 1 1 1 
M27R 1 1 1 1 1 1 1 1 
F28R 1 1 1 1 1 1 1 1 
F29R 1 1 1 1 1 2 1 2 
M31R 1 1 2 1 1 2 1 1 
M32R 1 1 1 1 1 1 1 1 
M35R 1 2 1 2 1 2 1 2 
M36N 1 1 1 1 1 1 1 1 
F37N 0 1 1 0 1 0 0 1 
F38N 1 1 1 0 1 1 1 1 
M39N 0 1 0 0 1 0 0 0 
F40N 1 1 1 1 1 1 1 1 
M41N 1 1 1 1 1 2 1 1 
F42N 1 1 1 1 1 2 1 1 
M43N 1 1 1 1 1 1 1 1 
F44N 1 1 1 1 1 1 1 1 
F45N 0 2 1 2 0 2 1 1 
         
 
PRKDC MOS CHD7 MYBL NCOA2 TPD52 E2F5 RAD54B 
        
Gain 0(0%) 2(6.5%) 3(9.7%) 4(12.9%) 1(3.2%) 9(29%) 0(0%) 3(9.7%) 
Disomy 28(90.3%) 28(90.3%) 27(87.1%) 24(77.4%) 27(87.1%) 19(61.3%) 28(90.3%) 27(87.1%) 
Loss 3(9.7%) 1(3.2%) 1(3.2%) 3(9.7%) 1(3.2%) 3(9.7%) 3(9.7%) 1(3.2%) 
         
a Sample identifiers ending in “O” are osteosarcomas, “E” are Ewing sarcomas, “R” are 
rhabdomyosarcomas, “N” are neuroblastomas.  
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Table 3.11 Chromosome 8q Copy number status in tumour cohort (cont.) 
                   
 
 Categories: 2=Gain; 1=Disomic; 0=Loss  
       
Gene  ST7 EIF3E EIF3H EXT1 RNF139 MYC DDEF1 
Samples        
F9Oa 1 1 1 1 1 1 1 
F10O 1 1 1 1 1 1 1 
M11O 1 1 1 1 1 1 1 
F12O 0 2 2 2 2 2 1 
M46O 2 2 2 2 1 1 1 
M13E 1 1 1 1 1 1 1 
M14E 1 2 1 2 1 1 1 
F15E 1 1 1 1 1 1 1 
M16E 1 1 1 1 1 1 1 
F17E 1 1 1 1 1 1 1 
F18E 1 0 1 1 1 1 1 
M22E 1 1 1 1 1 1 1 
F24E 1 1 1 2 1 1 1 
M25R 1 1 1 1 1 1 1 
F26R 1 1 1 1 1 1 1 
M27R 1 1 1 1 1 1 1 
F28R 1 1 1 1 1 1 1 
F29R 1 1 1 0 1 2 1 
M31R 1 1 1 1 1 1 1 
M32R 1 1 1 0 1 1 1 
M35R 1 1 1 0 1 1 1 
M36N 1 1 1 1 1 1 1 
F37N 0 1 0 0 0 1 1 
F38N 1 1 0 1 1 1 1 
M39N 0 1 0 1 1 1 1 
F40N 1 1 1 1 1 1 1 
M41N 1 1 1 1 1 1 1 
F42N 1 1 1 1 1 1 1 
M43N 1 1 1 1 1 1 1 
F44N 1 1 1 1 1 1 1 
F45N 0 2 0 0 0 1 0 
        
 
ST7 EIF3E EIF3H EXT1 RNF13 MYC DDEF1 
       
Gain 1(3.2%) 4(12.9%) 2(6.5%) 4(12.9%) 1(3.2%) 2(6.5%) 0(0%) 
Disomy 26(83.9%) 26(83.9%) 25(80.6%) 22(71.0%) 28(90.3%) 29(93.5%) 30(96.8%) 
Loss 4(12.9%) 1(3.2%) 4(12.9%) 5(16.1%) 2(6.5%) 0(0%) 1(3.2%) 
        
a Sample identifiers ending in “O” are osteosarcomas, “E” are Ewing sarcomas, “R” are 
rhabdomyosarcomas, “N” are neuroblastomas.  
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Table 3.11 Chromosome 8q Copy number status in tumour cohort (cont.) 
                   
 
 Categories: 2=Gain; 1=Disomic; 0=Loss  
        
Gene  KCNQ3 SLA KHDRBS3 KCNK9 PTK2 PTP4A RECQL4 
Samples        
F9Oa 1 1 1 0 1 1 1 
F10O 1 2 1 1 1 1 1 
M11O 1 1 1 1 1 1 0 
F12O 1 1 1 0 0 0 1 
M46O 1 2 2 1 1 1 1 
M13E 1 1 1 1 1 1 1 
M14E 1 1 1 1 1 1 1 
F15E 1 1 1 1 1 1 1 
M16E 1 1 1 1 1 1 1 
F17E 1 2 1 0 1 1 1 
F18E 1 1 1 1 1 1 1 
M22E 1 2 1 0 1 1 1 
F24E 1 1 1 1 1 1 1 
M25R 1 1 1 1 1 1 1 
F26R 1 1 1 1 1 1 1 
M27R 1 1 1 1 1 1 1 
F28R 1 1 1 1 1 1 1 
F29R 1 1 1 0 1 0 1 
M31R 1 1 1 1 1 1 1 
M32R 1 1 1 1 1 1 1 
M35R 1 2 1 0 1 0 1 
M36N 1 1 1 1 1 1 1 
F37N 0 1 0 1 1 1 2 
F38N 1 1 1 1 1 1 2 
M39N 1 1 0 1 1 1 2 
F40N 1 1 1 1 1 0 1 
M41N 1 1 1 1 1 1 2 
F42N 1 1 1 0 1 1 1 
M43N 1 1 1 1 1 1 1 
F44N 1 1 1 1 1 1 1 
F45N 0 2 0 0 0 0 0 
 
 
      
 
KCNQ3 SLA KHDR KCNK9 PTK2 PTP4A RECQL4 
       
Gain  0(0%) 6(19.4%) 1(3.2%) 0(0%) 0(0%) 0(0%) 4(12.9%) 
Disomy 29(93.5%) 25(80.6%) 27(87.1%) 23(74.2%) 29(93.5%) 26(83.9%) 25(80.6%) 
Loss 2(6.5%) 0(0%) 3(9.7%) 8(25.8%) 2(6.5%) 5(16.1%) 2(6.5%) 
        
a Sample identifiers ending in “O” are osteosarcomas, “E” are Ewing sarcomas, “R” are 
rhabdomyosarcomas, “N” are neuroblastomas. 
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Table 3.12 Copy number status at 9 reference genes in 31 tumour samples 
                    
 
Categories: 2=Gain; 1=Disomic; 0=Loss 
 
 
 
Ref 3p Ref 5q Ref 11p Ref 11p Ref 11q Ref 12p Ref 13q Ref 13q Ref 17p 
          
Gene VHL 
 
IL4 
 
EHF 
 
HIPK3 
 
CTTN 
 
CD27 
 
ABCC4 
 
ARHGEF7 
 
PMP22 
 
Sample           
F9Oa 0 1      1 1 1 0 0 1 2 
F10O 1 1 1 1 1 0 0 1 2 
M11O 0 1 1 1 0 1 0 1 1 
F12O 0 0 0 1 1 0 1 1 0 
M46O 0 1 0 1 1 1 1 1 1 
M13E 1 1 1 1 1 1 1 1 1 
M14E 0 1 1 1 1 0 1 1 1 
F15E 1 1 0 1 1 1 1 1 1 
M16E 1 1 0 1 1 0 1 1 1 
F17E 1 1 1 2 1 0 1 1 1 
F18E 1 1 1 1 1 1 1 1 1 
M22E 1 2 1 2 1 0 1 1 1 
F24E 1 1 1 1 1 1 1 1 1 
M25R 1 1 1 1 1 0 1 1 1 
F26R 1 1 0 1 1 1 1 1 0 
M27R 1 2 1 2 1 1 1 1 1 
F28R 1 2 1 1 1 1 0 1 1 
F29R 0 0 2 1 0 1 1 1 0 
M31R 0 1 1 1 0 1 1 1 1 
M32R 1 1 1 1 1 1 1 1 1 
M35R 1 2 1 2 1 0 1 1 1 
M36N 1 1 0 1 1 1 1 1 2 
F37N 1 1 1 1 2 2 1 1 2 
F38N 0 1 0 1 2 1 1 1 1 
M39N 1 1 0 1 2 2 1 1 2 
F40N 1 1 1 1 1 1 1 1 1 
M41N 0 1 0 1 1 1 1 1 0 
F42N 1 2 1 2 1 0 1 1 1 
M43N 1 1 1 1 2 1 1 1 1 
F44N 1 1 0 0 0 1 1 1 1 
F45N 0 2 0 2 1 0 2 1 0 
          
 
Ref 3p Ref 5q Ref 11p Ref 11p Ref 11q Ref 12p Ref 13q Ref 13q Ref 17p 
Gene  VHL 
 
IL4 
 
EHF 
 
HIPK3 
 
CTTN 
 
CD27 
 
ABCC4 
 
ARHGEF7 
 
PMP22 
 
Gain (%) 0(0) 6(19.4) 1(3.2) 6(19.4) 4(12.9) 2(6.4) 1(3.2) 0(0) 5(16.1) 
Disomy (%) 21(67.7) 23(74.19) 19(61.3) 24(77.4) 23(74.19) 18(58.1) 26(83.9) 31(100.0) 21(67.7) 
Loss (%) 10(32.3) 2(6.4) 11(35.5) 1(3.2) 4(12.9) 11(35.4) 4(12.9) 0(0) 5(16.1) 
          
a Sample identifiers ending in “O” are osteosarcomas, “E” are Ewing sarcomas, “R” are 
rhabdomyosarcomas, “N” are neuroblastomas. 
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Figure 3.4 MLPA probe ratios obtained for the Rhabdomyosarcoma sample 
F29R. Probe ratios (Y axis) as (A) individual values from 4 independent experiments 
(B) mean probe ratios ± SE. On the X axis, brown columns represent genes located 
on chromosome 8p, blue columns represent genes located on chromosome 8q, and 
red columns represent reference probes. The orange column highlights high-level of 
copy number gain at one reference locus. Probe ratios between 0.7 and 1.3 were 
considered in the normal range or disomic, probe ratios below 0.7 were considered 
copy number loss, and probe ratios above 1.3 were considered copy number gain. 
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Figure 3.5 MLPA probe ratios obtained for the MCF-10A cell line. Probe ratios (Y 
axis) as (A) individual values from 4 independent experiments (B) mean probe ratios 
± SE. On the X-axis, brown columns represent genes located on chromosome 8p, 
blue columns represent genes located on chromosome 8q, while dark blue columns 
highlight two probes that gave highly variable results (for EIF3E and EXT1). Probe 
ratios between 0.7 and 1.3 were considered in the normal range or disomic, probe 
ratios below 0.7 were considered copy number loss, and probe ratios above 1.3 
were considered copy number gain. 
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Figure 3.6 MLPA probe ratios obtained for the Ewing sarcoma sample F15E. 
Probe ratios (Y axis) as (A) individual values from 4 independent experiments, and 
(B) mean probe ratios ± SE. On the X-axis, brown columns represent genes located 
on chromosome 8p, blue columns represent genes located on chromosome 8q, and 
bright blue columns highlight two probes that gave highly variable results. Probe 
ratios between 0.7 and 1.3 were considered in the normal range or disomic, probe 
ratios below 0.7 were considered copy number loss, and probe ratios above 1.3 
were considered copy number gain. 
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3.4 Discussion 
Chromosome 8 contains a number of important genes that are amplified in specific 
adult cancers such as prostate (Tomlins et al., 2007) and breast (Rodriguez et al., 
2007), and in childhood cancers such as osteosarcoma (Man et al., 2004), Burkitt 
lymphoma (De Falco et al., 2007) and some leukaemias (Le Beau et al., 2002). In 
this study we present a detailed analysis of DNA copy number changes at 30 genes 
across chromosome 8 in four different types of paediatric solid tumours with the aim 
of associating gene copy number alterations with tumour type. 
 
Although the MLPA technique has increased in use, over recent years (Fig 3.1), it 
has seldom been applied to a study of paediatric solid tumours. Among the four 
types of cancers studied in this project, only neuroblastoma has been previously 
examined using MLPA. Ambros et al. (2011) presented and validated MLPA to better 
assign patients to certain genetic risk groups, and also to discover genomic regions 
of interest with possible clinical impact. A neuroblastoma-specific MLPA kit was 
designed by the SIOP (Europe) Neuroblastoma Biology committee in cooperation 
with MRC-Holland, testing 310 neuroblastomas and 8 neuroblastoma cell lines in 9 
different SIOPEN reference laboratories. The study concluded that the technique 
was reliable as the results were validated with FISH for MYCN amplification, 
cost-effective when a large number of samples is analysed in one experiment and 
the robustness is based on the PCR technique itself (Ambros et al., 2011). 
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3.4.1 Previous research examining chromosome 8 copy number using MLPA 
Buffart et al. (2005) used a chromosome 8 specific MLPA kit to measure the DNA 
copy number status of 25 chromosome 8 genes in primary colorectal cancer and 
metastatic disease. Two genes located at chromosome 8q23-24, namely MYC and 
PTP4A3, were shown to be amplified and overexpressed in primary colorectal 
cancer and metastases. The majority of primary tumours and their corresponding 
liver metastases presented similar gains and losses, with significant difference for 
only TPD52 and EIF3S6, where gain was higher in liver metastases (Buffart et al., 
2005). Subsequently, Buffart et al. (2009) studied DNA copy number changes in 58 
individual genes in 63 formalin-fixed and paraffin-embedded gastric 
adenocarcinomas, using different MLPA kits for chromosome 8, 13 and 20. They 
reported that 11 MLPA probes located in 8 genes on chromosome 8, showed copy 
number gains, with frequencies from 25.4% (TPD52) to 73% (MYC) (Buffart et al., 
2009).  
 
Bremmer et al. (2005) used normal tissue, preneoplastic lesions and oral squamous 
cell carcinoma with a partial kit for chromosome 8 (5 probes in 5 genes located on 
chromosome 8) as well as other MLPA kits, to develop and evaluate a noninvasive 
screening test for oral preneoplastic lesions. Here, MLPA was described as a 
sensitive, reliable, high-throughput and easy to perform technique (Bremmer et al., 
2005).  
 
More recently Rumiato et al. (2011) analysed 59 esophageal cancer samples with 4 
MLPA kits, including the chromosome 8 kit. They reported high frequency of copy 
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number loss of four genes of 8p: DLGAP2, MSRA, CTSB and ChGn, in squamous 
cell carcinoma. Yong et al. (2014) examined 33 oral squamous cell carcinomas using 
the chromosome 8 MLPA kit. The most frequent copy number losses were found on 
chromosome 8p, while the most frequent copy number gains were found on 
chromosome 8q, at EIF3E, MYC, RECQL4 and MYBL1. 
3.4.2 Six Breast cell lines: included in this study as known positive controls 
We analysed six breast cell lines with chromosome 8 copy number changes that had 
been reported previously (Table 3.1). Five of 6 cell lines presented copy number loss 
at most chromosome 8p loci (Table 3.13), except MCF-10. This is a spontaneously 
immortalized breast cell line, considered epithelial in origin, as it does not show 
characteristics of invasiveness or tumour formation (Marella et al., 2009).  
Of the other five cell lines, SK-BR-3 has previously shown three well defined 
chromosome 8 regions, namely copy number loss from 8p23.3-p11.1, and two 
regions with copy number gain at 8q13.1-q21.3 that contains TPD52, and 
8q23.2-q24.21, that includes MYC (Choschzick et al., 2010; Rodriguez et al., 2007). 
The amplification of MYC in SK-BR-3 cell lines was also previously demonstrated by 
Schouten et al. (2002); where they used two different MLPA probe mixtures sets that 
contained 41 different probes specific for human DNA (Schouten et al., 2002). The 
fact that our results in breast cell lines are broadly in accordance to those reported in 
the literature cited suggest that our results are reliable. 
3.4.3 Chromosome 8p copy number in paediatric solid tumours 
Among these tumours, the osteosarcomas group showed copy number loss at 7/8 
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chromosome 8p loci, whereas Ewing sarcoma and rhabdomyosarcomas had very 
few evident copy number changes. Neuroblastomas showed copy number losses at 
ChGn in 5/10 (50%) cases, followed by MSRA in 4/10 (40%) cases (Table 3.13). 
MSRA (Methionine sulfoxide reductase A), located at 8p23.1, was considered by Lei 
et al. (2007) as a possible candidate metastasis suppressor gene. This gene was 
disomic in Ewing sarcoma and rhabdomyosarcoma, whereas it exhibited losses in 
both osteosarcoma (2/5, 40%) and neuroblastoma (4/10, 40%). 
 
ChGn or CSGALNACT1, (Chondroitin sulfate N-acetylgalactosaminyltransferase 1), 
is a member of the GalNac-transferase gene family, expressed in most biological 
tissues and cell types. This gene showed copy number loss in 50% (5/10) of 
neuroblastomas and in 20% (1/5) of osteosarcomas. 
To our knowledge, the specific role of these genes in neuroblastoma or 
osteosarcoma has not been well studied yet. It is the first time that specific genes 
with copy number losses located in 8p has been associated with neuroblastomas or 
osteosarcomas, results that could be the basis of further study. 
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Table 3.13 Copy number results obtained using MLPA in a cohort of 31 paediatric solid tumours and 6 breast cell lines 
 
                                8p (8 genes)                                                                        Chromosome 8q (22 genes)  
 
Genes 
D
LG
A
P2
 
M
FH
A
S 
M
SR
A
 
G
A
TA
4 
C
TS
B
 
TU
SC
3 
C
hG
n 
FG
FR
1 
PR
K
D
C
 
M
O
S 
C
H
D
7 
M
YB
L 
N
C
O
A
2 
TP
D
52
 
E2
F5
 
R
A
D
54
B
 
ST
7 
EI
F3
E 
EI
F3
H
 
EX
T1
 
R
N
F1
39
 
M
YC
 
D
D
EF
1 
K
C
N
Q
3 
SL
A
 
K
H
D
R
B
S3
 
K
C
N
K
9 
PT
K
2 
PT
P4
A
 
R
EC
Q
L4
 
Samples                               
F 9-O 1a 1 1 1 1 1 1 1 1 1 1 1 1 2b 1 1 1 1 1 1 1 1 1 1 1 1 0c 1 1 1 
F 10-O 1 1 1 1 1 1 1 1 1 0 1 2 1 2 1 1 1 1 1 1 1 1 1 1 2 1 1 1 1 1 
M 11-O 1 1 2 1 1 2 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 
F 12-O 0 1 0 0 0 1 0 0 1 1 2 2 2 0 0 1 0 2 2 2 2 2 1 1 1 1 0 0 0 1 
M 46-O 0 0 0 0 1 1 1 1 1 1 1 1 1 1 1 2 2 2 2 2 1 1 1 1 2 2 1 1 1 1 
M 13-E 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
M 14-E 1 1 1 1 1 2 1 1 1 1 1 1 1 1 1 1 1 2 1 2 1 1 1 1 1 1 1 1 1 1 
F 15-E 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
M 16-E 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
F 17-E 1 1 1 1 1 2 1 1 1 1 2 1 1 2 1 1 1 1 1 1 1 1 1 1 2 1 0 1 1 1 
F 18-E 1 2 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 
M 22-E 1 1 1 1 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 1 0 1 1 1 
F 24-E 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 1 1 1 1 1 1 1 1 1 1 
M 25-R 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
F 26-R 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
M 27-R 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
F 28-R 1 1 1 1 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
F 29-R 1 1 1 1 1 1 1 1 1 1 1 1 1 2 1 2 1 1 1 0 1 2 1 1 1 1 0 1 0 1 
M 31-R 1 1 1 1 1 2 1 1 1 1 2 1 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
M 32-R 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 
M 35-R 1 1 1 1 1 2 1 1 1 2 1 2 1 2 1 2 1 1 1 0 1 1 1 1 2 1 0 1 0 1 
M 36-N 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
F 37-N 1 2 0 1 2 1 0 2 0 1 1 0 1 0 0 1 0 1 0 0 0 1 1 0 1 0 1 1 1 2 
F 38-N 2 1 0 1 1 1 0 1 1 1 1 0 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 2 
M 39-N 1 2 0 1 1 1 0 1 0 1 0 0 1 0 0 0 0 1 0 1 1 1 1 1 1 0 1 1 1 2 
F 40-N 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 
M 41-N 1 1 1 1 1 2 1 1 1 1 1 1 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 
F 42-N 1 1 1 1 1 2 1 1 1 1 1 1 1 2 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 
M 43-N 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
F 44-N 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
F 45-N 2 0 0 0 2 2 0 0 0 2 1 2 0 2 1 1 0 2 0 0 0 1 0 0 2 0 0 0 0 0 
AU565 0 0 0 0 0 0 0 0 0 1 1 1 1 2 1 0 0 0 2 2 2 2 1 0 0 0 0 0 0 1 
HCC2157 0 0 0 0 0 1 0 0 2 2 2 2 2 2 2 2 1 2 2 1 1 2 1 1 1 1 1 1 1 2 
MCF-7 0 0 0 0 0 0 0 0 1 1 1 1 0 1 1 2 2 2 1 1 2 2 2 1 1 1 0 1 1 1 
MCF-10A 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 1 1 2 1 1 1 1 1 
MDA-MB-231 0 0 0 0 0 0 0 0 2 1 2 2 1 2 1 1 1 1 1 1 0 1 2 1 1 1 0 1 1 1 
SKBR 3 0 0 0 0 0 0 0 0 1 1 1 1 1 2 1 0 0 0 2 2 2 2 1 0 1 0 0 0 0 0 
a1 = diploid copy number 
b2  = copy number gain 
c0  = copy number loss
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3.4.4 Chromosome 8q copy number in paediatric solid tumours 
The osteosarcoma cohort showed copy number loss at 8/22 loci and copy number 
gain at 13/22 loci. This finding, comprising of a moderate number of copy number 
changes across 8q (Table 3.13) was not in agreement with the literature. Typically, 
OS is characterized by the presence of heterogeneous complex chromosomal 
abnormalities (Ragland et al., 2002), with a high degree of aneuploidy, gene 
amplification, and multiple unbalanced structural chromosomal rearrangements 
(Sandberg et al., 2000). In contrast, only one sample here showed copy number gain 
(at MYC) and one other sample showed copy number loss at RECQL4 (Tables 3.11, 
3.13). 
 
Instability of chromosome 8q has been described by many laboratories, often 
involving MYC, in cytoband 8q24.21, which is gained at varying frequencies (Bayani 
et al., 2003; Smida et al., 2010; Stock et al., 2000). Commonly, other regions of 8q, 
including 8q23-qter, 8q21.3-8q23, and 8q21 also undergo copy number gains (dos 
Santos Aguiar et al., 2007; Kresse et al., 2009; Smida et al., 2010). In addition, copy 
number gain of RECQL4, mapping within 8q23-qter, has been reported as a frequent 
event in osteosarcoma (Maire et al., 2009; Nishijo et al., 2004).  
 
In this study, the chromosome 8q locus that showed the most frequent copy number 
gain was TPD52, followed by SLA. TPD52 or Tumour Protein D52 (8q21.13) has 
been associated with cellular transformation, proliferation and metastasis and its 
overexpression has been demonstrated in various adult cancers (Byrne et al., 2010). 
In paediatric cancers, TPD52 immunostaining was analysed in a large cohort of 
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Ewing sarcoma familial tumours, and was detected significantly more frequently in 
disseminated versus localized tumours (Machado et al., 2011). Among the 8q loci we 
have studied: TPD52 showed copy number gain in all four solid tumours classes 
tested here: namely, 2/5 (40%) osteosarcomas, 1/8 (25%) Ewing sarcomas, 3/8 
(37.5%) rhabdomyosarcomas, and 3/10 (30%) neuroblastomas (Tables 3.11 and 
3.13).  
 
SLA also known as Src-like-adaptor (8q24.22) is an adapter protein, that negatively 
regulates T-cell receptor (TCR) signalling (Dragone et al., 2006). In the present 
study, SLA showed copy number gain in 2/5 (40%) osteosarcomas, 2/8 (25%) Ewing 
sarcomas, 1/8 (12.5%) rhabdomyosarcoma, and 1/10 (10%) neuroblastoma (Tables 
3.11 and 3.13). 
 
Another result that we did not expect was that in Ewing sarcoma, gain of the entire 
chromosome 8 was not identified for any sample, and only 5/22 chromosome 8q loci 
showed copy number gain (Table 3.13). This was also surprising, as it is known that 
gain of chromosome 8 is one of the most prominent features of this type of tumour 
(Savola et al., 2009; Toomey et al., 2010). 
 
In the osteosarcoma samples, when Fisher’s exact test was applied (Appendix 1), a 
significant difference was shown (p= 0.016) between the expected number of copy 
number events per category and the actual count at 8p loci and 8q loci. The number 
of copy number losses at 8p was significantly higher than expected, as also was the 
number of copy number gains in 8q. In this regards, the OS group is comparable 
with the breast cancer controls. This matter is discussed further in a later chapter, in 
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relation to the general nature of chromosome mutation, and its effect on 
simultaneous patterns of gains versus loss. 
3.4.5 Technical considerations  
The MRC-Holland MLPA® technique guide (Schouten et al., 2002) suggests that 
MLPA can be performed using 50 to 100 ng of DNA. However, in our hands 50 ng of 
DNA was insufficient (data not shown). Combaret et al. (2012) reported similar 
problems, and Stuppia et al. (2012) recommended using 100 to 200 ng of genomic 
DNA for optimal results.  
 
This problem is exacerbated when DNA is derived from tumour samples containing 
less than 50% neoplastic cells. In such cases of tumour mosaicism, it can be difficult 
to detect copy number changes for a specific gene, as the presence of normal cells 
can mask the detection of abnormal cells (Stern et al., 2004). Similarly, Ambros et al. 
(2011) mentioned that discrepant results may be obtained due to low tumour cell 
content, particularly in post-therapy specimens. Another limitation of MLPA is its 
inability to detect “balanced” rearrangements, where copy number is preserved at 
normal levels (Bravaccini et al., 2012). In this project a proportion of Ewing 
sarcomas, alveolar rhabdomyosarcomas and neuroblastomas may well have had 
balanced translocations (whereas the same would be much less likely for 
osteosarcomas and embryonal rhabdomyosarcomas).  
 
It has also been reported that MLPA analysis can be compromised by the presence 
of unreliable probes (Stuppia et al., 2012). We obtained some evidence of this, 
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shown in Fig 3.5 and Fig 3.6, where it can be seen that the MLPA chromosome 8 kit 
may include some MLPA probes that lack reproducibility.  
 
While MLPA comprises a relatively rapid and convenient technique, not all of our 
results conformed to the literature’s expectations. This led us to undertake further 
copy number analyses, for the same control cell lines and paediatric tumour cohort, 
using aCGH testing (Chapter 4). 
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Chapter 4  
Analysis of copy number in paediatric solid tumours 
using array Comparative Genomic Hybridization 
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4.1 Introduction 
Array Genomic hybridization (aCGH) was designed to detect DNA copy number 
alterations such as gene amplifications, aneuploidy, deletions and non-reciprocal 
translocations, which are characteristic features of cancer genomes (Kallioniemi, 
2008). aCGH has been widely used to analyze DNA copy number aberrations on a 
genome-wide scale in a single experiment (Yatsenko et al., 2009). Whereas MLPA, 
(chapter 3) obtains copy number data for a restricted number of genes, aCGH allows 
us to define rearrangements in a more detailed and comprehensive manner across 
the whole genome.  
 
Array CGH uses two types of genomic DNA, tumoural and reference DNA, that are 
differentially labeled with fluorochromes, usually Cy3 and Cy5 respectively. Samples 
are hybridized to a microarray that contains oligonucleotide probes, which can be 
customized to particular genes, or designed to analyze all known genes. After 
hybridization, the amount of fluorescent signal can be measured and a ratio between 
tumour and reference DNA can be calculated based on the ratio of the signal 
intensity.  
 
In this project we used a customized design from the Agilent eArray SurePrint G3 
2x400K. This array contained a total of 420,288 distinct biological 60-mer 
oligonucleotide probes. The array provided high resolution on chromosome 8, with a 
median probe spacing of 1.92 kb for chromosome 8, and high resolution in 95 genes 
important in cancer, with 250 bp spacing https://earray.chem.agilent.com/suredesign 
(Table 4.1). The rest of the human genome was provided with even whole-genome 
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coverage of 253,502 probes with 11.8 kb median probe spacing (Table 4.2). The 
probe sequences and gene annotations were based on NCBI Build 37 of the human 
genome, and UCSC version hg19 released in February 2009. 
 
Array CGH has revolutionized cytogenetic diagnostics and has given the clinician a 
greater appreciation of variability in the clinical presentation of many well-described 
conditions (Cytrynbaum et al., 2005; Gropman et al., 2007). The introduction of 
aCGH in clinical practice has effectively eliminated all the technical impediments of 
traditional cytogenetics and FISH (Table 1.6), and allowed the detection of such 
conditions with relative, but not complete, independence from the clinician's 
diagnostic judgment (Bejjani et al., 2008). These advantages explain why the use of 
aCGH for the diagnosis of constitutional anomalies is progressing faster than the use 
of expression microarrays for the prediction of clinical outcome (e.g., in cancer), for 
which a few applications are entering clinical practice (Bejjani et al., 2008). 
  
A major limitation for using array CGH is the high experimental cost. However high 
quality DNA, as obtained from cell lines or fresh frozen tissue, minimizes 
hybridization failures and therefore overall costs. As with other clinical diagnostic 
methods, there are other limitations to aCGH technology. aCGH is not able to 
identify balanced rearrangements such as translocations, ring chromosomes or 
inversions, as the copy number is not affected (Holcomb et al., 2011). 
 
As was discussed previously (section 1.4), gains of chromosome 8 are amongst the 
most common cytogenetic events that occur in cancer. Nevertheless few studies 
have examined copy number changes of chromosome 8 in childhood solid tumours 
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(section 1.5). The design of these arrays allowed us to examine the status of genes 
tested by MLPA, copy number changes at important genes involved in cancer, as 
well as broader cytogenetic changes affecting any region of the genome. 
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Table 4.1 Cancer genes with lower oligonucleotide probe spacing according to 
Agilent eArray data 
Name Chromosome Cytogenetic location 
   
JUN Chr 1 1p32.1 
LCK Chr 1 1p35.1 
MYCL1/MYCL Chr 1 1p34.2 
NRAS Chr 1 1p13.2 
SKI Chr 1 1p36.33 
TAL1 Chr 1 1p33 
NTRK1 Chr 1 1q23.1 
ABL2 Chr 1 1q25.2 
FGR Chr 1 1p36.11 
MSH2 Chr 2 2p21 
MYCN Chr 2 2p24.3 
REL Chr 2 2p16.1 
FOSL2 Chr 2 2p24.2 
HER4/ERBB4 Chr 2 2q34 
MLH1 Chr 3 3p22.2 
RAF1 Chr 3 3p25.2 
TGFBR2 Chr 3 3p24.1 
THRB Chr 3 3p24.2 
VHL Chr 3 3p25.3 
HEK/EPHA3 Chr 3 3p11.1 
KIT Chr 4 4q12 
MCC Chr 5 5q22.2 
APC Chr 5 5q21 
CSF1R Chr 5 5q32 
FER Chr 5 5q21.3 
MAS1 Chr 6 6q25.3 
MYB Chr 6 6q23.3 
PIM1 Chr 6 6p21.2 
ROS1 Chr 6 6q22.1 
WAF1/CDKN1A Chr 6 6p21.2 
FYN Chr 6 6q21 
MET Chr 7 7q31.2 
EGFR/ ERBB-1 Chr 7 7p11.2 
WNT2 Chr 7 7q31.2 
LYN Chr 8 8q12.1 
MOS Chr 8 8q12.1 
MYBA/MYBL1 Chr 8 8q13.1 
MYC Chr 8 8q24.21 
TPD52 Chr 8 8q21.13 
INK4B/CDKN2B Chr 9 9p21.3 
INK4A/CDKN2A Chr 9 9p21.3 
PTC/RET Chr 10 10q11.21 
KIP2/CDKN1C Chr 11 11p15.4 
CBL Chr 11 11q23.3 
CCND1 Chr 11 11q13.3 
ERGB2/FLI1 Chr 11 11q24.3 
ETS1 Chr 11 11q24.3 
FGF3 Chr 11 11q13.3 
FRA1/FOSL1 Chr 11 11q13.1 
HRAS1 Chr 11 11p15.5 
HSTF1/FGF4 Chr 11 11q13.3 
WT1 Chr 11 11p13 
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Table 4.1 Cancer genes with lower oligonucleotide probe spacing according to 
Agilent eArray data (cont.) 
Name Chromosome Cytogenetic location 
   
KRAS2A Chr 12 12p12.1 
WNT1 Chr 12   12q13.12 
CDK4 Chr 12 12q14.1 
ELK3 Chr 12 12q23.1 
ERBB3 Chr 12 12q13.2 
HST2/FGF6 Chr 12   12p13.32 
RB1 Chr 13 13q14.2 
BRCA2 Chr 13 13q13.1 
MAX Chr 14 14q23.3 
FOS Chr 14 14q24.3 
BCL2ALPHA/BCL2A1 Chr 15 15q25.1 
FES Chr 15 15q26.1 
E-CAD/CDH1 Chr 16 16q22.1 
INT2/INTS2 Chr 17 17q23.2 
NF1 Chr 17 17q11.2 
RASD1 Chr 17 17p11.2 
TOP3A Chr 17 17p11.2 
TP53/P53 Chr 17 17p13.1 
THRA/ ERBA1/ NR1A1 Chr 17 17q21.1 
BRCA1/BRAT1 Chr 17   17q21.31 
CRK Chr 17 17p13.3 
ERBB2 Chr 17                   17q12 
BCL2BETA/BCL2 Chr 18   18q21.33 
DCC Chr 18 18q21.2 
DPC4/SMAD4 Chr 18 18q21.2 
YES1 Chr 18  18p11.32 
JUNB Chr 19 19p13.2 
JUND Chr 19  19p13.11 
AKT2 Chr 19 19q13.2 
BCL3 Chr 19   19q13.32 
VAV1 Chr 19 19p13.3 
SRC Chr 20   20q11.23 
MYBB/MYBL2 Chr 20 20q13.12 
RBAP/E2F1 Chr 20   20q11.22 
HCK Chr 20   20q11.21 
TIAM1 Chr 21   21q22.11 
ERG Chr 21 21q22.2 
ETS2 Chr 21 21q22.2 
NF2 Chr 22 22q12.2 
PDGFB Chr 22 22q13.1 
BCR Chr 22   22q11.23 
DBL/MCF2 Chr X Xq27.1 
ELK1 Chr X   Xp11.23 
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Table 4.2 Customized Agilent eArray SurePrint G3 2X400K array  
 
Information gathered from booklet provided by Agilent eArray customized array  
 
 
 
 
 
 
 
 
 
 
 
 
  
Probe location Number of probes Median Probe 
Spacing (kb) 
Chromosome 8 
 
52,639 1.92 
Genes important in oncology 
n =95 
39,654 0.25-0.5 
Whole genome 
 
420,288 11.81 
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4.2 Aims for aCGH  
1. To obtain copy number data for chromosome 8 in our cohort of paediatric 
solid tumours and breast cancer cell lines.  
 
2. To allow a broader assessment of copy number gains and losses in the same 
cohort in order to identify regions commonly gained or lost. 
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4.3 Results  
When employing aCGH, the presence of chromosomal imbalances can be detected 
and quantified by calculating the ratio of signal intensities of test DNA versus 
reference DNA. For statistical purposes, these ratios are usually converted to a log2 
(test/ref) ratio. The log2 (Cy5/Cy3) scaling has the consequence of centring the ratios 
at approximately zero, making DNA copy number losses appear negative, and copy 
number gains positive. To correct for experimental artefacts, aCGH data are 
normalized so that the ratio for a diploid genome is set to a standard value, usually 
1.0 on a linear scale (0.0 on a log2 scale), and threshold values are established for 
loss, no change, and gain status relative to the diploid reference DNA (Yatsenko et 
al., 2009). The typical mean normal ratio for aCGH has been established as 0.0 
±0.25 on log2 scale, indicating equal copy number within test and reference sample 
DNA (Yatsenko et al., 2009). A change in log2 (Cy5/Cy3) ratio in a chromosome 
region between 0.25 - 0.75 was classified as genomic gain, > 0.75 as high copy 
number gain, < -0.25 as hemizygous loss, and < -0.75 as homozygous deletion 
(Rothenberg et al., 2010). Oligonucleotide microarray data were obtained using 
Agilent Feature Extraction software 10.10, and were imported into Agilent 
CytoGenomics software V2.7.2 and Nexus Copy number v7.5 for analysis. The 
threshold setting to make a positive call was at least 5 consecutive probes, and the 
built-in QC thresholds, e.g. MAPD < 0.3, were used. 
 
According to the characteristics of the design of these arrays (Table 4.2), 
genome-wide results will be presented first with common regions of genomic gain or 
loss identified, including genes of known relevance to cancer (Table 4.1). Results for 
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chromosome 8 will then be presented for each tumour type, and finally aCGH results 
for genes previously explored by MLPA will be described. 
4.3.1 Chromosome 8 copy number changes in breast cell lines  
A genomic compound plot showing copy number changes for all cell lines, showed 
that chromosome 8q presented more copy number gains than other chromosomes 
with the exception of chromosome 1q (Fig 4.1).  
 
Breast cancer cell lines (n=5) showed copy number loss at almost every 
chromosome 8p locus (Fig 4.2), MCF-10A cells however presented a disomic copy 
number in chromosome 8p (Fig 4.2B). 
 
Copy number gains were frequently identified at MLPA chromosome 8q loci in all cell 
lines (Table 4.3). Four loci (EIF3H, EXT1, MYC and PTP4A3) were gained in all (6/6) 
cell lines, followed by RNF139 which was gained in 83% (5/6) cell lines and 12 loci 
were gained in 67% (4/6) cell lines. These copy number changes are broadly 
consistent with those reported previously in these breast cell lines (Table 3.1). All 
Individual genome copy number views for each cell line are shown in Appendix 2.  
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Figure 4.1 Genomic copy number changes in breast cell lines (n=6). Blue 
indicates copy number gain events plotted above the baseline. Losses are shown in 
red below the baseline. A. Compound plot showing frequency of gain/loss on all 
chromosomes. The Y axis indicates the percentage of the cell lines population 
showing a copy number gain/loss at specific points along the genome (X axis, Chr 1 
è Chr Y). Dark blue and dark red indicate more than two-fold copy gain and 
homozygous loss, respectively. B. Individual copy number plots for each cell line. 
The Y axis represents the copy number events for each cell line. The X axis, shows 
copy number gain/loss across the genome, the baseline indicates disomic copy 
number. The compound and individual plots were generated using Nexus Copy 
number software v 7.5. 
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Figure 4.2 Chromosome 8 copy number gain/loss measured in breast cell lines (n=6). Blue indicates copy number gain 
events and are plotted above the baseline. Losses are shown in red below the baseline. A. Compound plot showing frequency of 
gain/loss along chromosome 8, shown as an ideogram above and also according to Mb position on the X axis. The Y axis indicates 
the percentage of cell lines showing copy number gain/loss at specific points along chromosome 8. Dark blue and dark red indicate 
more than two-fold copy gain and homozygous loss, respectively. B. Individual copy number plots for each cell line. The Y axis 
represents the copy number events for each cell line. The X axis, shows copy number gain/loss along chromosome 8 and the 
baseline indicates disomic copy number. The compound and individual plots were generated using Nexus Copy number software 
v7.5. 
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Table 4.3 Chromosome 8 copy number status of genes previously examined 
using MLPA in breast cell lines (n=6) 
          
 
AU565 HCC2157 MCF-7 MCF-10A MDA-MB-231 SK-BR-3 Gain Disomic Loss 
          
Genes       n(%) n(%) n(%) 
          
DLGAP2 0 0 0 1 0 0 0(0) 1(17) 5(83) 
MFHAS1 0 0 0 1 0 0 0(0) 1(17) 5(83) 
MSRA 0 0 0 1 0 0 0(0) 1(17) 5(83) 
GATA4 0 0 0 1 0 0 0(0) 1(17) 5(83) 
CTSB 0 0 0 1 0 0 0(0) 1(17) 5(83) 
TUSC3 0 1 0 1 0 0 0(0) 2(33) 5(83) 
ChGn 0 0 0 1 0 0 0(0) 1(17) 5(83) 
FGFR1 0 0 0 1 0 0 0(0) 1(17) 5(83) 
PRKDC 1 2 1 1 2 2 3(50) 3(50) 0(0) 
MOS 1 2 1 1 2 2 3(50) 3(50) 0(0) 
CHD7 1 2 1 1 2 2 3(50) 3(50) 0(0) 
MYBL1 1 2 1 1 2 2 3(50) 3(50) 0(0) 
NCOA2 2 2 0 1 2 2 4(67) 1(17) 1(17) 
TPD52 2 2 1 1 2 2 4(67) 2(33) 0(0) 
E2F5 2 2 1 1 2 2 4(67) 2(33) 0(0) 
RAD54B 0 2 2 1 2 0 3(50) 1(17) 2(33) 
ST7 0 2 2 2 2 0 4(67) 0(0) 2(33) 
EIF3E 0 2 2 2 2 0 4(67) 0(0) 2(33) 
EIF3H 2 2 2 2 2 2 6(100) 0(0) 0(0) 
EXT1 2 2 2 2 2 2 6(100) 0(0) 0(0) 
RNF139 2 2 2 2 0 2 5(83) 0(0) 1(17) 
MYC 2 2 2 2 2 2 6(100) 0(0) 0(0) 
DDEF1 1 2 2 2 2 1 4(67) 2(33) 0(0) 
KCNQ3 0 2 2 2 2 1 4(67) 1(17) 1(17) 
SLA 1 2 2 2 2 1 4(67) 2(33) 0(0) 
KHDRB
S3 1 2 2 2 2 1 4(67) 2(33) 0(0) 
KCNK9 0 2 2 2 2 0 4(67) 0(0) 2(33) 
PTK2 0 2 2 2 2 0 4(67) 0(0) 2(33) 
PTP4A3 2 2 2 2 2 2 6(100) 0(0) 0(0) 
RECQL4 2 2 2 1 1 2 4(67) 2(33) 0(0) 
          
 2= copy number gain; 1= disomic; 0= copy number loss 
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4.3.2 Compound plots indicating common copy number changes in paediatric 
solid tumours  
Compound copy number plots were derived to show significant peaks using all data 
obtained from aCGH experiments. This feature was used to establish the significance 
of the copy number aberrations in a region. The software applies the Significance 
Testing for Aberrant Copy number (STAC), that was developed to test the 
significance of DNA copy number aberrations across multiple array experiments 
(Diskin et al., 2006). The algorithm identifies a set of copy number changes that are 
stacked on top of each other, such that they would not occur randomly. The cut-off 
35% frequency was used, suggested by Nexus software and traditionally used by 
researchers (Diskin et al., 2006). Therefore common copy number gains and losses 
present in more than 35% (11/31) of samples, and significant at p=0.05 were 
considered of potential interest. STAC was then used to indicate common regions of 
copy number gains or losses in the 4 types of cancer in our study. Tables constructed 
from the significant peaks and compound plots will be presented according to high 
frequency, significant p-value and common events observed.  
 
Genes commonly gained across the 4 types of cancers were located at chromosome 
22q11.22. In osteosarcomas, copy number gain was shown at MIR650, PRAME and 
IGLL5 among other genes, with frequency of 80% and p=0.001 (one-tailed z-test) 
(Table 4.4). These same genes presented copy number gain in Ewing sarcoma with a 
frequency of 62.5% and p=<0.001 (Table 4.5), and in ERMS with frequency of 83.3% 
and p=0.001 (Table 4.6). Similarly in neuroblastoma, common copy number gain was 
present at chromosome 22q11.22 including PRAME, BCR and IGLL5, with a 
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frequency of 70% and p value=<0.001 (Table 4.7). ARMS (n=2), no significant peaks 
were present at 22q11.22, however, two genes with copy number loss were at 
chromosome 5q31.1 (SAR1B and SEC24A) with frequency of 100% and p=0.002 
(Table 4.8). 
 
The customized array also offered cancer genes with lower oligonucleotide probe 
spacing (n=95) (Table 4.1). From this list, no gene consistently showed copy number 
gain or loss in all samples. According to tumour type, genes that consistently showed 
gain/loss were included in Table 4.10. In osteosarcomas, 6/95 cancer genes showed 
copy number loss, and BRCA2 at chromosome 13q13.1 presented copy number loss 
in 4/5 samples, and copy number gain in 1/5 samples. No cancer genes from this list 
presented copy number changes in any samples of Ewing sarcoma. In ERMS, CRK 
at chromosome 17p13 showed copy number gain in 5/6 samples and loss in 1/6 
sample. Only 2/96 genes showed copy number gain in the two ARMS samples 
namely WNT1 on chromosome 12q13.12 and CDK4 located on chromosome 
12q14.19. The 10 neuroblastoma samples did not present any copy number loss at 
any of the 95 genes, however copy number gain was measured in 8/10 samples at 
MYCN at chromosome 2p24.3 (Table 4.9). 
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Table 4.4 Common copy number changes in osteosarcoma n=5 
        
 
Chromosome Region 
Length (bp) 
Number of 
genes 
Event Frequency 
% 
p-Value Gene Symbols 
       
Chr14q13.1 231169 3 CN Loss 60 0.046 SPTSSA, EAPP, SNX6 
Chr14q23.2 249246 3 CN Loss 60 0.046 WDR89, JA429503, SGPP1 
Chr14q32.33 461433 12 CN Gain 80 0.018 IGH, DKFZp686O16217, IGHE, IGHG1, IGHD, 
FLJ00382, MIR4539, AK128652, KIAA0125, ADAM6, 
BC042994, LINC00226 
Chr22q11.22 793423 17 CN Gain 80 0.001 VPREB1, LOC96610, BMS1P20, ZNF280B, 
ZNF280A, PRAME, LL22NC03-63E9.3, LOC648691, 
BCR, POM121L1P, DQ597441, GGTLC2, 
DKFZp667J0810, MIR650, MIR5571, IGLL5, 
DQ575049 
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Table 4.5 Common copy number changes in Ewing sarcoma n=8 
 
Chromosome	 Region 
Length (bp)	
Number 
of genes 
Event	 Frequency 
%	
p-Value	 Gene Symbols	
       
Chr1q21.2 192043 2 CN Loss 37.5 0.005 NBPF25P, BC062745 
Chr3q26.1 90142 1 CN Gain 37.5 <0.001 BC073807 
Chr4p14 151263 2 CN Loss 50 0.007 UBE2K, PDS5A 
Chr4p14 90942 2 CN Loss 50 0.007 MIR4802, RBM47 
Chr6q21 312590 4 CN Loss 37.5 0.034 CDK19, BC047513, AMD1, GTF3C6 
Chr10q21.3 208948 5 CN Loss 50 0.002 PBLD, HNRNPH3, RUFY2, DNA2, SLC25A16 
Chr15q11.1 - q11.2 2231225 44 CN Gain 50 <0.001 DQ576041, DQ571479, BC107108, DQ592463, CHEK2P2, 
HERC2P3, HERC2P7, DQ582073, GOLGA6L6, DQ594309, 
DQ595648, DQ600342, DQ582939, DQ578838, GOLGA8CP, 
DQ572979, JB175342, NBEAP1, DQ573684, DQ595048, 
MIR3118-2, MIR3118-3, MIR3118-4, POTEB2, POTEB, 
POTEB3, NF1P2, MIR5701-1, MIR5701-2, MIR5701-3, CT60, 
LINC01193, LOC646214, CXADRP2, DQ583164, DQ582260, 
DQ590589, DQ587539, POTEB3, DQ786202, 
LOC101927079, LOC727924, OR4M2, OR4N4 
Chr15q25.2 164959 11 CN Gain 37.5 0.017 CPEB1, DQ601936, CPEB1-AS1, LOC283692, AP3B2, 
LOC338963, ACTG1P17, LOC283693, SNHG21, 
SCARNA15, FSD2 
Chr17q21.31 624031 9 CN Loss 50 0.009 KANSL1, KANSL1-AS1, LRRC37A, ARL17A, ARL17B, 
NSFP1, LRRC37A2, ARL17A, NSF 
Chr19q13.12 239303 10 CN Gain 50 <0.001 ZNF461, LINC01534, ZNF567, ZNF850, AX747375, 
LOC728485, BC024306, ZNF790-AS1, ZNF790, ZNF345 
Chr21p11.2 - p11.1 269522 7 CN Gain 37.5 0.001 TPTE, Mir_548, BAGE3, BAGE2, BAGE4, BAGE5, BAGE 
Chr22q11.22 324442 11 CN Gain 62.5 <0.001  VPREB1, PRAME, BCR, POM121L1P, DQ597441, GGTLC2, 
DKFZp667J0810, MIR650, MIR5571, IGLL5, DQ575049 
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Table 4.6 Common copy number changes in ERMS n=6 
       
Chromosome Region 
Length (bp) 
Number 
of genes 
Event Frequency 
% 
p-Value Gene Symbols 
       
Chr3p25.2 2666 1 CN Loss 83.3 <0.001 RAF1 
Chr14q32.33 81594 9 CN Gain 66.7 <0.001 IGH, DKFZp686O16217, IGHE, IGHG1, IGHD, FLJ00382, 
MIR4539, AK128652, KIAA0125 
Chr15q15.2 354412 2 CN Loss 83.3 0.032 TTBK2, UBR1 
Chr15q15.2 - q15.3 101353 5 CN Loss 83.3 0.032 TGM7, LCMT2, ADAL, ZSCAN29, TUBGCP4 
Chr17q25.3 29047 4 CN Gain 66.7 <0.001 ASPSCR1, STRA13, LRRC45, RAC3 
Chr18p11.32 222088 
6 
CN Loss 50.0 0.026 
LOC102723376, DUX4, MIR8078, ROCK1P1, USP14, 
THOC1 
Chr19q13.12 223669 
10 
CN Gain 66.7 0.001 
ZNF461, LINC01534, ZNF567, ZNF850, AX747375, 
LOC728485, BC024306, ZNF790-AS1, ZNF790, ZNF345 
Chr22q11.22 813789 11 CN Gain 83.3 0.001  VPREB1, PRAME, BCR, POM121L1P, DQ597441, 
GGTLC2, DKFZp667J0810, MIR650, MIR5571, IGLL5, 
DQ575049 
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Table 4.7 Common copy number changes in neuroblastoma n=10	
       
Chromosome	 Region 
Length (bp)	
Number of 
genes 
Event	 Frequency 
%	
p-Value	 Gene Symbols	
	 	 	 	 	 	 	
Chr1p13.2 58755 1 CN Gain 50 0.018 TSPAN2 
Chr2p24.3 273543 5 CN Gain 80 <0.001 LOC101926966, AK093525, MYCNUT, MYCNOS, 
MYCN 
Chr3q26.1 90142 1 CN Gain 40 <0.001 BC073807 
Chr9q31.3 137178 1 CN Loss 40 0.048 SVEP1 
Chr10q11.21 30154 1 CN Gain 40 <0.001 RET 
Chr13q14.2 5807 1 CN Gain 50 0.021 RB1 
Chr14q32.33 81594 9 CN Gain 70 <0.001 IGH, DKFZp686O16217, IGHE, IGHG1, IGHD, 
FLJ00382, MIR4539, AK128652, KIAA0125 
Chr15q25.2 164959 11 CN Gain 40 0.002 CPEB1, DQ601936, CPEB1-AS1, LOC283692, 
AP3B2, LOC338963, ACTG1P17, LOC283693, 
SNHG21, SCARNA15, FSD2 
Chr19p13.12 189489 6 CN Loss 50 0.028 OR7C1, OR7A5, OR7A10, OR7A17, OR7C2, SLC1A6 
Chr19q13.12 149777 7 CN Gain 40 <0.001 ZNF850, AX747375, LOC728485, BC024306, ZNF790-
AS1, ZNF790, ZNF345 
Chr20p13 42334 1 CN Loss 40 0.004 SIRPB1 
Chr22q11.22 338246 12 CN Gain 70 <0.001 PRAME, LL22NC03-63E9.3, LOC648691, BCR, 
POM121L1P, DQ597441, GGTLC2, DKFZp667J0810, 
MIR650, MIR5571, IGLL5, DQ575049 
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Table 4.8 Common copy number changes in ARMS n=2 
       
Chromosome	 Region Length	 Number 
of genes 
Event	 Frequency %	 p-Value	 Gene Symbols	
       
Chr3p25.2 5133 1 CN Loss 100 0.001 RAF1 
Chr3q26.1 124085 1 CN Gain 100 0.018 BC073807 
Chr4p14 230779 2 CN Loss 100 0.029 UBE2K, PDS5A 
Chr5q21.3 3587 1 CN Gain 100 0.004 FER 
Chr5q31.1 97963 2 CN Loss 100 0.002 SAR1B, SEC24A 
Chr5q32 34588 2 CN Gain 100 0.004 HMGXB3, CSF1R 
Chr8p11.22 161902 2 CN Gain 100 0.005 ADAM5, ADAM3A 
Chr11p15.4 159414 3 CN Loss 100 0.007 DENND5A, TMEM41B, IPO7 
Chr11q11 117974 4 CN Gain 100 0.025 OR4C11, OR4P4, OR4S2, OR4C6 
Chr17q21.31 409201 6 CN Loss 100 0.039 KANSL1, KANSL1-AS1, LRRC37A, ARL17A, 
ARL17B, NSFP1 
Chr19q13.12 232489 10 CN Gain 100 0.014 ZNF461, LINC01534, ZNF567, ZNF850, 
AX747375, LOC728485, BC024306, ZNF790-
AS1, ZNF790, ZNF345 
Chr20p13 42334 1 CN Loss 100 0.003 SIRPB1 
ChrXp11.22 265786 2 CN Loss 100 0.011 PHF8, FAM120C 
ChrXq28 94845 4 CN Gain 100 0.01 IL9R, WASH1, WASH6P, DDX11L16 
  
 
    
 
 
  144 
    
Table 4.9 Cancer genes with lower oligonucleotide probe spacing with recurrent gain/loss in each type of tumour  
    
    
Osteosarcomas 
 n=5 
ERMS 
n=6 
ARMS 
n=2 
Neuroblastoma  
n=10 
            
Chr.a Gene 
Copy 
Number Chr. Gene 
Copy 
Number Chr. Gene 
Copy 
Number Chr. Gene 
Copy 
Number 
	 	 	 	 	 	 	 	 	
   
3p25.2 RAF  Loss (5/5) 17p13.3 CRK  Loss (5/6) 12q13.12 WNT1  Gain (2/2) 2p24.3 MYCN Gain (8/10) 
5q22.2 APC  Loss (5/5) 
 
 Gain (1/6) 12q14.1 CDK4  Gain (2/2) 
   5q21.3 FER  Loss (5/5) 
         13q13.1 BRCA2  Loss (4/5) 
   
   
     Gain (1/5) 
   
   
   13q14.2 RB1  Loss (5/5) 
         17p13.1 TP53  Loss (5/5) 
         
            aChr. = chromosome 
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4.3.3 Copy number changes by aCGH in genes previously examined by MLPA 
on chromosome 8 in 31 solid tumours 
Most osteosarcomas showed no evidence of copy number gain or loss at the 
chromosome 8p loci examined using MLPA (Fig 4.3). 10/22 chromosome 8q genes 
were gained in 4/5 (80%) samples, and KCNK9 showed copy number gain in all 
osteosarcomas (Table 4.10). Gain of the entire chromosome 8 was evident in 3/8 
Ewing sarcoma samples (Fig 4.4). The highest copy number gains were found at 
CHD7, MYBL1 and PTP4A3 in 4/8 (50%) samples (Table 4.11). Results for 
rhabdomyosarcomas were not split into ARMS and ERMS samples as in previous 
section; these tumour types were predominantly disomic at chromosome 8 loci 
(Fig 4.5), but RECQL4 showed copy number gain in 7/8 (87%) samples (Table 4.12). 
In neuroblastoma samples, few chromosome 8 copy number gains were found (Fig 
4.6), and 3 genes DLGAP2, EXT1 and PTP4A3A were gained in 4/10 (40%) 
samples (Table 4.13). Individual genome copy number results for each paediatric 
solid tumour are shown in Appendix 3. 
4.3.4 Statistical Analysis for loci examined by MLPA 
Application of the Fisher’s exact test to aCGH data for MLPA genes showed that for 
osteosarcoma, the numbers of 8p losses and 8q gains were significantly higher than 
expected. For the other tumour types, Fisher's exact test did not reach statistical 
significance (Table 4.14). 
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Table 4.10 Copy number changes by aCGH at chromosome 8 MLPA genes in 
osteosarcoma n=5 
 
  
	 	 	Gene Gain Disomy Loss 
    
DLGAP2 1(20%) 4(80%) 0(0%) 
MFHAS1 2(40%) 3(60%) 0(0%) 
MSRA 1(20%) 4(80%) 0(0%) 
GATA4 1(20%) 4(80%) 0(0%) 
CTSB 0(0%) 5(100%) 0(0%) 
TUSC3 1(20%) 4(80%) 0(0%) 
ChGn 1(20%) 4(80%) 0(0%) 
FGFR1 1(20%) 3(60%) 1(20%) 
PRKDC 2(40%) 3(60%) 0(0%) 
MOS 2(40%) 1(20%) 2(40%) 
CHD7 3(60%) 1(20%) 1(20%) 
MYBL1 4(80%) 1(20%) 0(0%) 
NCOA2 2(40%) 1(20%) 2(40%) 
TPD52 3(60%) 1(20%) 1(20%) 
E2F5 1(20%) 3(60%) 1(20%) 
RAD54B 4(80%) 1(20%) 0(0%) 
ST7 3(60%) 1(20%) 1(20%) 
EIF3E 4(80%) 1(20%) 0(0%) 
EIF3H 4(80%) 1(20%) 0(0%) 
EXT1 4(80%) 1(20%) 0(0%) 
RNF139 3(60%) 2(40%) 0(0%) 
MYC 3(60%) 2(40%) 0(0%) 
DDEF1 2(40%) 3(60%) 0(0%) 
KCNQ3 4(80%) 1(20%) 0(0%) 
SLA 4(80%) 1(20%) 0(0%) 
KHDRBS3 4(80%) 1(20%) 0(0%) 
KCNK9 5(100%) 0(0%) 0(0%) 
PTK2 4(80%) 1(20%) 0(0%) 
PTP4A3 4(80%) 1(20%) 0(0%) 
RECQL4 3(60%) 2(40%) 0(0%) 
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Figure 4.3 Chromosome 8 copy number alterations measured in osteosarcoma 
(n=5). Blue indicates copy number gain events shown above the baseline. Losses are 
shown in red below the baseline. A. Compound plot showing frequency of gain/loss 
along chromosome 8, shown as an ideogram above and also according to Mb position 
on the X axis. The Y axis indicates the percentage of osteosarcomas showing copy 
number change gain/loss at a specific point along chromosome 8. Dark blue and dark 
red indicate more than two-fold copy gain and homozygous loss, respectively. B. 
Individual copy number plots for each osteosarcoma. The Y axis represents the copy 
number events for each osteosarcoma. The X axis shows copy number gain/loss along 
chromosome 8 and the baseline indicates disomic copy number. The compound and 
individual plots were generated using Nexus Copy number software v 7.5. 
  
A. 
B. 
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Table 4.11 Copy number changes by aCGH at chromosome 8 MLPA genes in 
Ewing sarcoma n=8 
	 	 	 	
	 	 	 	Gene Gain Disomy Loss 
    
DLGAP2 4(50%) 4(50%) 0(0%) 
MFHAS1 2(25%) 5(63%) 1(13%) 
MSRA 3(38%) 5(63%) 0(0%) 
GATA4 2(25%) 6(75%) 0(0%) 
CTSB 2(25%) 6(75%) 0(0%) 
TUSC3 3(38%) 5(63%) 0(0%) 
ChGn 3(38%) 5(63%) 0(0%) 
FGFR1 2(25%) 6(75%) 0(0%) 
PRKDC 2(25%) 6(75%) 0(0%) 
MOS 1(13%) 7(88%) 0(0%) 
CHD7 4(50%) 4(50%) 0(0%) 
MYBL1 4(50%) 4(50%) 0(0%) 
NCOA2 3(38%) 5(63%) 0(0%) 
TPD52 2(25%) 5(63%) 1(13%) 
E2F5 2(25%) 6(75%) 0(0%) 
RAD54B 2(25%) 6(75%) 0(0%) 
ST7 3(38%) 5(63%) 0(0%) 
EIF3E 3(38%) 5(63%) 0(0%) 
EIF3H 3(38%) 5(63%) 0(0%) 
EXT1 3(38%) 5(63%) 0(0%) 
RNF139 2(25%) 6(75%) 0(0%) 
MYC 2(25%) 6(75%) 0(0%) 
DDEF1 3(38%) 5(63%) 0(0%) 
KCNQ3 3(38%) 5(63%) 0(0%) 
SLA 3(38%) 5(63%) 0(0%) 
KHDRBS3 3(38%) 5(63%) 0(0%) 
KCNK9 2(25%) 6(75%) 0(0%) 
PTK2 3(38%) 5(63%) 0(0%) 
PTP4A3 4(50%) 4(50%) 0(0%) 
RECQL4 2(25%) 6(75%) 0(0%) 
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Figure 4.4 Chromosome 8 copy number alterations measured in Ewing sarcoma 
(n=8). Blue indicates copy number gain events shown above the baseline. Losses are 
shown in red below the baseline. A. Compound plot showing frequency of gain/loss 
along chromosome 8, shown as an ideogram above and also according to Mb position 
on the X axis. The Y axis indicates the percentage of Ewing sarcomas showing copy 
number change gain/loss at a specific point along chromosome 8. Dark blue and dark 
red indicate more than two-fold copy gain and homozygous loss, respectively. B. 
Individual copy number plots for Ewing sarcoma. The Y axis represents the copy 
number events for each Ewing sarcoma. The X axis shows copy number gain/loss 
along chromosome 8 and the baseline indicates disomic copy number. The compound 
and individual plots were generated using Nexus Copy number software v 7.5. 
 
 
  
A. 
B. 
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Table 4.12 Copy number changes by aCGH at chromosome 8 MLPA genes in 
rhabdomyosarcoma n=8 
	 	 	 	    
Genes Gain Disomy Loss 
    
DLGAP2 2(25%) 6(75%) 0(0%) 
MFHAS1 0(0%) 8(100%) 0(0%) 
MSRA 1(13%) 7(87%) 0(0%) 
GATA4 0(0%) 8(100%) 0(0%) 
CTSB 0(0%) 8(100%) 1(13%) 
TUSC3 0(0%) 8(100%) 0(0%) 
ChGn 0(0%) 8(100%) 0(0%) 
FGFR1 0(0%) 7(87%) 1(13%) 
PRKDC 0(0%) 7(87%) 1(13%) 
MOS 0(0%) 8(100%) 0(0%) 
CHD7 0(0%) 8(100%) 0(0%) 
MYBL1 0(0%) 8(100%) 0(0%) 
NCOA2 1(13%) 6(75%) 1(13%) 
TPD52 2(25%) 5(62%) 1(13%) 
E2F5 1(13%) 6(75%) 1(13%) 
RAD54B 1(13%) 6(75%) 1(13%) 
ST7 1(13%) 7(87%) 0(0%) 
EIF3E 1(13%) 6(75%) 1(13%) 
EIF3H 1(13%) 7(87%) 0(0%) 
EXT1 1(13%) 7(87%) 0(0%) 
RNF139 0(0%) 7(87%) 1(13%) 
MYC 1(13%) 6(74%) 1(13%) 
DDEF1 0(0%) 7(87%) 1(13%) 
KCNQ3 2(25%) 6(75%) 0(0%) 
SLA 2(25%) 6(75%) 0(0%) 
KHDRBS3 2(25%) 6(75%)       0(0%) 
KCNK9 0(0%) 8(100%) 0(0%) 
PTK2 0(0%) 6(75%) 2(25%) 
PTP4A3 2(25%) 6(75%) 0(0%) 
RECQL4 7(87%) 1(13%) 0(0%) 
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Figure 4.5 Chromosome 8 copy number alterations measured in 
rhabdomyosarcoma (n=8). Two cases (M27R and M32R) were ARMS samples, all 
others were ERMS samples. Blue indicates copy number gain events shown above the 
baseline. Losses are shown in red below the baseline. A. Compound plot showing 
frequency of gain/loss along chromosome 8, shown as an ideogram above and also 
according to Mb position on the X axis. The Y axis indicates the percentage of 
rhabdomyosarcomas showing copy number change gain/loss at a specific point along 
chromosome 8. Dark blue and dark red indicate more than two-fold gain and 
homozygous loss, respectively. B. Individual copy number plots for rhabdomyosarcomas. 
The Y axis represents the copy number events for each rhabdomyosarcomas. The X axis 
shows copy number gain/loss along chromosome 8 and the baseline indicates disomic 
copy number. The compound and individual plots were generated using Nexus Copy 
number software v 7.5.  
A. 
B. 
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Table 4.13 Copy number changes by aCGH at chromosome 8 MLPA genes in 
neuroblastoma n=10 
	 	 	 	
	 	 	 	Gene Gain Disomy Loss 
    
DLGAP2 4(40%) 6(60%) 0(0%) 
MFHAS1 1(10%) 9(90%) 0(0%) 
MSRA 2(20%) 8(80%) 0(0%) 
GATA4 1(10%) 9(90%) 0(0%) 
CTSB 1(10%) 9(90%) 0(0%) 
TUSC3 1(10%) 9(90%) 0(0%) 
ChGn 1(10%) 9(90%) 0(0%) 
FGFR1 2(20%) 8(80%) 0(0%) 
PRKDC 2(20%) 8(80%) 0(0%) 
MOS 2(20%) 8(80%) 0(0%) 
CHD7 1(10%) 9(90%) 0(0%) 
MYBL1 2(20%) 7(70%) 1(10%) 
NCOA2 1(10%) 9(90%) 0(0%) 
TPD52 1(10%) 9(90%) 0(0%) 
E2F5 2(20%) 8(80%) 0(0%) 
RAD54B 1(10%) 8(80%) 1(10%) 
ST7 1(10%) 9(90%) 0(0%) 
EIF3E 1(10%) 9(90%) 0(0%) 
EIF3H 1(10%) 9(90%) 0(0%) 
EXT1 4(40%) 6(60%) 0(0%) 
RNF13 2(20%) 8(80%) 0(0%) 
MYC 2(20%) 8(80%) 0(0%) 
DDEF1 2(20%) 8(80%) 0(0%) 
KCNQ3 2(20%) 8(80%) 0(0%) 
SLA 2(20%) 8(80%) 0(0%) 
KHDRBS3 1(10%) 9(90%) 0(0%) 
KCNK9 3(30%) 7(70%) 0(0%) 
PTK2 2(20%) 8(80%) 0(0%) 
PTP4A3 4(40%) 6(60%) 0(0%) 
RECQL4 3(30%) 6(60%) 1(10%) 
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Figure 4.6 Chromosome 8 copy number alterations measured in neuroblastoma 
(n=10). Blue indicates copy number gain events shown above the baseline. Losses are 
shown in red below the baseline. A. Compound plot showing frequency of gain/loss 
along chromosome 8, shown as an ideogram above and also according to Mb position 
on the X axis. The Y axis indicates the percentage of neuroblastomas showing copy 
number change gain/loss at a specific point along chromosome 8. Dark blue and dark 
red indicate more than two-fold copy gain and homozygous loss, respectively. B. 
Individual copy number plots for neuroblastomas. The Y axis represents the copy 
number events for each neuroblastoma. The X axis shows copy number gain/loss along 
chromosome 8 and the baseline indicates disomic copy number. The compound and 
individual plots were generated using Nexus Copy number software v 7.5. 
  
A. 
B. 
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Table 4.14 Statistical analysis of chromosome 8p versus 8q using Fisher’s exact 
test for each type of tumour 
p-values ≤ 0.05 were considered statistically significant 
Categories: 2=Gain; 1=Disomy; 0=Loss	
	
Osteosarcoma Category 2 Category 1 Category 0 
   8p 8 31 1 
   8q 72 30 8 
   
 
p=1.1E-7 
   
       Ewing sarcoma Category 2 Category 1 Category 0 
   8p 21 42 1 
   8q 59 116 1 
   
 
p=0.60 
     
       ARMS Category 2 Category 1 Category 0 
   8p 0 14 2 
   8q 1 33 10 
   
 
p=0.4695 
     
       ERMS Category 2 Category 1 Category 0 
   8p 3 45 0 
   8q 24 107 1 
   
 
p=0.0678 
     
       Neuroblastoma Category 2 Category 1 Category 0 
   8p 13 67 0 
   8q 42 175 3 
   
 
p=0.59 
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4.4 Discussion 
The importance of chromosome 8 in different types of cancer was revealed in the 
study of Myllykangas et al. (2006) where they performed a bibliomics survey using 
838 published chromosomal CGH results for 73 distinct neoplasms. These analyses 
showed that 8p23-q12 and 8q23 are hot spot areas, with a significant 
overrepresentation of cancer genes. Chromosome 8 was one of the most frequently 
amplified chromosomes across all tumour types (Myllykangas et al., 2006).  
4.4.1 Chromosome 8 copy number changes in breast cell lines  
Cancer cell lines have been used to investigate cancer pathobiology as well as to 
test new therapies (Kao et al., 2009). Cell lines are also used to study genomic 
alterations assuming that they reflect the genotype and phenotype of the primary 
tumour. Tsuji et al. (2010) studied the differences and similarities between cell lines 
and primary tumour tissue using aCGH, and concluded that established cell lines 
carry cell line-specific DNA copy number aberrations together with recurrent 
aberrations detected in primary tumour tissues. Structural and numerical alterations 
of chromosome 8 in breast cell lines have been reported, including partial or 
complete deletions of 8p and gains of 8q (Rummukainen et al., 2001) (Table 3.2).   
 
In this project, 5 breast cell lines showed copy number loss for almost every MLPA 
locus on 8p, except TUSC3 in HCC2157 cells. MCF-10A cells have been previously 
reported to carry 2 copies of chromosome 8p (Marella et al., 2009), which was 
confirmed in the present study (Fig 4.2). In SK-BR-3 cells, two amplicons have been 
reported, namely 8q21-23, that contains putative target genes TPD52 and WWP1, 
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and 8q24 that contains MYC (Rodriguez-Pinilla et al., 2007; Ruiz et al., 2006). Copy 
number gain was also measured at TPD52 and MYC in SK-BR-3 cells using aCGH 
(Table 4.3). Kao et al. (2009) studied 52 breast cancer cell lines using aCGH, which 
include 5/6 cell lines used in the present study, and 25/30 genes examined by 
MLPA. In most cases, 104/125 (83%), there was agreement between their findings 
(data not shown) and our results (Kao et al., 2009), suggesting that reproducible 
aCGH results were generated in the present study.   
4.4.2 Common regions of copy number change in paediatric solid tumours 
Chromosome 22q11.22 was commonly gained in the paediatric solid tumours 
analysed, and harbours genes such as PRAME, VPREB1, and POM121L1P, among 
others (Tables 4.4, 4.5, 4.6, and 4.7). PRAME, or preferentially expressed antigen in 
melanoma, is an attractive potential target for tumour immunotherapy as PRAME is 
overexpressed in many solid tumours and haematological malignancies whilst 
showing minimal expression in normal tissues (Bankovic et al., 2010). For example, 
PRAME transcripts can be detected by QRT-PCR analysis in approximately 20–30% 
of patients with chronic leukaemia, but not in normal donors (Paydas et al., 2007).  
 
High expression of PRAME has been associated with poor prognosis in solid 
tumours such as neuroblastoma and breast cancer (Doolan et al., 2008). Specifically 
in neuroblastoma patients, high expression of PRAME is linked with advanced 
tumour stage, older age at diagnosis, and poor clinical outcome (Doolan et al., 2008; 
Oberthuer et al., 2004). Tan et al. (2012) reported that PRAME was expressed in five 
osteosarcoma cell lines and in more than 70% of osteosarcoma patient specimens. 
Furthermore, PRAME siRNA knockdown significantly suppressed proliferation, 
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colony formation, and G1 cell cycle arrest in U-2OS cells, thus suggesting that 
PRAME plays an important role in cell proliferation and disease progression in 
osteosarcoma (Tan et al., 2012). Although no literature was found relating Ewing 
sarcoma or rhabdomyosarcoma with PRAME, the reported studies in other solid 
tumours indicate this gene could be a relevant target for future studies. The other 
genes in this region have not been explored in the present study. 
 
The criteria to select genes from the list of genes important in cancer (Table 4.1) 
were consistency in gain or loss in each tumour type, high frequency, p-value and 
literature that supported importance and novelty (Table 4.9). Osteosarcomas (n=5) 
presented copy number loss at 6 cancer genes: RAF (3p25.2), involved in a 
signalling pathway as an important factor of osteosarcoma growth and metastasis 
(Yu et al., 2011), APC (5q21), RB1 (13q14.2) and TP53 (17p13.1) widely known to 
be involved in osteosarcoma tumourigenesis and progression (Kansara et al., 2014; 
Martin et al., 2012), and BRCA2 (13q13.1) and FER (5q21.3). No previous literature 
describes these last 2 genes in osteosarcoma. 
 
In ERMS (n=6), CRK (17p13.3) was lost in 5/6 cases. Previously implicated in 
cancers such as lung, breast, gliomas, gastric cancer, sarcomas, ovarian and 
hematopoietic cancers (Sriram et al., 2010), CRK is a proto-oncogene that encodes 
a member of an adapter protein family that binds to several tyrosine-phosphorylated 
proteins (Park et al., 2008); no literature was found relating CRK with ERMS. The 
genomic region 12q13-q14 that includes WNT1 (12q13.12) and CDK4 (12q14.1) 
showed copy number gain in alveolar rhabdomyosarcomas (n=2) (Table 4.8). 
Amplification of this genomic region has been found in diverse tumours such as lung 
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cancer (Myllykangas et al., 2007), liposarcomas (Shimada et al., 2006), and 
anaplastic astrocytoma (Backlund et al., 2005). Barr et al. (2009) reported that a 
12q13-q14 region was amplified preferentially in PAX3-FOXO1-positive ARMS 
cases, and was associated with significantly worse progression and overall survival 
that was independent of gene fusion status. 
4.4.3 Copy number changes in chromosome 8 genes examined by MLPA in the 
solid tumour cohort 
The solid tumour showing the most chromosome 8 copy number changes was 
osteosarcoma, predominantly copy number gains at chromosome 8q. This is 
consistent with the literature that classifies osteosarcomas as a solid tumour with an 
unusually high frequency of genome rearrangements, and the presence of a 
complex karyotype as hallmarks (Kansara et al., 2014; Man et al., 2004).  
 
From the list of genes on chromosome 8 examined by MLPA, only KNCK9 (8q24.3) 
showed copy number gain in all 5 osteosarcomas. KNCK9, or potassium channel 
gene subfamily K member 9, has been associated with tumourigenesis of 
osteosarcoma, after induced fluctuations in extracellular pH significantly reduced the 
proliferation rate of MG63 human osteoblast-like cells (Li et al., 2013). Not many 
recent studies correlate copy number gain of this gene with tumourigenesis or 
progression of this solid tumour, thus KCNK9 may represent a candidate gene for 
further study. 
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Ewing sarcomas showed trisomy of chromosome 8 in 3/8 cases, which is one of the 
characteristics of this solid tumour, albeit typically reported in 50-60 % of cases 
(Mackintosh et al., 2010).  
In rhabdomyosarcoma, RECQL4 (8q24.3) showed copy number gain in 7/8 (83%) 
cases, representing 6/6 ERMS and 1/2 ARMS. The protein encoded by RECQL4 has 
been associated with the formation of a member of the RecQ helicases. The 
helicases bind to the DNA and temporarily unwind the two double DNA helix, 
participates in cell cycle control/checkpoint and DNA damage repair (Nishijo et al., 
2004). Not much literature was found relating to this gene with rhabdomyosarcoma, 
although germline mutations in RECQL4 have been associated with osteosarcoma 
risk (Hicks et al., 2007). Amplification and overexpression of RECQL4 have been 
reported in colorectal (Buffart et al., 2005), breast (Fang et al., 2013), laryngeal 
(Saglam et al., 2007), and cervical cancers (Narayan et al., 2007).  
 
In neuroblastoma, no chromosome 8 gene presented copy number gain or loss for 
the majority of samples, with most genes showing a disomic pattern in most (9/10) 
samples. Some authors attribute the flat or disomic pattern of neuroblastoma with a 
higher amount of Schwann cell stroma (more than 50%), this being composed of 
normal cells in differentiating/maturing neuroblastomas with diploid DNA content and 
lack of aberrations (Ambros et al., 2011). However in this project we did not 
performed any pathology test showing the stromal cell percentage to be sure about 
this fact.  
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4.4.4 Limitations 
The size of the tumour cohort was a limiting factor, since finding genes with copy 
number change, with statistical significance, was a challenge in such a small 
population. While we nonetheless identified numerous significant peaks of gain or 
loss in the tumour types analysed (Tables 4.4 - 4.8), including genes of known 
significance such as MYCN in neuroblastoma (Table 4.7), the small sample numbers 
reduced our ability to be confident of the significance of many of these results. 
 
The aCGH technique also presents inherent limitations, as it is unable to detect 
balanced rearrangements as translocations and inversions. Thus we could have 
overlooked important genes related to the four cancers that we studied. Such is the 
case in ARMS where the main characteristic is a reciprocal chromosomal 
translocation t(2;13) in approximately 70% of the ARMS cases, and a less common 
t(1;13) variant detected in approximately 10% of ARMS (Wang, 2012). Similarly, over 
80% of Ewing sarcomas present with t(11;22) (Jahromi et al., 2012). Finally, the 
need for specialised equipment, materials and processes to perform aCGH makes 
this technique still unavailable to many scientists, and expensive for regular clinical 
application.   
4.4.5 Summary and conclusions 
aCGH is a complex technique that requires prior basic cytogenetic knowledge and 
attention to detail. Performing aCGH on well-studied breast cell lines produced 
results with good concordance with the literature, indicating that the technique 
performed correctly in our hands. Our custom design that focused attention on 95 
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genes with known importance in cancer also facilitated comparisons between our 
results and these of previous studies. However, it is an undeniable fact that 
molecular techniques such as aCGH generate lots of data, which in turn are 
processed by means of complex algorithms. In this deluge of information, we are 
confronted with the problem of high dimensional statistics and performing such 
analyses is not an easy task. We therefore relied on specialised software packages, 
an area that is also evolving quickly. 
In the next chapter of this dissertation, aCGH copy number data for specific 
chromosome 8 genes will be compared with the results of quantitative PCR, and our 
previous MLPA results.  
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Chapter 5  
Comparison of 3 techniques for the assessment of 
DNA copy number as applied to solid paediatric 
tumour samples and breast cell lines 
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5.1 Introduction 
Throughout this project we have presented literature supporting the notion that, for 
chromosome 8, copy number variation can range from whole copies of 
chromosome 8, through whole chromosome arms, to individual genes. In various 
ways, each has the potential to make some contribution to the development of 
cancer. Chromosome 8 alterations in childhood cancers include the gain of the 
entire chromosome 8 in Ewing sarcoma (Toomey et al., 2010), translocation t(2;8) 
producing the  fusion gene PAX3/NCOA2 in rhabdomyosarcomas (Sumegi et al., 
2010), t(8;14), t(2;8), t(8;14;18) and (8;22) translocations in Burkitt lymphoma 
(Schmitz et al., 2012), and recurrent  focal gains of 8q24 in acute myeloid 
leukaemia (Kuhn et al., 2012).  
 
Techniques to identify alterations in DNA copy number include MLPA, aCGH, 
quantitative PCR (qPCR) and next generation sequencing (Carter, 2007). aCGH 
profiling is currently a gold standard technique for measurement of DNA copy 
number (Hayes et al., 2013). aCGH targets thousands of genomic sites 
simultaneously in a single patient, allowing broad coverage of the genome. 
However, possible disadvantages include expense, and the considerable amount 
of time required to analyse the data. MLPA has emerged as an alternative, being a 
relatively economic and rapid technique that can be applied to many samples 
simultaneously, with the constraint that the number of genes that can be assayed 
at once is limited (Stuppia et al., 2012). 
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To complement our research in this area (chapters 3 and 4), we used a third 
technique, qPCR, to assess chromosome 8 copy number at particular loci in a 
subset of the samples analysed. This technique presents many advantages, such 
as its low consumable and instrumentation costs, fast turnaround and assay 
development time, and high sensitivity among others (Table 1.10). These qPCR 
experiments were performed to resolve discrepancies in copy number results, as 
measured by aCGH and MLPA. This process of resolution will be described below.  
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5.2 Aims 
1. To compare the results obtained by the MLPA “Salsa kit P014-A1” for 
chromosome 8q loci with results obtained for the same loci using aCGH.  
 
2. To perform qPCR for a subset of genes analysed by both MLPA and aCGH, 
and compare the results obtained by these 3 techniques. 
 
3. To identify the most reliable technique for assessing chromosome 8 copy 
number status in childhood solid tumours. 
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5.3 Results 
Comparison of MLPA versus aCGH copy number results was made based on the 
results for the 30 genes included in the MLPA kit (Table 2.3). The genes MYC and 
RECQL4 each included two sets of MLPA probes per gene. In order to compare 
the results from MLPA with the results from aCGH, results obtained for the two 
sets of MLPA probes were averaged for each gene. 
 
In the case of aCGH we used a customized 60-mer-oligonucleotide high density 
array with 52,639 probes mapping throughout chromosome 8, with approximately 
even spacing. In the initial stage aCGH data were analysed using the Agilent 
proprietary software “CytoGenomics”. While this could visualize the basic aCGH 
results, this software was not sufficiently versatile for our final analysis. “Nexus 
v7.5”, on the other hand, offered better flexibility, and plotting functionality at 
frequencies not available in CytoGenomics. Both packages aim to detect and 
quantify copy number by calculating the ratio of signal intensities obtained for test 
DNA versus reference DNA. Nexus uses the intensity values to arrive at log2 
ratios that are segmented hierarchically into neighbouring regions, using 
BioDiscovery’s “Rank Segmentation” algorithm. At the completion of this process, 
the entire genome can be represented as a series of segments, with each 
segment having a “cluster value” which is the median log2 ratio value of all the 
probes in that region. 
 
To facilitate comparison of data obtained via two different numeric scales (MLPA 
uses a linear scale, whereas aCGH uses a logarithmic scale), copy number data 
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from MLPA and aCGH analyses were converted to 3 categories; gain (coded as 
2), normal range (or disomy, coded as 1) and copy number loss (coded as 0). 
Category tables (see chapter 3 for MLPA, and Appendix 4 for aCGH) for each 
technique were used to construct a summary table that compares agreements and 
disagreements between the results obtained by MLPA and aCGH (Table 5.1). 
5.3.1 Comparison of copy number results obtained using MLPA or aCGH 
across all measured chromosome 8 loci in 6 breast cell lines 
When comparing MLPA and aCGH results for loci of chromosome arm 8p and 8q 
loci for the 6 breast cell lines, all chromosome 8p loci (6 cell lines x 8 genes = 48 
data points) showed concordant results using MLPA and aCGH (Table 5.2). 
However, for chromosome 8q loci the percentage of concordance was only 53% 
(70 concordant results /22 chromosome 8q genes x 6 cell lines) (Table 5.2). 
Examples of two cell lines comparing results obtained by MLPA and aCGH are 
presented in Figures 5.1 and 5.2. 
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Table 5.1 Agreement and disagreement between MLPA and aCGH copy number results in breast cell lines (n=6) 
 
                                8p (8 genes)                                                                        Chromosome 8q (22 genes)  
 
Genes è  
 
 
 
Cell lines ê  
D
LG
A
P2
 
M
FH
A
S 
M
SR
A
 
G
A
TA
4 
C
TS
B
 
TU
SC
3 
C
hG
n 
FG
FR
1 
PR
K
D
C
 
M
O
S 
C
H
D
7 
M
YB
L 
N
C
O
A
2 
TP
D
52
 
E2
F5
 
R
A
D
54
B
 
ST
7 
EI
F3
E 
EI
F3
H
 
EX
T1
 
R
N
F1
39
 
M
YC
 
D
D
EF
1 
K
C
N
Q
3 
SL
A
 
K
H
D
R
B
S3
 
K
C
N
K
9 
PT
K
2 
PT
P4
A
 
R
EC
Q
L4
 
AU565 A1 A A A A A A A D2 A A A D A D A A A A A A A A A D D A A D D 
HCC2157 A A A A A A A A A A A A A A A A D A A D D A D D D D D D D A 
MCF7 A A A A A A A A A A A A A A A A A A D D A A A D D D D D D D 
MCF10A A A A A A A A A A A A A A A A A D D D D D A D D A D D D D A 
MDAMB231 A A A A A A A A A D A A D A D D D D D D A D A D D D D D D A 
SKBR3 A A A A A A A A D D D D D A D A A A A A A A A D A D A A D D 
Agreement % 100 100 100 100 100 100 100 100 67 67 83 83 50 100 50 83 50 67 50 33 67 83 67 17 33 0 33 33 0 50 
 
1A= Agreement,   
2D=Disagreement  
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Table 5.2 Summary of agreement between MLPA and aCGH results obtained 
In 6 breast cell lines at chromosome 8p and 8q loci  
 
  
Chromosome 8 Number of genes X 6 cell lines 
Agreement 
% 
8p 
(8 genes) 48 48 (100%) 
8q 
(22 genes) 132 70 (53%) 
8p + 8q 180 118 (66%) 
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8p genes                8q genes 
8pter            8qter 
 
 
Figure 5.1 Comparison of copy number predictions obtained using MLPA 
(orange) and aCGH (blue) at chromosome 8p and 8q loci in MCF-10A cells. 
Copy number categories are shown on the Y axis (0 = copy number loss, 1 = 
disomy, 2 = copy number gain), whereas the loci examined are shown on the X axis. 
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8p genes       8q genes 
 8pter               8qter 
 
 
 
Figure 5.2 Comparison of copy number predictions obtained using MLPA 
(orange) and aCGH (blue) at chromosome 8p and 8q loci in SK-BR-3 cells. 
Copy number categories are shown on the Y axis (0 = copy number loss, 1 = 
disomy, 2 = copy number gain), whereas the loci examined are shown on the X axis. 
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5.3.2 Comparison of MLPA and aCGH copy number results obtained for the 
paediatric solid tumour cohort, according to tumour type 
As comparison of MLPA and aCGH results revealed different levels of agreement for 
chromosome 8p versus 8q loci in the breast cell lines, we performed similar analyses 
for the paediatric solid tumour types examined in this study. For osteosarcoma 
samples (n=5) there was 60% (24/40) agreement between MLPA and aCGH results 
for chromosome 8p loci, and 44% (48/110) agreement for chromosome 8q loci. The 
total percentage of agreement was 48% (72/150) for all chromosome 8 loci (Tables 
5.3 and 5.7). Results for a single (but representative) osteosarcoma case are shown 
in Figure 5.3. 
 
In Ewing sarcoma (n=8), the percentage agreement was 61% (39/64) for 8p loci and 
63% (110/176) for 8q loci, a total of 62% agreement for all chromosome 8 loci 
(Tables 5.4 and 5.7). Again, the results for a single Ewing sarcoma case are shown 
as an example in Figure 5.4. 
 
For rhabdomyosarcoma (n=8) we noted 88% (56/64) agreement between MLPA and 
aCGH results at chromosome 8p loci, 75% (132/176) agreement for chromosome 8q 
loci, and 78% (188/240) agreement for all chromosome 8 loci (Tables 5.5 and 5.7). 
Results for a ERMS case are shown in Figure 5.5 as an example. Finally, for 
neuroblastoma (n=10), 58% (46/80) agreement was noted between MLPA and 
aCGH results for chromosome 8p loci, and 62% (136/220) agreement was noted 
between MLPA and aCGH results for chromosome for 8q loci, with a total of 61% 
  173 
(182/300) agreement noted for all chromosome 8 loci (Tables 5.6 and 5.7). Results 
for a single neuroblastoma case are shown in Figure 5.6. 
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Table 5.3 Agreement and disagreement between MLPA and aCGH copy number results in osteosarcoma (n=5) 
 
                                
8p (8 genes)                                                                         Chromosome 8q (22 genes)  
 
 
Genes è 
 
 
 
Samples ê 
D
LG
A
P2
 
M
FH
A
S 
M
SR
A
 
G
A
TA
4 
C
TS
B
 
TU
SC
3 
C
hG
n 
FG
FR
1 
PR
K
D
C
 
M
O
S 
C
H
D
7 
M
YB
L 
N
C
O
A
2 
TP
D
52
 
E2
F5
 
R
A
D
54
B
 
ST
7 
EI
F3
E 
EI
F3
H
 
EX
T1
 
R
N
F1
39
 
M
YC
 
D
D
EF
1 
K
C
N
Q
3 
SL
A
 
K
H
D
R
B
S3
 
K
C
N
K
9 
PT
K
2 
PT
P4
A
 
R
EC
Q
L4
 
F9O A1 A A A A A A A A D2 D D D A D D D D D D D D D D D D D D D D 
F10O A A A A A A A D A A D A D D A A A A A A A A A A D A D D D D 
M11O D D A D A A A D A D A A D D A D D D D D A A A D D D D A A D 
F12O D D D D D A D D D D A A A A A D A A A A A A A D D D D D D A 
M46O D D D D A A A A D A D D A D A A A A A A D D D D A A D D D D 
Agreement % 40 40 60 40 80 100 80 40 60 40 40 60 40 40 80 40 60 60 60 60 60 60 60 20 20 40 0 20 20 20 
 
1A= Agreement  
2D=Disagreement  
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Figure 5.3 Comparison of copy number predictions obtained using MLPA 
(orange) and aCGH (blue) at chromosome 8p and 8q loci in osteosarcoma 
M11O case. Copy number categories shown on the Y axis (0 = copy number loss, 1 
= disomy, 2 = copy number gain), whereas the loci examined are shown on the X 
axis.
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Table 5.4 Agreement and disagreement between MLPA and aCGH copy number results in Ewing sarcoma (n=8) 
 
          
8p (8 genes)                                                                         Chromosome 8q (22 genes) 
 
Genes è 
 
 
Samples ê D
LG
A
P2
 
M
FH
A
S 
M
SR
A
 
G
A
TA
4 
C
TS
B
 
TU
SC
3 
C
hG
n 
FG
FR
1 
PR
K
D
C
 
M
O
S 
C
H
D
7 
M
YB
L 
N
C
O
A
2 
TP
D
52
 
E2
F5
 
R
A
D
54
B
 
ST
7 
EI
F3
E 
EI
F3
H
 
EX
T1
 
R
N
F1
39
 
M
YC
 
D
D
EF
1 
K
C
N
Q
3 
SL
A
 
K
H
D
R
B
S
3 
K
C
N
K
9 
PT
K
2 
PT
P4
A
 
R
EC
Q
L4
 
M13E D2 A1 A A A A A A A A D D A A A A A A A A A A A A A A A A D D 
M14E D A D A A A D A A A D D D A A D D A D A A A D D D D A D A A 
F15E D D D D D D D D D D D D D D D D D D D D D D D D D D D D D A 
M16E D D D D D D D D D A D D D D D A D D D D D D D D D D D D D A 
F17E A A A A A D A A A A D A A D A A A A A A A A A A D A D A D A 
F18E A D A A D A A A A A A A A A A A A D A A A A A A A A A A A A 
M22E A D A A A D A A A A A A A D A A A A A A A A A A D A D A A A 
F24E A A A A A A A A A A A A A A A A A A A D A A A A A A A A A D 
Agreement  
% 50 50 62.5 75 62.5 50 62.5 75 75 87.5 37.5 50 62.5 50 75 75 62.5 62.5 62.5 62.5 75 75 62.5 62.5 37.5 62.5 50 62.5 50 75 
 
1A= Agreement  
2D=Disagreement 
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Figure 5.4 Comparison of copy number predictions obtained using MLPA 
(orange) and aCGH (blue) at chromosome 8p and 8q loci in Ewing sarcoma 
M22E case. Copy number categories shown on the Y axis  (0  = copy number loss, 
1 = disomy, 2 = copy number gain), whereas the loci examined are shown on the X 
axis. 
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Table 5.5 Agreement and disagreement between MLPA and aCGH copy number results in rhabdomyosarcoma (n=8) 
 
 
8p (8 genes)                                                                         Chromosome 8q (22 genes) 
 
Genes è 
 
 
Samples ê D
LG
A
P2
 
M
FH
A
S 
M
SR
A
 
G
A
TA
4 
C
TS
B
 
TU
SC
3 
C
hG
n 
FG
FR
1 
PR
K
D
C
 
M
O
S 
C
H
D
7 
M
YB
L 
N
C
O
A
2 
TP
D
52
 
E2
F5
 
R
A
D
54
B
 
ST
7 
EI
F3
E 
EI
F3
H
 
EX
T1
 
R
N
F1
39
 
M
YC
 
D
D
EF
1 
K
C
N
Q
3 
SL
A
 
K
H
D
R
B
S
3 
K
C
N
K
9 
PT
K
2 
PT
P4
A
 
R
EC
Q
L4
 
M25R D2 A1 D A A A A A A A A A A A A A A A A A A A A D D D A A A D 
F26R A A A A A A A A A A A A A A A A A A A A A A A A A A A A D D 
M27R A A A A D A A D D A A A D D D D A D A A D D D A A A A D A A 
F28R A A A A A D A A A A A A A A A A A A A A A A A A A A A D A D 
F29R D A A A A A A A A A A A A A D A D D A D A A A A A A D A D D 
M31R A A A A A D A A A A D A D A A A A A D D A A A A D D A A A D 
M32R A A A A A A A A A A A A A A A A A A A D A A A A A A A A A D 
M35R A A A A A D A A A D A D A D A D A A A D A A A D D A D A D D 
Agreement 
 % 75 100 87.5 100 87.5 62.5 100 87.5 87.5 87.5 87.5 87.5 75 75 75 75 87.5 75 87.5 50 87.5 87.5 87.5 75 62.5 75 75 75 62.5 12.5 
 
1A= Agreement   
2D=Disagreement  
 
 
 
 
  179 
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  8pter                               8qter 
 
 
Figure 5.5 Comparison of copy number predictions obtained using MLPA 
(orange) and aCGH (blue) at chromosome 8p and 8q loci in ERMS F29R 
case. Copy number categories shown on the Y axis (0 = copy number loss, 1 = 
disomy, 2 = copy number gain), whereas the loci examined are shown on the X 
axis. 
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Table 5.6 Agreement and disagreement between MLPA and aCGH copy number results in neuroblastoma (n=10) 
 
 
  8p (8 genes)                                                                                   Chromosome 8q (22 genes) 
 
Genes è 
 
 
Samples ê D
LG
A
P2
 
M
FH
A
S 
M
SR
A
 
G
A
TA
4 
C
TS
B
 
TU
SC
3 
C
hG
n 
FG
FR
1 
PR
K
D
C
 
M
O
S 
C
H
D
7 
M
YB
L 
N
C
O
A
2 
TP
D
52
 
E2
F5
 
R
A
D
54
B
 
ST
7 
EI
F3
E 
EI
F3
H
 
EX
T1
 
R
N
F1
39
 
M
YC
 
D
D
EF
1 
K
C
N
Q
3 
SL
A
 
K
H
D
R
B
S
3 
K
C
N
K
9 
PT
K
2 
PT
P4
A
 
R
EC
Q
L4
 
M36N A
1 A A A A A D2 A A A A A A A A A A A A A A A A A A A A A D A 
F37N A D D A D A D D D A A D A D D A D A D D D A A D A D A A A D 
F38N D A D A A A D A A A A D A A A A A A D D A A A A A A A A A D 
M39N D D D A A A D D D D D D A D D A D A D D A D D D D D A D D D 
F40N D A A A A A A A A A A D A A A A A A A A A A A A A A D A D D 
M41N D A A A A D A A A A A A A D A A A A A A A A A A A A D A D D 
F42N A A A A A D A A A A A A A D A A A A A A A A A A A A D A A A 
M43N A A A A A A A A A A A A A A A A A A A A A A A A A A A A A D 
F44N D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D 
F45N D D D D D D D D D D A D D D A A D D D D D A D D D D D D D D 
Agreement % 40 60 50 80 70 60 40 60 60 70 80 40 80 40 70 90 60 80 50 50 70 80 70 60 70 60 50 70 40 20 
 
1A= Agreement   
2D=Disagreement  
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 8p genes          8q genes 
   8pter              8qter 
 
 
Figure 5.6 Comparison of copy number predictions obtained using MLPA 
(orange) and aCGH (blue) at chromosome 8p and 8q loci in neuroblastoma 
M39N case. Copy number categories shown on the Y axis (0 = copy number loss, 
1  = disomy, 2 = copy number gain), whereas the loci examined are shown on the X 
axis. 
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Table 5.7 Summary of agreement between MLPA and aCGH results obtained in the overall solid tumour cohort (n=31) 
  
       
Chr 8 
Osteosarcoma n=5 Ewing sarcoma n=8 Rhabdomyosarcoma n=8 Neuroblastoma n=10 
N˚ concordant results 
N˚ genes x N˚ tumours 
 
Agreement 
(%) 
N˚ concordant results 
N˚ genes x N˚ tumours 
Agreement 
(%) 
 
N˚ concordant results 
N˚ genes x N˚ tumours 
 
Agreement 
(%) 
N˚ concordant results 
N˚ genes x N˚ tumours 
Agreement 
(%) 
8p 
(8 genes) 24/40 60% 39/64 61% 56/64 88% 46/80 58% 
8q 
(22 genes) 48/110 44% 110/176 63% 132/176 75% 136/220 62% 
8p + 8q 72/150 48% 149/240 62% 188/240 78% 182/300 61% 
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5.3.3 Selection of genes for qPCR 
It was clear that there were disagreements between the chromosome 8p and 8q 
copy number results obtained by MPLA and aCGH techniques (Table 5.7, 
Appendixes 5 and 6). To quantify differences and propose genes to be used for copy 
number validation using a third technique, MLPA and aCGH results were plotted 
using the software package “MS Excel”, to calculate differences between the copy 
number results of both techniques.  
 
To clarify which genes presented results with a greater degree of disagreement, we 
calculated the average distance between copy number categories for each gene. For 
each patient and gene, if the copy number categories predicted by both techniques 
were the same, the difference was 0. If one technique predicted disomic copy 
number and the other predicted either gain or loss, the difference was 1. If one 
technique predicted copy number gain and the other predicted copy number loss, the 
difference was 2 (Table 5.8). Mean values across all patients for each gene gave us 
the mean difference per gene (Table 5.9), where results were then sorted in 
descending order. RECQL4 presented with the largest difference (0.71), followed by 
PTP4A3 (0.61), KCNK9 (0.58), EXT1 and TPD52 (0.48 for both). Accordingly, these 
genes were chosen for validation with an independent technique, namely 
quantitative PCR. We also selected MYC as a control because this gene presented 
the least mean difference between the techniques (0.23) (Table 5.9).  
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Table 5.8 Summary of agreement/disagreement between copy number results 
obtained using MLPA or aCGH for chromosome 8 loci  
                       8p (8 genes)                                           Chromosome 8q (22 genes)  
 
Genes è  
 
 
 
Samples
ê  
D
LG
A
P2
 
M
FH
A
S 
M
SR
A
 
G
A
TA
4 
C
TS
B
 
TU
SC
3 
C
hG
n 
FG
FR
1 
PR
K
D
C
 
M
O
S 
C
H
D
7 
M
YB
L 
N
C
O
A
2 
TP
D
52
 
E2
F5
 
R
A
D
54
B
 
ST
7 
EI
F3
E 
EI
F3
H
 
EX
T1
 
R
N
F1
39
 
M
YC
 
D
D
EF
1 
K
C
N
Q
3 
SL
A
 
K
H
D
R
B
S
3 
K
C
N
K
9 
PT
K
2 
PT
P4
A
 
R
EC
Q
L4
 
F9O 
a
0 0 0 0 0 0 0 0 0 
b
1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 
c
2 1 1 1 
F10O 0 0 0 0 0 0 0 1 0 0 1 0 1 1 0 0 0 0 0 0 0 0 0 0 1 0 1 1 1 1 
M11O 1 1 0 1 0 0 0 1 0 1 0 0 1 1 0 1 1 1 1 1 0 0 0 1 1 1 1 0 0 1 
F12O 1 1 1 1 1 0 1 1 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 1 1 1 2 2 2 0 
M46O 1 1 1 1 0 0 0 0 1 0 1 1 0 1 0 0 0 0 0 0 1 1 1 1 0 0 1 1 1 1 
M13E 1 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 
M14E 1 0 1 0 0 0 1 0 0 0 1 1 1 0 0 1 1 0 1 0 0 0 1 1 1 1 0 1 0 0 
F15E 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 
M16E 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 0 
F17E 0 0 0 0 0 1 0 0 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 1 0 1 0 1 0 
F18E 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 
M22E 0 1 0 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 
F24E 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 
M25R 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 1 
F26R 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 
M27R 0 0 0 0 1 0 0 1 1 0 0 0 1 1 1 1 0 1 0 0 1 1 1 0 0 0 0 1 0 0 
F28R 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 
F29R 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 1 0 1 0 0 0 0 0 0 1 0 1 1 
M31R 0 0 0 0 0 1 0 0 0 0 1 0 1 0 0 0 0 0 1 1 0 0 0 0 1 1 0 0 0 1 
M32R 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 
M35R 0 0 0 0 0 1 0 0 0 1 0 1 0 1 0 1 0 0 0 1 0 0 0 1 1 0 1 0 2 1 
M36N 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 
F37N 0 1 1 0 1 0 1 1 1 0 0 1 0 1 1 0 1 0 1 2 2 0 0 1 0 1 0 0 0 1 
F38N 1 0 1 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 2 
M39N 1 1 2 0 0 0 1 1 2 1 1 2 0 1 2 0 1 0 1 1 0 1 1 1 1 1 0 1 1 1 
F40N 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 1 
M41N 1 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 1 
F42N 0 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 
M43N 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 
F44N 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
F45N 1 1 1 1 1 1 1 1 1 1 0 1 1 1 0 0 1 1 1 1 1 0 1 1 1 1 1 1 1 1 
 
a Copy number categories concordant between MLPA and aCGH (0).  
b One technique predicted disomic copy number and the other predicted gain or loss (1). 
c One technique predicted copy number gain and the other predicted copy number loss ( 2). 
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Table 5.9 Ranked scores for the degree of disagreement between copy number 
results obtained using MLPA or aCGH for chromosome 8 loci 
Rank	 Gene	
	
Mean	
Difference	
	 	 	
1	 RECQL4a	 0.71	
2	 PTP4A3	 0.61	
3	 KCNK9	 0.58	
4	 EXT1	 0.48	
5	 DLGAP2	 0.48	
6	 SLA	 0.48	
7	 TPD52	 0.48	
8	 MYBL	 0.45	
9	 KCNQ3	 0.42	
10	 PTK2	 0.42	
11	 KHDRBS3	 0.39	
12	 MSRA	 0.39	
13	 CHD7	 0.35	
14	 EIF3H	 0.35	
15	 MFHAS	 0.35	
16	 TUSC3	 0.35	
17	 ChGn	 0.32	
18	 FGFR1	 0.32	
19	 NCOA2	 0.32	
20	 PRKDC	 0.32	
21	 ST7	 0.32	
22	 DDEF1	 0.29	
23	 E2F5	 0.29	
24	 EIF3E	 0.29	
25	 RNF139	 0.29	
26	 CTSB	 0.26	
27	 MOS	 0.26	
28	 RAD54B	 0.26	
29	 GATA4	 0.23	
30	 MYC	 0.23	
 
a Genes shown in bold were selected for qPCR validation. 
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5.3.4 Overview of qPCR 
qPCR is a powerful tool used for research and diagnostics, as it can provide an 
estimate of copy number, relative to control DNA and a control gene, for any 
particular target gene (Wang et al., 2013a). In the last decade, qPCR has been used 
to validate copy number status as determined by aCGH results in different cancers 
(Ferreira et al., 2008; Lipska et al., 2013; Pasic et al., 2010; Pazzaglia et al., 2009). 
qPCR offers advantages such as operating in a closed system, therefore no post-
PCR manipulations are needed. All reaction products are detected by the Rotor-
Gene 6 as the reaction progresses in real time. qPCR also offers high throughput 
screening capacity, and is a highly sensitive technique (Wang et al., 2013a). One of 
its specific advantages for this particular project is that it is possible to perform qPCR 
on minimal amounts of genomic DNA (25 to 40 ng). qPCR was therefore used to 
validate copy number results obtained using MLPA and/or aCGH. 
  
Due to the small amounts of DNA remaining for many samples after having applied 
the initial techniques, we were unable to perform these qPCR tests for all samples 
and all genes. A group of genes was selected based on the calculated differences 
between MLPA and aCGH copy number results (Tables 5.8 and 5.9). Six 
chromosome 8q genes (RECQL4, PTP4A3, KCNK9, EXT1, TPD52, and MYC) were 
amplified in 7 tumour samples (one osteosarcoma F10O, 2 Ewing sarcomas M13E 
and F15E, 2 rhabdomyosarcomas F28R and M32R and 2 neuroblastomas F38N and 
F44N) plus 2 cell lines: HCC2157 and SK-BR-3.  
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Copy numbers of target genes were normalized using VAV2, which has been 
previously used as a qPCR genomic control by Mosse et al. (2007). The disomic 
state of VAV2 was also predicted in each tumour sample and cell lines using Nexus 
copy number software (data not shown). This gene was included in triplicate in every 
assay. Also, a genomic normal female DNA control (Promega) was used as a 
calibrator. All copy number data were calculated as described in section 2.8. All copy 
number results for qPCR were converted to copy number categories (as described 
earlier) so they could be compared directly with MLPA and aCGH results (Table 
5.10).  Relative copy numbers of 1.4 - 2.6 were considered disomic: below 1.39 was 
considered copy number loss and above 2.61 was considered copy number gain (as 
per study of Pazzaglia et al. (2009)). As an example of this categorisation process, 
qPCR results for RECQL4 are shown in Figure 5.7.  
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Figure 5.7 Relative RECQL4 copy number measured using qPCR. Copy number 
results are shown on the Y axis as means ± SE from 3 independent experiments 
(I,  II, III), normalized to the results obtained for the normal female control (F.C.) 
which was set at 2.0. On the X axis, the 7 samples, 2 cell lines and normal female 
control (F.C.) are shown.  
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Table 5.10 Copy number results obtained using qPCR and resulting copy number 
categories 
	 	 	
RECQL4 
	
PTP4A3 
Sample Copy number  
Copy number 
categorya 
 
Sample Copy number 
Copy number 
category 
F10O	 2.77	 2	
	
F10O	 2.74	 2	
M13E	 4.71	 2	
	
M13E	 4.18	 2	
F15E	 1.95	 1	
	
F15E	 3.79	 2	
F28R	 4.06	 2	
	
F28R	 2.07	 1	
M32R	 3.07	 2	
	
M32R	 2.24	 1	
F38N	 1.20	 0	
	
F38N	 2.44	 1	
F44N	 6.81	 2	
	
F44N	 3.31	 2	
HCC2157	 2.91	 2	
	
HCC2157	 3.06	 1	
SK-BR-3	 3.27	 2	
	
SK-BR-3	 2.98	 2	
	 	 	 	 	 	 	
	 	 	 	 	 	 	KCNK9 
 
EXT1 
Sample Copy number  
Copy number 
category 
 
Sample Copy number 
Copy number 
category 
F10O	 3.46	 2	
	
F10O	 2.05	 1	
M13E	 1.92	 1	
	
M13E	 3.22	 2	
F15E	 6.97	 2	
	
F15E	 3.67	 2	
F28R	 2.36	 1	
	
F28R	 1.93	 1	
M32R	 2.06	 1	
	
M32R	 1.89	 1	
F38N	 1.66	 1	
	
F38N	 2.89	 2	
F44N	 3.28	 2	
	
F44N	 2.74	 2	
HCC2157	 3.80	 2	
	
HCC2157	 3.22	 2	
SK-BR-3	 0.17	 0	
	
SK-BR-3	 3.91	 2	
	 	 	 	 	 	 	
TPD52 
 
MYC 
Sample Copy number  
Copy number 
category 
 
Sample Copy number 
Copy number 
category 
F10O	 2.63	 1	
	
F10O	 2.23	 1	
M13E	 1.55	 1	
	
M13E	 2.35	 1	
F15E	 3.16	 2	
	
F15E	 2.68	 2	
F28R	 2.05	 1	
	
F28R	 1.80	 1	
M32R	 1.86	 1	
	
M32R	 1.81	 1	
F38N	 1.40	 1	
	
F38N	 1.74	 1	
F44N	 2.79	 2	
	
F44N	 2.93	 2	
HCC2157	 4.07	 2	
	
HCC2157	 6.45	 2	
SK-BR-3	 18.08	 2	
	
SK-BR-3	 26.59	 2	
aCategories: 2=Gain; 1=Disomy; 0=Loss	
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5.3.5 qPCR results 
Results for all techniques are presented in Table 5.11, which shows the agreement 
between copy number results obtained using MLPA versus qPCR, and using aCGH 
versus qPCR. In terms of the agreement between MLPA and qPCR, the percentage 
of estimates in agreement, ranged from 11.1% (1/9 samples) for RECQL4, through 
to 33% (3/9 samples) for PTP4A3 and EXT1, 56% (5/9 samples) for KCNK9, 67% 
(6/9 samples) for TPD52 and 78% (7/9 samples) for MYC (Table 5.11). In contrast, 
qPCR and aCGH showed 100% agreement (9/9 samples) for all genes but one, 
EXT1, which showed 89% agreement (8/9 samples). These results demonstrate that 
aCGH copy number results could be more frequently validated by qPCR than MLPA 
results (Table 5.11). 
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Table 5.11 Comparison of copy number categories resulting from MLPA versus 
qPCR, and qPCR versus aCGH  
   
RECQL4 
 
PTP4A3 
Samples MLPA qPCR aCGH 
 
Samples MLPA qPCR aCGH 
F10O 1a 2 2 
 
F10O 1 2 2 
M13E 1 2 2 
 
M13E 1 2 2 
F15E 1 1 1 
 
F15E 1 2 2 
F28R 1 2 2 
 
F28R 1 1 1 
M32R 1 2 2 
 
M32R 1 1 1 
F38N 2 0 0 
 
F38N 1 1 1 
F44N 1 2 2 
 
F44N 1 2 2 
HCC2157 2 2 2 
 
HCC2157 1 2 2 
SK-BR-3 0 2 2 
 
SK-BR-3 0 2 2 
Agreement 1/9 
 
9/9 
 
Agreement 3/9 
 
9/9 
         KCNK9 
 
EXT1 
Samples MLPA qPCR aCGH 
 
Samples MLPA qPCR aCGH 
F10O 1 2 2 
 
F10O 1 1 1 
M13E 1 1 1 
 
M13E 1 2 1 
F15E 1 2 2 
 
F15E 1 2 2 
F28R 1 1 1 
 
F28R 1 1 1 
M32R 1 1 1 
 
M32R 0 1 1 
F38N 1 1 1 
 
F38N 1 2 2 
F44N 1 2 2 
 
F44N 1 2 2 
HCC2157 1 2 2 
 
HCC2157 1 2 2 
SK-BR-3 0 0 0 
 
SK-BR-3 2 2 2 
Agreement 5/9 
 
9/9 
 
Agreement 3/9 
 
8/9 
         TPD52 
 
MYC 
Samples MLPA qPCR aCGH 
 
Samples MLPA qPCR aCGH 
F10O 2 1 1 
 
F10O 1 1 1 
M13E 1 1 1 
 
M13E 1 1 1 
F15E 1 2 2 
 
F15E 1 2 2 
F28R 1 1 1 
 
F28R 1 1 1 
M32R 1 1 1 
 
M32R 1 1 1 
F38N 1 1 1 
 
F38N 1 1 1 
F44N 1 2 2 
 
F44N 1 2 2 
HCC2157 2 2 2 
 
HCC2157 2 2 2 
SK-BR-3 2 2 2 
 
SK-BR-3 2 2 2 
Agreement	 6/9  9/9 Agreement	 7/9  9/9 
aCategories: 2=Gain; 1=Disomy; 0=Loss 
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5.4 Discussion 
The results of this chapter support the use of a multi-platform approach to detect 
copy number alterations in tumour samples.  We first used MLPA, a well-established 
PCR-based technique (Homig-Holzel et al., 2012). The second approach, aCGH, is 
a more elaborate technique with high-resolution and genome-wide scope. Whereas 
we noted 100% (48/48) agreement between the categorical copy number results 
obtained at 8p loci using MLPA and aCGH in 6 breast cell lines, the agreement 
between the two techniques was only 53% (70/132) at chromosome 8q loci (Table 
5.2). Furthermore, in the solid tumour cohort, overall percentage agreement was 
67% for 8p loci and 61% for chromosome 8q loci (Table 5.7).  
 
Other groups have also reported discrepancies between MLPA and aCGH copy 
number results. Ambros et al. (2011) tested 310 neuroblastoma samples and 8 
neuroblastoma cell lines, where they examined 100 loci across chromosomes 1, 2, 
3, 4, 7, 9, 11, 12, 14, and 17 using MLPA and aCGH. The data analysis for MLPA 
was done using prototype MLPAVizard software and aCGH used CNAG 3.0 
software. The results produced by each technique were compared and achieved 
strong agreement of 99.5%. The 0.5% of divergent results were said to be due to low 
tumour cell content and, specifically for neuroblastoma, a so-called flat disomic 
profile that can be caused by less than 60% tumour cell content, in those 
neuroblastomas with a higher amount of Schwann cell stroma (Ambros et al., 2011). 
Combaret et al. (2012) compared these same techniques in 91 neuroblastoma 
samples, examining chromosomes 1, 2, 3, 4, 7, 9, 11, 12, 14, and 17. Combaret et 
al. (2012) used Agilent software to analyze the aCGH results, and MLPAVizard 
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software to analyze the results of MLPA. They reported 82% agreement between 
MLPA and aCGH, as 5.5% neuroblastoma MLPA results were not interpretable, and 
12% cases showed discrepancies between the two techniques. No other technique 
was used to clarify copy number disagreements, although the authors stated that 
MLPA does not always provide conclusive results for genome analysis (Combaret et 
al., 2012).   
 
In our project, we identified 36% disagreement between MLPA and aCGH in our 
paediatric tumour cohort, and to our knowledge, this is the first time such a high 
discrepancy has been reported. We decided to use qPCR to validate the genomic 
copy number results of MLPA and/or aCGH. Data from the 3 techniques (Table 5.11) 
showed clear differences. Interestingly RECQL4 was the worst performing gene 
when MLPA and qPCR were compared, and MYC was the best performing gene 
(Table 5.11), supporting our choice of genes for qPCR validation (Table 5.9).  
 
MLPA was especially poor in its prediction of copy number gain, where for example; 
MLPA reported copy number gain at RECQL4 in sample F38N (when loss was 
reported by other two techniques), and at TPD52 in sample F10O (when qPCR and 
aCGH both reported disomy). On the other hand, MLPA also failed to detect gain in 
many other samples (Table 5.11). This indicates that MLPA more frequently failed to 
detect copy number gain (false negative data) than it produced false positive data.  
This suggests that using MLPA alone to study chromosome 8q copy number gain 
may result in false-negative results.  
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Both rhabdomyosarcoma samples presented RECQL4 copy number gain using 
qPCR and aCGH (Table 5.11). It is known that this gene plays an important role in 
maintaining genome integrity, as a member of the RecQ helicase family, unwinding 
complementary strands of DNA for processes such as transcription of RNA, DNA 
repair, and recombination and replication processes for which single-stranded DNA 
is required (Davari et al., 2010). Amplification and overexpression of RECQL4 has 
been reported in breast (Thomassen et al., 2009), laryngeal (Saglam et al., 2007) 
and cervical cancer (Narayan et al., 2007), which is consistent with our results in 7/8 
rhabdomyosarcoma samples, as detected by aCGH (Table 4.12). 
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5.5 Summary and conclusions 
When applied to the six breast tumour cell lines tested here, MLPA demonstrated 
excellent concordance of copy number results for 8p loci. On the other hand, 8q loci 
showed relatively poor concordance, with 70/132 (53%) copy number category 
agreements. In the paediatric solid tumour cohort, our results showed similar 
relatively poor concordance, for both chromosome 8p and 8q loci. 
 
Use of qPCR supported results obtained by aCGH in almost every case (53/54 
comparisons) versus much poorer agreement with MLPA (25/54 comparisons). 
Results from aCGH appear to be more reliable than those from MLPA and so we 
urge caution, when applying this particular MLPA kit for copy number studies of 
human tumour samples. 
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Chapter 6  
General Discussion 
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6.1 Introduction 
Cancer is the second most common cause of death in children in developed 
countries (Kaatsch, 2010). Furthermore, childhood solid tumours present genetic, 
biological and environmental causes that are different from those of adult solid 
tumours (Scotting et al., 2005).  
 
For many years, the recognition of somatic genomic events has been an important 
component of diagnosis, prognosis and therapy selection in paediatric oncology 
(Janeway et al., 2013). Recent technological advances that facilitate this 
characterization at the molecular level, such as high-density aCGH and next-
generation sequencing, have led to the detection of many gene aberrations that 
could be identified as drivers for particular types of cancer (Heitzer et al., 2013). 
However at the time that this study commenced (2010), few studies had examined 
copy number changes of specific genes on chromosome 8 in childhood solid 
tumours. The current project thus aimed to assess chromosome 8 copy number 
changes in a cohort of 31 solid tumours, using MLPA and aCGH methodologies. 
Results presented in this thesis demonstrate that while MLPA (chapter 3) presents 
numerous advantages, the results obtained using the particular kit employed 
(SALSA MLPA KIT P014-A1) differed from those obtained using both aCGH (chapter 
4) and qPCR (chapter 5).  
6.2 MLPA as a stand-alone technique for measuring copy number changes 
MLPA is a technique that received growing interest from the scientific community, 
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over some years, with applications in different fields. One of the most attractive 
advantages of this technique is that, being based on PCR, quick results can be 
obtained without substantial cost, as long as the laboratory already has some basic 
infrastructure in place (Hochstenbach et al., 2005). However, some studies have 
reported discrepancies between copy number results produced by MLPA and aCGH; 
Stuppia et al. (2012) mentioned that the analysis of results obtained using MLPA 
could be difficult to interpret due to the presence of unreliable probes. An unreliable 
probe gives different results when an experiment is repeated, while other probes 
from the same experiment show consistent results, Hence this is not a problem of 
the experimental procedure. Instead, it is a problem inherent to the probe per se 
(Combaret et al., 2012; Niba et al., 2014). 
 
This creates uncertainties about which MLPA probes are reliable and which are not, 
and which MLPA kits have been sufficiently validated against another techniques. 
This is particularly clear from the Ambros et al. (2011) study, where 3 different MLPA 
kits for neuroblastoma comprising 100 loci in total were analysed by inter-laboratory 
comparative testing. After the establishment of interpretation guidelines and SNP-
array validation, that particular study led to a modification of the original A1 version 
of the MLPA kits, through inclusion of additional probes on chromosome arms 1q, 
3q, 4q, 7p, 9p and 11p, exchanging of the probes on chromosome 2p, and omitting 
the probes for MYCN. Together these alterations led to the release of the revised 
“B1” versions of the kits. It seems therefore that MLPA is a technique that is 
constantly developing.  
 
According to Conraths et al. (2006), there are basic guidelines that a molecular 
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technique should follow if it is going to be used under routine diagnostic conditions or 
for epidemiological studies. It is necessary to assess the sensitivity and specificity of 
the technique, and these parameters can be estimated by comparing the method 
with an existing reliable method, or recognised “gold standard” technique (Conraths 
et al., 2006). The P014-A1 kit did not meet this criterion, as in our study at least, this 
kit failed validation using aCGH, considered now as a gold standard technique for 
measurement of DNA copy number. To our knowledge, this is the first time any 
publication has validated the entire set of probes of this particular MLPA kit. .  
 
There is a belief in the scientific community that a technique that has been released 
to the market for over a decade and has been used in many fields is a ready-to-be-
used technique. The previous chromosome 8 kit version (P014-A1) has been 
released to the market and reported in a number of peer-reviewed MLPA 
publications (Bremmer et al., 2005; Buffart et al., 2005; Buffart et al., 2009; Rumiato 
et al., 2011). The Buffart group published the results of using 29 MLPA probes 
covering 25 genes on chromosome 8 to compare DNA copy number status in 
colorectal cancer according to the presence/absence of metastatic disease (Buffart 
et al., 2005), whereas Buffart et al. (2009) used an MLPA probe mix that contained 
11 probe sets on chromosome 8, and other probes on other chromosomes to study 
copy number aberration in gastric cancer. In both publications, aCGH was used as 
validation technique and no disagreement was reported between the two techniques 
at any loci (Buffart et al., 2005; Buffart et al., 2009).  
 
More recently, Yong et al. (2014) used the MLPA kit P014-A1 to analyze 33 oral 
squamous cell carcinoma samples, and reported amplification at the EIF3E locus in 
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9/33 samples. However in our study, EIF3E represented one of 2 clearly unreliable 
MLPA probe sets within the kit.  
 
MRC Holland released a new kit for chromosome 8 (P014-B1) in late 2013, with new 
probes and 12 reference probes in total, implying that this is an improved product 
relative to P014-A1. However, there is no published analysis that compares the 
performance of the two kit versions. One of the consequences of launching a new kit 
to market without notice is that previous results may be automatically obsolete, and it 
may be difficult to compare results obtained with the two kit versions, if the previous 
version is withdrawn from sale.  
6.3 aCGH results of other genes genome-wide 
Using all data obtained from our aCGH experiments, it was possible to observe 
particular genes that showed significant copy number gain/loss in each tumour type. 
To do this we used Nexus software’s “Significant Peak” feature, selecting each 
tumour type to obtain tables that showed individual genes with significant peaks, 
presented according to high frequency, significant p-value and commonalities of 
copy number gain or loss observed (section 4.3.2).  
 
While it was our aim to focus upon chromosome 8, we in fact found, after comparing 
all specific regions found for each tumour type, a common region of copy number 
gain at chromosome 22 band q11.22. Ten genes located in this region showed copy 
number gain including PRAME, or “preferentially expressed antigen in melanoma”, 
with frequencies from 62.5% in Ewing sarcomas to 83.3% in embryonal 
rhabdomyosarcoma (Tables 4.4, 4.5, 4.6 and 4.8). High expression of PRAME has 
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been associated with poor prognosis in solid tumours such as breast cancer and 
neuroblastoma (Oberthuer et al., 2004). In breast cancer, high PRAME expression 
correlates with increased probability of metastases (Epping et al., 2008). In 
neuroblastoma patients, high expression of PRAME is associated with advanced 
tumour stage, older age at diagnosis, and poor clinical outcome (Oberthuer et al., 
2004). In osteosarcoma biopsy samples, PRAME protein was found in more than 
70% of patients (Tan et al., 2012). In the same study siRNA knockdown of PRAME 
in U-2OS osteosarcoma cells significantly suppressed proliferation and colony 
formation, and promoted G1 cell cycle arrest, suggesting that PRAME plays an 
important role in cell proliferation and disease progression in osteosarcoma (Tan et 
al., 2012). This gene is over-expressed in many solid tumours and haematological 
malignancies, whilst showing minimal expression in normal tissues. It is therefore a 
promising target for immunotherapy (Yan et al., 2011). Also, PRAME has been 
postulated as a potential therapeutic target for treatment of leukemias (Gunn et al., 
2009, (Gutierrez-Cosio et al., 2012), neuroblastoma (Oberthuer et al., 2004) and 
osteosarcoma (Tan et al., 2012). According to the results we found for this particular 
region, we suggest that PRAME copy number gain may be related to the ove-
expression of PRAME reported previously in neuroblastoma and osteosarcoma 
(Oberthuer et al. (2004) Tan et al. (2012). Future studies could also examine the 
expression of this gene in Ewing sarcoma and embryonal rhabdomyosarcoma, as 
these have not been studied in this context. 
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6.4 Summary of aCGH chromosome 8 results obtained for 6 breast cell lines 
and the solid tumour cohort for genes examined by MLPA 
Chromosomal alterations in chromosome 8 have been frequently observed in many 
cancers. Gains of chromosome 8q and losses of 8p, described by El Gammal et al. 
(2010) as 8p-/8q+, are common in prostate cancer (El Gammal et al., 2010), breast 
cancer (Choschzick et al., 2010), colorectal cancer (Jasmine et al., 2012), 
hepatocellular carcinoma (Roessler et al., 2012) and oral squamous cell carcinoma 
(Yoshioka et al., 2013) among others, suggesting a possible relationship between 
loss of tumour suppressor genes located on the chromosome 8p arm and gain of 
genes that trigger carcinogenic processes located on the chromosome 8q arm (El 
Gammal et al., 2010; Roessler et al., 2012). In our project, this same pattern was 
observed in 5/6 breast cell lines consistent with previous publications (section 3.3.1 
and 4.4.1). However for paediatric solid tumour samples, this pattern was not 
observed.  
 
Of the 4 tumour types examined, osteosarcoma showed more copy number 
gains/losses overall, which is consistent with the literature which states that 
osteosarcomas are characterized by chromosomal instability and high copy number 
gene amplification (Lim et al., 2005). Of the genes included in the MLPA kit, KCNK9 
showed copy number gain in all osteosarcomas (5/5) and in 4/6 breast cell lines 
analysed by aCGH. Mu et al. (2003) reported that KCNK9 was amplified and 
overexpressed in breast tumours and breast cell lines, concluding that KCNK9 
confers resistance to both hypoxia and serum deprivation, suggesting that its 
amplification and overexpression plays a physiologically important role in human 
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breast cancer. Lately KCNK9 has been found to be expressed in epithelial ovarian 
cancer, conferring a significant survival advantage in patients with increased 
expression (Innamaa et al., 2013). These investigations highlight the potential 
importance of copy number gain of KCNK9 in osteosarcoma, an aspect that could be 
explored in future studies.  
 
One of the most prominent features of Ewing sarcoma is the recurring trisomy of 
chromosome 8 (Savola et al., 2009). According to Toomey et al. (2010), gains of the 
entire chromosome 8 have been reported by nearly every CGH study, and these 
occur in 23-80% of Ewing sarcoma samples. In our project, gain of whole 
chromosome 8 occurred in 37% (3/8) of Ewing sarcoma samples tested using 
aCGH, which was consistent with previous results (Toomey et al., 2010).  
 
Chromosome 8 gain is commonly detected in ERMS (Wang, 2012). However, in our 
ERMS subset (n=6) we only observed 16/30 chromosome 8 loci showing copy 
number gain. This finding excludes the presence of full trisomy 8, in any of our six 
samples. Setting aside the possibility of analytical errors, this could be due to normal 
cells contamination or noisy samples leading to intermittent detection of copy 
number change, or simply because partiality in the small cohort we used.  
 
As the literature would predict, our ARMS subset (n=2), which is characterised by 
recurrent reciprocal and balanced translocation, did not show any major copy 
number change. Admittedly, the number of samples was too small to permit any 
statistical argument here, but nonetheless, our findings are consistent with the 
literature, for the ARMS tumour sub-category. In comparison with most other tumour 
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types, these are relatively lacking in copy number changes overall.  
 
RECQL4 showed copy number gain in 15/31 samples from the paediatric tumour 
cohort and 4/6 breast cell lines, as based on aCGH data. Amplification and 
overexpression of RECQL4 has been reported in cervical (Narayan et al., 2007), 
laryngeal (Saglam et al., 2007) and breast cancer (Thomassen et al., 2009). In this 
last study, RECQL4 was found to be a potential metastasis-promoting gene 
(Thomassen et al., 2009). Recently Fang et al. (2013) demonstrated that an 
increased copy number of RECQL4 plays an important role in tumourigenesis of 
breast cancer. They identified overexpression of RECQL4 due to gene amplification 
in both breast tumour tissues and breast tumour cell lines. In our project, we used 
two of the same cell lines used by Fang et al. (2013) and we obtained the same 
results at the RECQL4 locus, namely: disomic copy number for MDA-MB-231 and 
copy number gain for MCF-7 cells (see Appendix 5). In this regard, our results are in 
agreement with those of other studies.  
 
Most literature concerning RECQL4 and childhood cancer associates RECQL4 with 
osteosarcoma. For instance, Rothmund-Thomson syndrome (OMIM#268400), which 
is caused by mutations in RECQL4, has been strongly associated with predisposition 
to osteosarcoma (Wang et al., 2003). In our results, however, this gene showed copy 
number gain in 7/8 rhabdomyosarcomas, which is a novel finding that could form the 
basis of future investigations.  
 
In neuroblastoma samples, no chromosome 8 gene copy number gain or loss was 
consistently identified, across all of our 10 samples. However, when analysing the 
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data for cancer genes on other chromosomes (and hence with lower oligonucleotide 
probe spacing: see Table 4.1), copy number gain was detected in 8/10 samples at 
the MYCN locus on chromosome 2, band p24.3 (Table 4.10). MYCN amplification is 
a marker of critical importance in neuroblastoma, as it signifies aggressiveness and 
high metastatic potential (Ambros et al., 2011), in a subgroup of 20-30% cases 
(Cohn et al., 2004). As 80% of our neuroblastoma subset showed copy number gain 
in MYCN, and we saw a relatively flat copy number profile across chromosome 8; we 
may conclude that this is one type of tumour for which chromosome 8 copy number 
variation is not of prime importance. 
 
Finally: we consider the four genes RECQL4, PTP4A3, KCNK9, and EXT1, which 
presented copy number gain in most of the tumour cohort samples analysed by 
aCGH, but along with TPD52 and MYC, showed discrepant MLPA results in some 
cases. Most (5/6) genes showed 100% agreement between the results of aCGH and 
qPCR, except for EXT1 (with 89% agreement), supporting our conclusion that qPCR 
is an excellent, or “gold standard” technique for validation of copy number data 
obtained by other means.  
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Final conclusions 
Copy number changes at chromosome 8 are widely recognized in several cancers. 
The data presented in this thesis revealed some genes that had not previously been 
linked with specific cancers, such as KCNK9 (showing copy number gain in all 
osteosarcoma samples) and RECQL4 that showed copy number gain in most 
rhabdomyosarcomas. Also we present for the first time such data concerning the 
gene PRAME located at chromosome 22q11.22. This gene that showed copy 
number gain in all 4 solid tumour types examined, and has been proposed as a 
promising target for immunotherapy in some hematologic malignancies. However, it 
has not been subject to study in osteosarcoma, rhabdomyosarcoma or Ewing 
sarcoma. Further studies in these areas may prove to be beneficial. 
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Appendix 1. Statistical analysis 
Statistical analysis using Fisher’s exact test to assess differences in the number of 
samples per copy number category at 8p versus 8q loci 
p-values <0.05 were considered statistically significant 
Categories: 2=Gain; 1=Disomic; 0=Loss 
 
Osteosarcoma Category 2 Category 1 Category 0 
   8p 3 27 10 
   8q 19 82 9 
   
 p=0.01652 
     Ewing sarcoma Category 2 Category 1 Category 0 
   8p 4 59 1 
   8q 7 166 3 
   Fisher test p=0.70163 
     
   
    
Rhabdomyosarcoma Cat 2 Cat 1 Cat 0 
   8p 3 61 0 
   8q 10 159 7 
   
 p=0.32322 
     
 
     
 ARMS Category 2 Category 1 Category 0 
   8p 0 16 0 
   8q 0 43 1 
   
 p=0.26667 
     
       ERMS Category 2 Category 1 Category 0 
   8p 3 45 0 
   8q 10 116 6 
   
 p=0.39302 
     
     
 
 Neuroblastoma Category 2 Category 1 Category 0 
   8p 10 58 12 
   8q 11 173 36 
   
 
p=0.09000 
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Appendix 2. Copy number changes in cell lines 
Genome copy number changes measured in 6 breast cell lines. Log2 copy number at 
individual probes plotted on same scale around the vertical baseline (left of baseline, 
copy number loss, right of baseline, copy number gain). Shown to the left of each 
ideogram, sections of which are coloured either red (copy number loss) or blue (copy 
number gain). All Genome views were generated using Nexus copy number v 7.5. 
Cell line AU565 
 
 
Cell line HCC2157 
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Cell line MCF-7 
 
 
 
Cell line MCF10-A 
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Cell line MDA-MB-231 
 
 
 
Cell line SK-BR-3 
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Appendix 3. Copy number changes in solid tumours 
Genome copy number changes measured in paediatric solid tumours. Log2 copy 
number at individual probes plotted vertically on same scale (left of baseline, copy 
number loss, right of baseline, copy number gain). Shown to the left of each 
ideogram, sections of which are coloured either red (copy number loss) or blue (copy 
number gain). All Genome views were generated using Nexus copy number v 7.5. 
Sample: F9O 
 
 
Sample: F10O 
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Sample: M11O 
 
 
 
Sample: F12O 
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Sample: M46O 
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Sample: M13E  
 
 
Sample: M14E 
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Sample: F15E 
 
  
Sample: M16E 
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Sample: F17E 
 
 
 
Sample: F18E 
 
 
  249 
Sample: M22E 
 
 
 
Sample: F24E 
 
 
  250 
Sample: M27R (ARMS) 
 
 
 
Sample: M32R (ARMS) 
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Sample: M25R (ERMS) 
 
 
 
Sample: F26R (ERMS) 
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Sample: F28R (ERMS) 
 
 
 
Sample: F29R (ERMS) 
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Sample: M31R (ERMS) 
 
 
 
Sample: M35R (ERMS) 
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Sample: M36N 
 
 
 
Sample: F37N 
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Sample: F38N 
 
 
 
Sample: M39N 
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Sample: F40N 
 
 
Sample: M41N 
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Sample: F42N 
 
 
 
Sample: M43N 
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Sample: F44N 
 
 
 
Sample: F45N 
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Appendix 4. Copy number status using aCGH 
Copy number status for chromosome 8p MLPA genes in solid tumour cohort using 
aCGH 
Genes DLGAP2	 MFHAS1	 MSRA	 GATA4	 CTSB	 TUSC3	 ChGn	 FGFR1	
Samples         
F9O 1 1 1 1 1 1 1 1 
F10O 1 1 1 1 1 1 1 0 
M11O 2 2 2 2 1 2 2 2 
F12O 1 2 1 1 1 1 1 1 
M46O 1 1 1 1 1 1 1 1 
M13E 2 1 1 1 1 1 1 1 
M14E 2 1 2 1 1 2 2 1 
F15E 2 2 2 2 2 2 2 2 
M16E 2 2 2 2 2 2 2 2 
F17E 1 1 1 1 1 1 1 1 
F18E 1 1 1 1 1 1 1 1 
M22E 1 0 1 1 1 1 1 1 
F24E 1 1 1 1 1 1 1 1 
M25R 2 1 2 1 1 1 1 1 
F26R 1 1 1 1 1 1 1 1 
M27R 1 1 1 1 0 1 1 0 
F28R 1 1 1 1 1 1 1 1 
F29R 2 1 1 1 1 1 1 1 
M31R 1 1 1 1 1 1 1 1 
M32R 1 1 1 1 1 1 1 1 
M35R 1 1 1 1 1 1 1 1 
M36N 1 1 1 1 1 1 1 1 
F37N 1 1 1 1 1 1 1 1 
F38N 1 1 1 1 1 1 1 1 
M39N 2 1 2 1 1 1 1 2 
F40N 2 1 1 1 1 1 1 1 
M41N 2 1 1 1 1 1 1 1 
F42N 1 1 1 1 1 1 1 1 
M43N 1 1 1 1 1 1 1 1 
F44N 2 2 2 2 2 2 2 2 
F45N 1 1 1 1 1 1 1 1 
          DLGAP2 MFHAS1 MSRA GATA4 CTSB TUSC3 ChGn FGFR1 
        Gain 11(35.5%) 5(16.1%) 7(22.6%) 4(12.9%) 3(9.7%) 5(16.1%) 5(16.1%) 5(16.1%) 
Disomy 20(64.5%) 25(80.6%) 24(77.4%) 27(87.1%) 27(87.1%) 26(83.9%) 26(83.9%) 24(77.4%) 
Loss 0(0.0%) 1(3.3%) 0(0.0%) 0(0.0%) 1(3.3%) 0(0.0%) 0(0.0%) 2(6.5%) 
         
	
Categories 2: Gain; 1=Disomy; 0=Loss 
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Copy number status for chromosome 8q MLPA genes in solid tumour cohort using 
aCGH 
Genes PRKDC	 MOS	 CHD7	 MYBL1	 NCOA2	 TPD52	 E2F5	 RAD54B	
Samples         
F9O 1 2 2 2 2 2 2 2 
F10O 1 0 0 2 0 1 1 1 
M11O 1 0 1 1 0 2 1 2 
F12O 2 2 2 2 2 0 0 2 
M46O 2 1 2 2 1 2 1 2 
M13E 1 1 2 2 1 1 1 1 
M14E 1 1 2 2 2 1 1 2 
F15E 2 2 2 2 2 2 2 2 
M16E 2 1 2 2 2 2 2 1 
F17E 1 1 1 1 1 1 1 1 
F18E 1 1 1 1 1 1 1 1 
M22E 1 1 1 1 1 0 1 1 
F24E 1 1 1 1 1 1 1 1 
M25R 1 1 1 1 1 1 1 1 
F26R 1 1 1 1 1 1 1 1 
M27R 0 1 1 1 0 0 0 0 
F28R 1 1 1 1 1 1 1 1 
F29R 1 1 1 1 1 2 2 2 
M31R 1 1 1 1 2 2 1 1 
M32R 1 1 1 1 1 1 1 1 
M35R 1 1 1 1 1 1 1 1 
M36N 1 1 1 1 1 1 1 1 
F37N 1 1 1 1 1 1 1 1 
F38N 1 1 1 1 1 1 1 1 
M39N 2 2 1 2 1 1 2 0 
F40N 1 1 1 0 1 1 1 1 
M41N 1 1 1 1 1 1 1 1 
F42N 1 1 1 1 1 1 1 1 
M43N 1 1 1 1 1 1 1 1 
F44N 2 2 2 2 2 2 2 2 
F45N 1 1 1 1 1 1 1 1 
 
PRKDC MOS CHD7 MYBL1 NCOA2 TPD52 E2F5 RAD54B 
Gain 6(19.4%) 5(16.1%) 8(25.8%) 10(32.3%) 7(22.6%) 8(25.8%) 6(19.4%) 8(25.8%) 
Disomy 24(77.4%) 24(77.4%) 22(71.0%) 20(64.5%) 21(67.7%) 20(64.5%) 23(74.2%) 21(67.7%) 
Loss 1(3.2%) 2(6.5%) 1(3.2%) 1(3.2%) 3(9.7%) 3(9.7%) 2(6.4%) 2(6.4%) 
         
 
Categories: 2=Gain; 1=Disomy; 0=Loss 
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Copy number status for chromosome 8q MLPA genes in solid tumour cohort using 
aCGH (cont.) 
Genes ST7 EIF3E EIF3H EXT1 RNF139 MYC DDEF1 KCNQ3 
Samples         
F9O 2 2 2 2 2 2 2 2 
F10O 1 1 1 1 1 1 1 1 
M11O 2 2 2 2 1 1 1 2 
F12O 0 2 2 2 2 2 1 2 
M46O 2 2 2 2 2 2 2 2 
M13E 1 1 1 1 1 1 1 1 
M14E 2 2 2 2 1 1 2 2 
F15E 2 2 2 2 2 2 2 2 
M16E 2 2 2 2 2 2 2 2 
F17E 1 1 1 1 1 1 1 1 
F18E 1 1 1 1 1 1 1 1 
M22E 1 1 1 1 1 1 1 1 
F24E 1 1 1 1 1 1 1 1 
M25R 1 1 1 1 1 1 1 2 
F26R 1 1 1 1 1 1 1 1 
M27R 1 0 1 1 0 0 0 1 
F28R 1 1 1 1 1 1 1 1 
F29R 2 2 1 1 1 2 1 1 
M31R 1 1 2 2 1 1 1 1 
M32R 1 1 1 1 1 1 1 1 
M35R 1 1 1 1 1 1 1 2 
M36N 1 1 1 1 1 1 1 1 
F37N 1 1 1 2 2 1 1 1 
F38N 1 1 1 2 1 1 1 1 
M39N 1 1 1 2 1 2 2 2 
F40N 1 1 1 1 1 1 1 1 
M41N 1 1 1 1 1 1 1 1 
F42N 1 1 1 1 1 1 1 1 
M43N 1 1 1 1 1 1 1 1 
F44N 2 2 2 2 2 2 2 2 
F45N 1 1 1 1 1 1 1 1 
         
 
ST7 EIF3E EIF3H EXT1 RNF139 MYC DDEF1 KCNQ3 
Gain 8(25.8%) 9(29.0%) 9(29.0%) 12(38.7%) 7(22.6%) 8(25.8%) 7(22.6%) 11(35.5%) 
Disomy 22(71.0%) 21(67.7%) 22(71.0%) 19(61.3%) 23(74.2%) 22(71.0%) 23(74.2%) 20(64.5%) 
Loss 1(3.2%) 1(3.2%) 0(0.0%) 0(0.0%) 1(3.2%) 1(3.2%) 1(3.2%) 0(0.0%) 
          
Categories: 2=Gain; 1=Disomy; 0=Loss 
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Copy number status for chromosome 8q MLPA genes in solid tumour cohort 
using aCGH (cont.) 
Genes SLA	 KHDRBS3	 KCNK9	 PTK2	 PTP4A3	 RECQL4	
Samples       
F9O 2 2 2 2 2 2 
F10O 1 1 2 2 2 2 
M11O 2 2 2 1 1 1 
F12O 2 2 2 2 2 1 
M46O 2 2 2 2 2 2 
M13E 1 1 1 1 2 2 
M14E 2 2 1 2 1 1 
F15E 2 2 2 2 2 1 
M16E 2 2 2 2 2 1 
F17E 1 1 1 1 2 1 
F18E 1 1 1 1 1 1 
M22E 1 1 1 1 1 1 
F24E 1 1 1 1 1 2 
M25R 2 2 1 1 1 2 
F26R 1 1 1 1 2 2 
M27R 1 1 1 0 1 1 
F28R 1 1 1 0 1 2 
F29R 1 1 1 1 1 2 
M31R 2 2 1 1 1 2 
M32R 1 1 1 1 1 2 
M35R 1 1 1 1 2 2 
M36N 1 1 1 1 2 1 
F37N 1 1 1 1 1 1 
F38N 1 1 1 1 1 0 
M39N 2 1 1 2 2 1 
F40N 1 1 2 1 1 2 
M41N 1 1 2 1 2 1 
F42N 1 1 1 1 1 1 
M43N 1 1 1 1 1 2 
F44N 2 2 2 2 2 2 
F45N 1 1 1 1 1 1 
       
 
SLA KHDRBS3 KCNK9 PTK2 PTP4A3 RECQL4 
Gain 11(35.5%) 10(32.3%) 10(32.3%) 9(29.0%) 14(45.2%) 15(48.4%) 
Disomy 20(64.5%) 21(67.7%) 21(67.7%) 20(64.5%) 17(54.8%) 15(48.4%) 
Loss 0(0.0%) 0(0.0%) 0(0.0%) 2(6.5%) 0(0.0%) 1(3.2%) 
       
	
Categories: 2=Gain; 1=Disomy; 0=Loss 
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Appendix 5. Copy number categories in cell lines 
 
Copy number categories measured at chromosome 8p and 8q loci using MLPA or aCGH in breast cell lines 
 
                              
  8p (8 genes)                                                                                   Chromosome 8q (22 genes) 
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AU565 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 1 1 2 2 2 1 2 0 0 0 0 0 0 2 2 2 2 2 2 2 2 1 1 0 0 0 1 0 1 0 0 0 0 0 2 1 2 
HCC2157 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 1 2 1 2 2 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 2 2 
MCF-7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 1 1 0 0 1 1 1 1 2 2 2 2 2 2 1 2 1 2 2 2 2 2 2 2 1 2 1 2 1 2 0 2 1 2 1 2 1 2 
MCF-10A 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 1 2 1 2 1 2 1 2 2 2 1 2 1 2 2 2 1 2 1 2 1 2 1 2 1 1 
MDA-MB-231 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 2 1 2 2 2 2 2 1 2 2 2 1 2 1 2 1 2 1 2 1 2 1 2 0 0 1 2 2 2 1 2 1 2 1 2 0 2 1 2 1 2 1 1 
SK-BR-3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 2 1 2 1 2 1 2 1 2 2 2 1 2 0 0 0 0 0 0 2 2 2 2 2 2 2 2 1 1 0 1 1 1 0 1 0 0 0 0 0 2 0 2 
 
Categories: 2=Gain; 1=Disomy; 0=Loss 
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Appendix 6. Copy number categories in solid tumours 
 
Copy number categories measured at chromosome 8p and 8q loci using MLPA or aCGH in solid tumour cohort 
 
8p (8 genes)                                                                                   Chromosome 8q (22 genes) 
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F9O 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 1 2 1 2 1 2 2 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 0 2 1 2 1 2 1 2 
F10O 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 0 0 1 0 2 2 1 0 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 1 1 1 1 2 1 2 1 2 1 2 
M11O 1 2 1 2 2 2 1 2 1 1 2 2 2 2 1 2 1 1 1 0 1 1 1 1 1 0 1 2 1 1 1 2 1 2 1 2 1 2 1 2 1 1 1 1 1 1 1 2 1 2 1 2 1 2 1 1 1 1 0 1 
F12O 0 1 1 2 0 1 0 1 0 1 1 1 0 1 0 1 1 2 1 2 2 2 2 2 2 2 0 0 0 0 1 2 0 0 2 2 2 2 2 2 2 2 2 2 1 1 1 2 1 2 1 2 0 2 0 2 0 2 1 1 
M46O 0 1 0 1 0 1 0 1 1 1 1 1 1 1 1 1 1 2 1 1 1 2 1 2 1 1 1 2 1 1 2 2 2 2 2 2 2 2 2 2 1 2 1 2 1 2 1 2 2 2 2 2 1 2 1 2 1 2 1 2 
M13E 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 1 2 
M14E 1 2 1 1 1 2 1 1 1 1 2 2 1 2 1 1 1 1 1 1 1 2 1 2 1 2 1 1 1 1 1 2 1 2 2 2 1 2 2 2 1 1 1 1 1 2 1 2 1 2 1 2 1 1 1 2 1 1 1 1 
F15E 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 1 
M16E 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 1 1 2 1 2 1 2 1 2 1 2 1 1 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 1 
F17E 1 1 1 1 1 1 1 1 1 1 2 1 1 1 1 1 1 1 1 1 2 1 1 1 1 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 1 1 1 0 1 1 1 1 2 1 1 
F18E 1 1 2 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
M22E 1 1 1 0 1 1 1 1 1 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 1 1 1 0 1 1 1 1 1 1 1 
F24E 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 
Categories: 2=Gain; 1=Disomy; 0=Loss 
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Copy number measured at chromosome 8p and 8q loci using MLPA or aCGH in solid tumour cohort (Cont.) 
8p (8 genes)                                                                                   Chromosome 8q (22 genes) 
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M25R 1 2 1 1 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 1 2 1 2 1 1 1 1 1 1 1 2 
F26R 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 1 2 
M27R 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 0 1 0 1 1 1 1 1 1 1 0 1 0 1 0 1 0 1 1 1 0 1 1 1 1 1 0 1 0 1 0 1 1 1 1 1 1 1 1 1 0 1 1 1 1 
F28R 1 1 1 1 1 1 1 1 1 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 2 
F29R 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 2 1 2 2 2 1 2 1 2 1 1 0 1 1 1 2 2 1 1 1 1 1 1 1 1 0 1 1 1 0 1 1 2 
M31R 1 1 1 1 1 1 1 1 1 1 2 1 1 1 1 1 1 1 1 1 2 1 1 1 1 2 2 2 1 1 1 1 1 1 1 1 1 2 1 2 1 1 1 1 1 1 1 1 1 2 1 2 1 1 1 1 1 1 1 2 
M32R 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 
M35R 1 1 1 1 1 1 1 1 1 1 2 1 1 1 1 1 1 1 2 1 1 1 2 1 1 1 2 1 1 1 2 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 2 2 1 1 1 0 1 1 1 0 2 1 2 
M36N 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 1 1 
F37N 1 1 2 1 0 1 1 1 2 1 1 1 0 1 2 1 0 1 1 1 1 1 0 1 1 1 0 1 0 1 1 1 0 1 1 1 0 1 0 2 0 2 1 1 1 1 0 1 1 1 0 1 1 1 1 1 1 1 2 1 
F38N 2 1 1 1 0 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 0 
M39N 1 2 2 1 0 2 1 1 1 1 1 1 0 1 1 2 0 2 1 2 0 1 0 2 1 1 0 1 0 2 0 0 0 1 1 1 0 1 1 2 1 1 1 2 1 2 1 2 1 2 0 1 1 1 1 2 1 2 2 1 
F40N 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 1 1 0 1 1 2 
M4N 1 2 1 1 1 1 1 1 1 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 1 1 1 2 2 1 
F42N 1 1 1 1 1 1 1 1 1 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 
M43N 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 
F44N 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 
F45N 2 1 0 1 0 1 0 1 2 1 2 1 0 1 0 1 0 1 2 1 1 1 2 1 0 1 2 1 1 1 1 1 0 1 2 1 0 1 0 1 0 1 1 1 0 1 0 1 2 1 0 1 0 1 0 1 0 1 0 1 
Categories: 2=Gain; 1=Disomy; 0=Loss 
